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ABSTRACT 
 Dihydrodipicolinate Synthase (EC 4.3.3.7; DHDPS), the product of the dapA gene, is 
an enzyme that catalyzes the condensation of pyruvate and S-aspartate-β-semialdehyde 
into dihydrodipicolinate via an unstable heterocyclic intermediate, (4S)-hydroxy-2,3,4,5-
tetrahydro-(2S)-dipicolinic acid.  DHDPS catalyzes the first committed step in the 
biosynthesis of ʟ-lysine and meso-diaminopimelate; each of which is a necessary cross-
linking component between peptidoglycan heteropolysacharide chains of bacterial cell 
walls.  Therefore, strong inhibition of DHDPS would result in disruption of meso-
diaminopimelate and ʟ-lysine biosynthesis in bacteria leading to decreased bacterial 
growth and cell lysis.  Much attention has been given to targeting the active site for 
inhibition; however DHDPS is subject to natural feedback inhibition by ʟ-lysine at an 
allosteric site.  ʟ-Lysine is known to act as a partial uncompetitive inhibitor with respect to 
pyruvate and a partial mixed inhibitor with respect to ASA.  Little is known about how the 
protein structure facilitates the natural inhibition mechanism and mode of allosteric signal 
transduction.  This work presents ten high resolution crystal structures of DHDPS and the 
mutant Y110F-DHDPS with various substrates and inhibitors, including the first reported 
structure of DHDPS with ASA bound to the active site.  As a body of work these structures 
reveal residues and conformational changes which contribute to the inhibition of the 
enzyme.  Understanding these structure function relationships will be valuable for the 
design of future antibiotic lead compounds. 
 When an inhibitor binds to the allosteric site there is meaningful shrinkage in the solvent 
accessible volume between 33% and 49% proportional to the strength of inhibition.  
Meanwhile at the active site the solvent accessible volume increases between 5% and 35% 
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proportional to the strength of inhibition.  Furthermore, inhibitor binding at the allosteric 
site consistently alters the distance between hydroxyls of the catalytic triad (Y137-T47-
Y111’) which is likely to affect local pKa's.  Changes in active site volume and 
modification of the catalytic triad would inhibit the enzyme during the binding and 
condensation of ASA.   
 The residues H56, E88, R60 form a network of hydrogen bonds to close the allosteric 
site around the inhibitor and act as a lid.  Comparison of ʟ-lysine and bislysine bound to 
wild-type and Y110F DHDPS indicates that enhanced inhibition of bislysine is most likely 
due to increased binding strength rather than altering the mechanism of inhibition.  When 
ASA binds to the active site the network of hydrogen bonds among H56, E88 and R60 is 
disrupted and the solvent accessible volume of the allosteric site expands by 46%.  This 
observation provides some explanation for the reduced affinity of ʟ-lysine in high ASA 
concentrations.  
 ʟ-Lysine, but not other inhibitors, is found to induce dynamic domain movements in the 
wild-type DHDPS.  These domain movements do not appear to be essential to the inhibition 
of the enzyme but may play a role in cooperativity between monomers or governing protein 
dynamics.  The moving domain connects the allosteric site to the dimer-dimer interface. 
Several residues at the weak dimer interface have been identified as potentially involved 
in dimer-dimer communication including: I172, D173, V176, I 194, Y196, S200, N201, 
K234, D238, Y241, N242 and K245.  These residues are not among any previously 
identified as important for formation of the quaternary structure.  
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Chapter 1   Introduction 
1.1 Dihydrodipicolinate Synthase (DHDPS) as a herbicidal and antibiotic 
target  
In the last 50 years, bacterial resistance to antibiotics has emerged as a significant 
medical challenge.1  Therefore, one of the primary objectives of current medicinal 
chemistry is to identify new antibiotic targets for the development of new drugs.2 Inhibitors 
of bacterial cell wall synthesis are proven to be very successful as antibiotics.3  The 
bacterial cell wall requires meso-diaminopimelate (or ʟ-lysine in some organisms) for 
cross-linking of peptidoglycan chains (figure 1.1).  The dap pathway produces Meso-
diaminopimelate which is then decarboxylated to form the final product ʟ-lysine.  
Therefore enzymes of the dap pathway including dihydrodipicolinate synthase (DHDPS), 
encoded by dapA, are potential targets for drug development.4-8 The dapA gene encodes 
DHDPS which regulates the biosynthetic pathway through feedback inhibition (figure 1.2). 
This is demonstrated in bacterial strains with a deleted dapA gene, which are not viable 
and lyse in the absence of meso-diamenopimelate in the growth medium.9-11 
DHDPS (E.C. 4.2.1.52) is an allosterically regulated enzyme that catalyzes the first 
committed reaction of the ʟ-lysine biosynthesis pathway in plants, bacteria, and some 
fungi.  Specifically, DHDPS catalyzes the condensation of pyruvate and (S)-aspartate-β-
semialdehyde (ASA) to form (4S)-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid, which 
then spontaneously dehydrates to (S)-2,3-dihydropyridine-2,6-dicarboxylate 
(dihydrodipicolinate). 12-15  There has been ongoing interest in DHDPS since the 1960s, 
with most of the attention focusing on plant, and some bacterial DHDPS.  The plant enzyme 
allosterically regulates the production of ʟ-lysine within the cell through feedback 
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inhibition.  ʟ-Lysine, the final product of the biosynthesis pathway, acts as the allosteric 
modulator.  Plant DHDPS are very sensitive to ʟ-lysine inhibition, and typically have low 
micromolar IC50 values, where IC50 is the concentration required to achieve half of the 
maximum inhibition.16-18 Motivation for the study of plant DHDPS is removal of the 
mechanisms suppressing ʟ-lysine production in crops, which would allow for agricultural 
products with higher ʟ-lysine content and increased nutritional quality.  Additionally, the 
highly conserved sequence of plant DHDPS provides the possibility of designing non-
selective herbicides targeting DHDPS.  Some progress has been achieved in modifying the 
allosteric site of the plant enzyme to engineer crops insensitive to ʟ-lysine regulation, but 
there remain no compounds that are able to inactivate DHDPS and work as herbicides. 
 
 
Figure 1.1 – Two types of peptidoglycan found in bacterial species; each dependent on the final products 
of the dapA biosynthetic pathway. 
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Figure 1.2 – DHDPS is the first in a series of enzymes that make the unbranched dap biosynthetic 
pathway.  The products of this pathway are ʟ-lysine and meso-diaminopimelate.  The amount of ʟ-lysine in 
the cell controls the dap pathway through feedback inhibition at DHDPS. 
 
Bacterial DHDPS have less sequence identity between species than plant DHDPS’s.  
Bacterial DHDPS are also less sensitive to ʟ-lysine inhibition than DHDPS from plants. ʟ-
Lysine IC50 values of bacterial DHDPS range from micromolar and millimolar levels for 
DHDPS from Gram-negative bacteria to complete ʟ-lysine insensitivity for DHDPS from 
Gram-positive bacteria.19-23   
DHDPS is encoded by a dapA gene; studies have revealed that dapA- mutants are 
auxotrophic for diaminopimelate and undergo lysis in the absence of diaminopimelate in 
the medium.10  E. coli AT997 (a ΔdapA mutant strain) can be maintained on nutrient 
medium only if the medium is supplemented with diaminopimelate.9, 11  A systematic 
inactivation of the Bacillus subtilis genome lead to the classification of dapA as essential 
(i.e. bacteria lacking the dapA genes are not viable).24  Genome analysis and mapping by 
in vitro transposition in Haemophillus influenzae putatively identified dapA as an essential 
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gene.25  These results show that DHDPS is a potential target for drug development7; 
however, Schnell et al. has shown that Pseudomonas aeruginosa mutants with dapA 
deleted are viable, implying that dapA is not an optimal target for drug development against 
certain bacteria.26 
DHDPS has additional significance for sporulating bacteria. The product of the reaction 
catalyzed by DHDPS, dihydrodipicolinate, is a precursor for dipicolinate which can 
comprise up to 15% of dry weight of bacterial spores.27, 28  Mutants lacking DHDPS are 
not able to sporulate without supplementation of cultures with dipicolinate.28 The absence 
of this ʟ-lysine biosynthetic pathway in humans and its necessity in bacteria make DHDPS 
an attractive target for drug development.7 
1.2 Campylobacter jejuni: A human and animal pathogen 
C. jejuni is a Gram-negative helical bacterium, which readily engages in gene transfer 
contributing to the proliferation of antibiotic resistance.29  C. jejuni are remarkably virulent 
with the ability to enter and survive within host epithelial cells.30   Common strains of C. 
jejuni have developed resistance to most β-lactams, and the second generation of 
fluoroquinolone class of antibiotics including topoisomerase II and IV inhibitor 
Ciprofloxacin.31  The rise of antibacterial resistance is prevalent among many bacterial 
species.1  
 Basic symptoms of campylobacteriosis include diarrhea, fever, and vomiting, however 
many complications can arise. An infection of C. jejuni  can develop into serious 
autoimmune and neurological conditions such as Guillian-Barré syndrome and Miller-
Fisher syndrome 30, 32-34 Campylobacteriosis is also associated with Reiter’s syndrome, gall 
bladder inflammation, and irritable bowel syndrome.35, 36 Recently, C. jejuni was found to 
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cause spondylodiscitis, a complication where the infection enters the intervertebral discs 
of the spinal cord.37  As with other Gram-negative bacterial species, survival of C. jejuni 
depends on its ability to synthesize the components for the cell wall including the products 
of the dapA pathway controlled by DHDPS. 
1.3 DHDPS Reaction Mechanism 
DHDPS operates with a ping-pong, or "substituted-enzyme", catalytic mechanism 
(Scheme 1.1).19, 38-40  The first substrate, pyruvate, condenses with the catalytic K166 of 
the native enzyme forming a Schiff base.  The second substrate, ASA, binds and reacts 
with the enamine of the substituted DHDPS:pyr complex forming a new carbon-carbon 
bond via an aldol reaction.  In solution ASA exists as an equilibrium of a number of species 
(figure 1.3).  The current consensus, supported by NMR data, is that the hydrate form of 
ASA is involved in the DHDPS reaction mechanism.12, 41, 42  However, due to the reactivity 
of ASA with DHDPS:pyr the actually binding conformation of ASA has never been 
confirmed crystallographically.  The ligated intermediate then cyclizes, by trans-imination, 
into the unstable heterocyclic product (4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic 
acid (HTPA).38, 40  HTPA spontaneously dehydrates in solution forming 
dihydrodipicolinate, or enters the next step of the enzymatic pathway; reduction (with 
dehydration) catalyzed by dihydrodipicolinate reductase (DHDPR; Scheme 1.2).13  
 
Scheme 1.1 –  The kinetic mechanism of DHDPS.  Within the Scheme E refers to the unligated enzyme 
and F to the covalently substituted form.  Pyruvate is pyr, aspartate semialdehyde is ASA, and HTPA is (4S)-
4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid.41 
6 
 
 
 
 
Figure 1.3 – ASA has three resonance structures.  From left to right: hydrate, aldehyde, and lactol. 
 
Involvement of specific residues has been inferred from protein crystallography and site 
directed mutagenesis of DHDPS from various species.12, 21, 38, 43  In all species there is a 
conserved catalytic triad consisting of two tyrosine residues and one threonine; in addition 
to the key catalytic K166 residue.38  This catalytic triad has been proposed to act as a proton 
relay by transferring protons to and from the active site.38  DHDPS from most species exists 
as a tetramer in solution, 18, 40, 44-46   (figure 1.4) and one tyrosine in the catalytic triad 
belongs to the chain of an adjacent monomer (figure 1.5), and is believed to be involved in 
inter-monomer communication.47  Furthermore, a highly conserved arginine residue plays 
a significant role in binding and reaction of the second substrate ASA.43  The Michaelis 
constants have been published from a variety of sources and have a range between 0.19 – 
11 mM for pyruvate and 0.11 – 5.1 mM for ASA (Table 1.1).   
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Figure 1.4 – E. coli DHDPS with ʟ-lysine bound at the active site.  (PDB: 2ATS) The green line demarcates 
the tight dimer interface, and the red line marks the weak dimer interface.  The inhibitor lysine is shown as 
purple spheres, bound to the allosteric site. 
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Figure 1.5 – Interdigitation of Aromatic Residues at the Strong Dimer Interface  Cj-DHDPS:pyr:lys 
(PDB:4M19)47 solved by Cuylar Conly prior to undertaking this thesis work. Tyrosine 111 crosses the strong 
dimer interface to complete the active site catalytic triad of the neighboring monomer.  The tight dimer 
interface is indicated by the green line.  The ʟ-lysine inhibitor is shown in purple. 
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Table 1.1 – Kinetic constants of DHDPS from various sources 
Organism KM Pyruvate (mM) KM ASA (mM) 
Bacteria   
Campylobacter jejuni19 0.35 0.16 
Escherichia coli41 0.19 0.12 
Bacillus subtilis48  1.07 3.13 
Bacillus licheniformis49  5.3 2.6 
Bacillus sphericus50  9 5.1 
Bacillus megaterium51  0.5 0.46 
Plants   
Zea mays18 2.1 0.6 
Pisum sativum17  1.7 0.4 
Triticum aestivium16, 52  11.8 0.8 
 
 
Scheme 1.2 – The reaction catalyzed by DHDPS.  Biosynthesis of DHDP occurs in two steps.  First the 
DHDPS enzyme catalyzes condensation of pyruvate and ASA forming HTPA.  HTPA is released into the 
solution where it spontaneously dehydrates to form DHDP. 
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1.3.1 C. jejuni DHDPS Reaction Mechanism 
The active site of Cj-DHDPS centers on the catalytic Lys166, and includes the 
conserved catalytic triad of Tyr137, Thr37, Tyr111' (where the primed residue comes from 
the neighboring monomer of the tight-dimer). The active site is lined by a number of other 
residues believed to play minor roles in catalysis including: R142, I207, T48, G190, and 
N252.  DHDPS from C. jejuni has received less attention than other species therefore many 
details of the proposed mechanism have been inferred from mutagenesis studies on closely 
related homologues including E. coli DHDPS; where sequence alignment reveals that C. 
jejuni DHDPS shares 37% sequence identity with E. coli DHDPS.53-55  The details of the 
proposed catalytic mechanism of Cj-DHDPS are outlined in Scheme 1.3.  The kinetic 
constants of Cj-DHDPS are shown in Table 1.2.19  Substrate inhibition which is reported 
in some other species is not observed in DHDPS from C. jejuni.19, 21   
 
 
Table 1.2 –  Kinetic Constants for C. jejuni19 
KM(pyr) KM(ASA) kcat kcat/KM(pyr) kcat/KM(ASA) 
0.35 ± 0.02 mM 0.16 ± 0.01 mM 76 ± 1 s-1 (2.2 ± 0.1) x 105 M-1s-1 (4.8 ± 0.3) x 105 M-1s-1 
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Scheme 1.3 – Detailed catalytic mechanism of dihydrodipicolinate synthase.38, 40, 55 
  
 
1.4 Structure of Dihydrodipicolinate Synthase 
DHDPS from many species exists as a homotetramer in solution, 18, 44-46 however 
dimeric forms also occur,46, 56 and one DHDPS from Pisum sativum was reported as 
trimeric.17  The tetramer is best described as a dimer of tight dimers, and any dimeric forms 
constitute only the tight-dimer which is considered to be the minimum biologically relevant 
form.40  The monomer has a TIM barrel fold, a common versatile fold observed in many 
enzymes, consisting of eight α-helicis and eight β-strands.57, 58  DHDPS contains two 
structural domains: the N-terminal domain of DHDPS forms an 8-strand β/α-barrel 
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structure connected to the α-helical C-terminal domain.58  In tetrameric DHDPS there are 
four independent active sites and two dimeric allosteric sites, where ʟ-lysine binds, located 
at the tight-dimer interface (Figure 1.4). 
Many residues are conserved between species at the tight dimer interface.12, 59  In 
particular the side chains of tyrosine 110 and 111 (C. jejuni numbers) of each monomer 
interdigitate, forming a hydrophobic stack of their aromatic rings.58  This stacking forms a 
dense hydrophobic core and is considered to be responsible for the tight association 
between monomers.  The backbone conformation of these tyrosines is within the forbidden 
region of the Ramachandran plot, suggesting an evolved purpose in catalysis and/or 
inhibition.12, 47   
The tetramer is completed by a loose association of tight dimers.  In bacterial DHDPS 
tetramerization leaves a large water-filled cavity in the center of the tetramer.  In this so 
called head-to-head arrangement each monomer has contact with only two other monomers 
(figure 1.5).45, 60  In contrast, plant DHDPS are known to form a back-to-back tetramer.  In 
this back-to-back arrangement the weak dimer interface is on the opposite side of the tight 
dimer (relative to bacteria DHDPS), and the contact surface is entirely different.45, 59  Each 
monomer has one independent active site, and one half of a dimeric allosteric site; which 
is completed by the neighboring monomer at the tight dimer interface.  In bacterial DHDPS 
the active site opens into the center of the tetrameric arrangement, and the allosteric sites 
open away from the tetramer at opposite poles; while in plant DHDPS the active sites open 
away from the tetramer, and allosteric sites are open to the center of the tetramer (figure 
1.6).45, 60  
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Figure 1.6 –  Cj-DHDPS:pyr:lys tetramer (PDB:4M19)47 and Vitis vinifera (4HNN) Tetramer.60   
Panel A – The blue arrows indicate the allosteric binding site at the tight dimer interface. The red line denotes 
the weak dimer-dimer interface. Bound ʟ-lysine is depicted as spheres.  Black arrows indicate the location of 
each independent active site.  
*Structure was solved by Cuylar Conly during an undergraduate research project prior to undertaking this 
thesis.  
Panel B –  DHDPS from plants such as V. vinifera form a "back-to-back" tetramer.  ʟ-Lysine (purple spheres) 
is shown bound to the allosteric site which opens to the center of the tetrameric arrangement.  The black 
arrows denote the entrance to the active site which faces out from the tetramer. 
 
 
In E. coli, Miriwaldt et al.(1995) mapped nine residues in 3 helices from each monomer 
that form interactions across the weak dimer interface.58 Other species have been found to 
have many more weak dimer contacts;39, 61, 62 as much as 20 residues from each monomer 
in Thermotoga maritima.63  The structural role in tetramerization of these residues is 
suggested by the formation of a dimeric species, unable to form a tetramer.38, 64  In C. jejuni 
it was found that ʟ-lysine inhibition is cooperative across the weak dimer interface, as 
determined by Hill coefficients > 2.0.19  The Hill coefficient indicates that when ʟ-lysine 
binds at one dimeric allosteric site, it increases the affinity of ʟ-lysine at the other dimeric 
allosteric site across the weak dimer interface.  Therefore, interactions at the weak dimer 
interface must play a role in catalysis and inhibition, in addition to their structural role. 
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The active site of the enzyme is at the C-terminal ends of the β-strands, where one of 
the loops forms a short helix with a highly conserved arginine (Arg142 in C. jeuni 
numbering) whose side chain is situated over the β/α-barrel.  The active site surrounds the 
key catalytic residue: lysine (166 in C. jejuni DHDPS).  The absolute necessity of the 
catalytic lysine (K166) has been called into question in DHDPS from E. coli where the 
enzyme was demonstrated to function at 13% of the wild-type catalytic efficiency in the 
absence of the catalytic lysine (K166).65  Three more residues comprising the 'catalytic 
triad' are also highly conserved; two tyrosine's and a threonine.38, 66, 67  One tyrosine of the 
catalytic triad comes from the neighboring monomer crossing the tight dimer interface to 
do so.38, 47   
The allosteric site of DHDPS is located at the interface of the monomers forming each 
tight dimer of the tetramer.  ʟ-Lysine binding pockets are situated side by side on each 
monomer, forming a large regulatory site, where residues of both adjacent monomers 
contribute to binding of each molecule of ʟ-lysine.  Crystal structures of ʟ-lysine bound at 
the allosteric site of DHDPS have been obtained for several species (Arabidopsis thaliana, 
C. jejuni, E. coli, Pseudomonas aruginosa, Vitis vinifera), and residues responsible for 
coordination are known for these DHDPS.19, 40, 45, 47, 68, 69   
The residues forming the allosteric site are reasonably conserved across DHDPS from 
species which are sensitive to ʟ-lysine inhibition: gram negative bacteria, and plants 
(Figure A.1).  However, the allosteric site of DHDPS from ʟ-lysine-insensitive species is 
poorly conserved.39, 59, 63  These insensitive DHDPS often have naturally substituted 
residues in the allosteric cleft which either add bulk, invert electrostatic charge, or both.23, 
56  Notably, the allosteric site of DHDPS from Staphylococcus aureus,56 Corynebacterium 
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glutamicum,23 and T. maritima,63   are incompatible with ʟ-lysine binding.  In S. aureus for 
example, two of the eight residues making direct hydrogen bonds to ʟ-lysine in C. jejuni 
have been replaced by lysine residues.  These are His59 and Glu88 in C. jejuni, which are 
Lys58 and Lys86 in S. aureus respectively.56  The result of these mutations is that the 
allosteric site of Sa-DHDPS is shallower, more like a saucer than a cup, with a 
substantially different charge profile (figure 1.7).  The significance of these residues is 
confirmed in maize DHDPS, where a point variant of Glu162 to Lys (equivalent to Glu88 
in C. jejuni DHDPS) resulted in insensitivity to ʟ-lysine inhibition.12, 70  It is worth noting 
that although these enzymes are not inhibited by ʟ-lysine, there remains an opportunity to design 
non-lysine allosteric inhibitors for those enzymes insensitive to ʟ-lysine if we can better 
understand the mechanism of signal transduction.56 
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Figure 1.7 – Allosteric Site of S. aureus DHDPS superimposed on C. jejuni DHDPS.  Sa-DHDPS (3DI1) 
is shown in green superimposed on Cj-DHDPS shown in ghost white.  Key residues in the allosteric site of 
Cj-DHDPS (4LY8) are labeled for reference.  The conserved residues are Y110 and N84.  Other key residues 
have been substantially substituted. 
 
1.4.1    Structure of C. jejuni DHDPS 
Two crystal structures of C. jejuni DHDPS have been deposited in the PDB by the 
Center for Structural Genomics of Infectious Disease (CSGID): one in the apo-form (PDB: 
3M5V) and one with pyruvate at the active site (PDB: 3LER).  DHDPS from C. jejuni is a 
tetramer in solution and when crystallized.  There is a high degree of conservation in 
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secondary and tertiary structures relative to DHDPS from other species.  DHDPS from C. 
jejuni is closely related to DHDPS from E. coli which shares a 37% sequence identity, and 
all major structural features are conserved.53, 54  The tetramer forms in the head-to-head 
fashion typical of bacterial DHDPS.  The four active sites are open to a large cavity at the 
center of the tetramer.  The allosteric site of DHDPS is located at the interface of the 
monomers that make each tight dimer in the tetramer.  ʟ-Lysine binding pockets are 
situated side by side on each monomer, forming a large double binding site, where amino 
acid residues of both adjacent monomers are involved in binding each molecule of ʟ-
lysine.47 
 The crystal structures of DHDPS with ʟ-lysine bound at the allosteric site have been 
obtained for several species including Cj-DHDPS, which was solved by Conly et al. shortly 
before undertaking this thesis.47  The residues of importance at the allosteric site are readily 
predicted from comparison to DHDPS from homologous species (Arabidopsis thaliana, E. 
coli, Pseudomonas aeruginosa, Vitis vinifera).19, 40, 45, 68, 69   
The allosteric site of C. jejuni DHDPS is shown in Figure 1.8.  Each molecule of ʟ-
lysine will make hydrogen bonds with Ser51, Ala52, Leu54, His59, Tyr110, Asn84', and 
Glu88', while  His56 can form a cation π-interaction with the ε-amino group of ʟ-lysine 
(the amino acid residues indicated with a prime belong to the adjacent monomer (Figure 
1.8).47  The most conserved residue in the allosteric site of all DHDPS are Tyr110 and 
Asn84' (Figure A.1).  Despite the sequence divergence among bacterial DHDPS, including 
allosteric site residues, the architecture of allosteric sites of DHDPS from different species 
is very similar. 
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Figure 1.8 – Hydrogen bonding of ʟ-Lysine in the Allosteric Site of Cj-DHDPS.  Monomer A is depicted 
in orange, monomer B is shown in blue, and ʟ-lysine is shown as purple.  Each hydrogen bond is denoted by 
a blue dashed line. 
 
1.5 Inhibition of Dihydrodipicolinate synthase 
Dihydrodipicolinate synthase is the key regulation point in the biosynthesis of ʟ-lysine 
in plants and bacteria.  The activity of DHDPS is regulated by allosteric feedback inhibition 
from the pathway’s end product, ʟ-lysine.12, 14, 19, 52, 59, 71  Despite variations in ʟ-lysine 
sensitivity it is believed that the mechanism of inhibition will be the same across all species 
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of DHDPS.  To date, variable sensitivities to ʟ-lysine across species have been explained 
by alterations in the ʟ-lysine-binding site.  As discussed in section 1.4,  DHDPS can be 
divided into three groups based on their sensitivity to ʟ-lysine inhibition.72  Plant enzymes 
are strongly inhibited by ʟ-lysine with IC50’s between 0.01 – 0.05 mM.17, 18, 52, 73  Gram 
negative bacteria such as C. jejuni, produce DHDPS which is weakly inhibited by ʟ-lysine 
with IC50’s between 0.25 – 1.0 mM.14, 19, 50, 74  In Gram positive bacteria DHDPS appears 
not to be inhibited by ʟ-lysine at all (IC50 > 10 mM).27, 48, 51, 75-77 
1.5.1    Kinetic Models of ʟ-Lysine Inhibition 
Most DHDPS display partial ʟ-lysine inhibition, meaning some residual activity 
remains at saturating concentrations of ʟ-lysine, although there are a few examples of plant 
DHDPS where full ʟ-lysine inhibition is observed.71, 78  DHDPS from Gram-negative 
bacteria can be weakly, moderately or strongly inhibited by ʟ-lysine showing IC50 values 
from micromolar to millimolar range: 53 µM for N. meningitis,20 0.2 mM for E. coli,79 and 
0.7 mM for Sinorhizobium meliloti.80  Various research groups have reported different 
mechanisms of ʟ-lysine inhibition.  For instance: in Triticum aestivum (wheat) ʟ-lysine is a 
competitive inhibitor with respect to ASA and a noncompetitive inhibitor with respect to 
pyruvate;16 in DHDPS from Zea mays (corn) ʟ-lysine is a competitive inhibitor against 
pyruvate and a mixed inhibitor with respect to ASA.18  From E. coli and Bacillus subtilis 
ʟ-lysine is a non-competitive partial inhibitor with respect to ASA.21, 45  Due to the 
contradictory nature of reported inhibition models, the mechanism of ʟ-lysine inhibition 
remains controversial. Binding of ʟ-lysine to DHDPS has been shown to be cooperative 
for DHDPS from several sources including E. coli, S. meliloti, and V. vinifera.41, 45, 81, 82  
Only recently in the reports of Atkinson et al. and Skovpen et al. have cooperativity 
20 
 
coefficients been included while fitting kinetic models to experimental data.16, 17, 19, 41, 45, 81, 
82 
1.5.2    Plant DHDPS are highly sensitive to ʟ-Lysine Inhibition  
All known plant DHDPS are sensitive to ʟ-lysine inhibition, and this is one of the 
reasons why unmodified crops do not accumulate ʟ-lysine.  A number of research groups 
are working to increase ʟ-lysine content in crops to improve nutritional value.  Expressing 
bacterial DHDPS (ʟ-lysine-insensitive or reduced ʟ-lysine sensitivity) in several plants has 
achieved higher levels of ʟ-lysine in some crops, while other transgenic plants do not 
accumulate ʟ-lysine in high concentrations.  This is likely due to the existence some other 
down-regulation mechanism, or increased utilization of excess ʟ-lysine.45, 83-85    
1.5.3    DHDPS lacking ʟ-Lysine Inhibition 
DHDPS from gram-positive and select gram negative bacteria are known to be 
insensitive to ʟ-lysine inhibition.27, 48, 51, 56, 75-77  Among the ʟ-lysine sensitive DHDPS 
(from plants and gram-negative bacteria) specific mutations at the allosteric site will reduce 
or eliminate ʟ-lysine inhibition.  For example, A. thaliana becomes totally insensitive to ʟ-
lysine feedback inhibition upon substitution of Trp53 (His53 in E. coli, His56 in C. jejuni) 
for Arg.78  Mutations in  Zea mays DHDPS including S157N, E162K, A166T, and A166V 
(A79, E84 and L88, respectively, in E. coli and S83, E88, L92 in C. jejuni) also results in 
an enzyme insensitive to ʟ-lysine.70  Increased ʟ-lysine accumulation was observed in 
maize cells transformed with a plasmid bearing the A166V mutated DHDPS maize gene.86 
Among the DHDPS of gram-positive bacteria, weak ʟ-lysine inhibition is most likely 
caused by variations in the amino acid composition of the allosteric site which are 
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unfavorable for ʟ-lysine binding.22, 56, 63  For instance, binding is prevented by a clash of 
positive charges with the side chain of the allosteric ʟ-lysine when His56 is replaced by 
either lysine or arginine.  DHDPS from Gram-positive Corynebacterium glutamicum has 
Lysine in position 56, and is insensitive to ʟ-lysine feedback inhibition, making this 
organism useful for industrial production of ʟ-lysine.87  Staphylococcus aureus, known for 
its resistant strains to front-line antibiotics, contains dimeric DHDPS.56  This enzyme has 
Lys in positions 56 and 84, making the allosteric site shallow and changing the charge 
distribution in the binding pockets, with the end result of this enzyme being insensitive to 
ʟ-lysine inhibition.56  Currently there is no natural inhibitor known for ʟ-lysine-insensitive 
gram-positive DHDPS; making the design of inhibitors for the allosteric site an especially 
challenging task.  A deeper understanding of the mechanism for allostery in DHDPS would 
aid in de-novo inhibitor design. 
1.5.4    Inhibition of DHDPS from C. jejuni 
Skovpen and Palmer have recently characterized the inhibition of DHDPS from C. 
jejuni with its natural allosteric inhibitor, ʟ-lysine.19  C. jejuni DHDPS is strongly inhibited 
by ʟ-lysine with an apparent IC50 of 65 µM.19, 55  Substrate inhibition by ASA, which has 
been reported for DHDPS from some sources and/or with some ASA preparations, is not 
observed in DHDPS from C. jejuni.21  There is no evidence of significant cooperativity of 
substrates, but Hill coefficients indicate that there is cooperativity between allosteric sites 
across the weak dimer interface.19   
As with DHDPS from other species, Cj-DHDPS exhibits partial inhibition with 
approximately 10% residual activity at saturating concentrations of ʟ-lysine.19-21, 71  
Skovpen and Palmer find that ʟ-lysine binds highly cooperatively, and primarily to the 
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pyruvate substituted 'F form' of the enzyme during the ping-pong mechanism (Scheme 
1.1).19  ʟ-Lysine is an uncompetitive partial inhibitor with respect to pyruvate while ʟ-
lysine acts as a mixed partial inhibitor with respect to its second substrate, (S)-aspartate-β-
semialdehyde (ASA).  This differs from the kinetic models for inhibition reported for 
DHDPS from other sources.19 
Skovpen and Palmerdemonstrated in Cj-DHDPS that pyruvate promotes ʟ-lysine 
binding at the allosteric site, while ASA hinders the binding of ʟ-lysine.19, 55  In Cj-DHDPS, 
the IC50 value of ʟ-lysine decreases with increasing concentration of pyruvate up to a 
saturating value.  Conversely, IC50 values of ʟ-lysine increase with increasing 
concentration of ASA (Figure 1.9).  Simply stated, the presence of pyruvate increases the 
affinity of the allosteric site for ʟ-lysine, while the presence of ASA decreases the affinity 
of the allosteric site for ʟ-lysine.  In each case, the properties of the allosteric site have 
changed subtly, yet no structural link from allosteric site to active site has been clearly 
identified.   
 
Figure 1.9 – 19, 55  Relationship between IC50 of ʟ-lysine and concentration of substrates.  (●) Pyruvate is 
the variable substrate; concentration of ASA is 2.24 mM; (○) ASA is the variable substrate; concentration of 
pyruvate is  3.50 mM. 
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It was reported that Hill coefficients vary from 2.0 to 3.2 depending on substrate 
concentrations.  That the degree of cooperativity exceeds 2.0 indicates that the two 
allosteric sites are not entirely independent and binding of ʟ-lysine at one allosteric site 
will affect the binding of ʟ-lysine at the diametrically opposed binding site.  Therefore, the 
enzyme functions as a tetrameric catalyst, rather than as a dimer of independent dimers.19, 
55 
Further to the complexity of the observed inhibition is that ʟ-lysine at high 
concentrations induces antagonistic cooperativity in the second substrate, ASA.  The 
presence of ASA drives up the apparent inhibition constant of ʟ-lysine, and the presence 
of ʟ-lysine drives up the apparent KM of ASA; when ASA binds the active site ʟ-lysine 
may be rejected at the allosteric site, and vice versa.  It is possible that the observed 
cooperativity between ASA at each active site may be enhanced due to a rejection of ʟ-
lysine at the allosteric site, which induces rejection of ʟ-lysine at other allosteric sites 
therefore removing inhibition at other active sites.  Notwithstanding the empirical 
evidence, specifics of the signal transduction between active site and allosteric site, and 
between antipodal allosteric sites, remain unclear. 
1.5.5    DHDPS from C. jejuni made insensitive to ʟ-lysine inhibition 
The residues forming the aromatic core at the tight dimer interface are obvious 
candidates for involvement in the allosteric mechanism.  Tyrosine 111 crosses the tight 
dimer interface to complete the catalytic triad of the neighboring monomer while its 
neighbor tyrosine 110 makes a direct hydrogen bond to the inhibitor ʟ-lysine in the 
allosteric site.  Recently Skovpen and Palmer successfully mutated Tyr110 to 
phenylalanine in Cj-DHDPS.47, 55  The Y110F mutation in Cj-DHDPS dramatically affects 
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the ability of the enzyme to be inhibited by ʟ-lysine. Kinetic data obtained for the mutant 
Y110F indicates that the mutant apparently operates by the same kinetic mechanism as wt-
Cj-DHDPS, and shows only minor differences in the values of the Michaelis constants, as 
shown in Table 1.3.19, 47, 55  The value of kcat, however, is reduced about two-fold relative 
to wild-type Cj-DHDPS.  The importance of the side chain of Y110 to catalysis is not 
obvious, but likely derives from some effect on the adjacent Y111 which completes the 
catalytic triad, or on the nearby secondary and tertiary structure elements at the tight-dimer 
interface.  The removal of the hydroxyl group results in an estimated ʟ-lysine IC50 of about 
40 mM, an increase of three orders of magnitude (Figure 1.10).47, 55  This makes the enzyme 
insensitive to ʟ-lysine regulation at its physiological concentrations, however, when 
sufficiently saturated (> 80 mM) the Y110F enzyme displays partial ʟ-lysine inhibition 
(Figure 1.10).47, 55  The effect on inhibition is surprisingly large, suggesting that this 
particular hydrogen bond is a key contributor to inhibitory signal transduction. 
 
Table 1.3 – Kinetic constants for Y110F and wt-DHDPS.19, 47, 55  
 KM(pyr), mM KM(ASA), mM kcat, s-1 kcat/KM(pyr), M-1s-1 kcat/KM(ASA), M-1s-1 
Wt19, 55 0.35 ± 0.02 0.16 ± 0.01 76 ± 1 (2.2 ± 0.1) x 105 (4.8 ± 0.3) x 105 
Y110F47, 55 0.19 ± 0.01 0.12 ± 0.01 33 ± 1 (1.8 ± 0.1) x 105 (2.7 ± 0.1) x 105 
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Figure 1.10 – 47, 55 ʟ-Lysine inhibition curves for wt-DHDPS and Y110F-DHDPS. Left: ʟ-lysine inhibition 
curve for Y110F, (ASA 0.12 mM, pyruvate 3.70 mM). Right: Comparison of ʟ-lysine inhibition for Y110F 
() and wild-type (), (ASA 0.16 mM, pyruvate 3.50 mM). 
 
 
1.5.6    Allosteric Site Inhibitors 
A number of millimolar inhibitors targeting the allosteric site of the enzyme have been 
reported. 41, 55, 88  Among them are homoserine lactone, 2-aminocyclopentanone, (S)-
glutamic acid, (S)-aspartic acid, and S-(2-aminoethyl)-ʟ-cysteine (ʟ-thialysine): a ʟ-lysine 
mimic containing a sulfur atom.88  Despite a high structural similarity to ʟ-lysine, ʟ-
thialysine binds ten times more weakly in E. coli DHDPS than ʟ-lysine.41   
ʟ-Thialysine (Figure 1.11) is a very close mimic of ʟ-lysine, having just one replacement 
of the methylene group for sulfur in the side chain.  Yet ʟ-thialysine is a much weaker 
inhibitor.  In experiments with E. coli DHDPS, ʟ-thialysine has an inhibition constant about 
one order of magnitude (IC50 is approximately 30x higher) higher than that of ʟ-lysine.41  
C. jejuni DHDPS is even less sensitive to ʟ-thialysine inhibition than the E. coli enzyme, 
showing an apparent IC50 of 2 mM.
55   
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Figure 1.11 – ʟ-lysine and ʟ-thialysine 
 
Until recently, there have been no attempts at rational design of allosteric inhibitors for 
DHDPS.  Based on results from isothermal titration calorimetry, Phenix and Palmer 
suggested an effective inhibitor design should mimic a pair of bound ʟ-lysine molecules.82  
Later, Skovpen and Palmer successfully synthesized (2R,5R)-2,5-diamino-2,5-bis(4-
aminobutyl)hexanedioate colloquially known as "R,R-bislysine", which mimics two ʟ-
lysine molecules by joining the α-carbons with a two-carbon linker (Figure 1.12).55  This 
bis-inhibitor analog is over two orders of magnitude more effective than ʟ-lysine itself, 
likely because the entropic barrier to binding of the second inhibitor molecule has been 
eliminated.82   
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Figure 1.12 – (2R,5R)-2,5-diamino-2,5-bis(4-aminobutyl)hexanedioate; better known as R,R-bislysine 
 
1.5.6.1         R,R-bislysine is a potent Allosteric Inhibitor 
Similar to ʟ-lysine, R,R-bislysine is a partial inhibitor of Cj-DHDPS.19  At saturating 
concentrations of R,R-bislysine (>1.7 µM) the enzyme still demonstrates 7 – 10% of the 
maximal activity (Figure 1.13).55  Binding of R,R-bislysine is cooperative and the values 
of Hill coefficients (1.6 and 1.7) indicate that binding of a second molecule of R,R-
bislysine at one pair of adjacent allosteric sites in the dimer promotes binding of one 
molecule of R,R-bislysine at the polar opposite allosteric site of the other dimer.  In other 
words, Cj-DHDPS demonstrates inter-dimer cooperativity upon binding of R,R-bislysine.  
The inhibitor does not form any covalent bonds with the enzyme, and is therefore 
reversible.  Unlike ʟ-lysine, R,R-bislysine binds (and demonstrates inhibitory properties) 
to both the free enzyme (E form) and the enzyme-pyruvate complex (E:pyr) with different 
affinities, indicating a mixed partial model of inhibition.55  R,R-bislysine binds with similar 
affinity to all enzyme forms, with an average inhibition constant of 200 nM.  The inhibitory 
activity of R,R-bislysine is approximately 310 times higher than that of ʟ-lysine. 
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** Figure adapted with permission from the Thesis of YuliaSkovpen.55  
Figure 1.13 – R,R-bislysine inhibition curves for wild type DHDPS and Y110F. Concentrations of 
substrates: ASA 0.10 mM, pyruvate 3.7 mM.  
 
Prior to attempting the synthesis of R,R-bislysine, the inhibitory properties of another ʟ 
-lysine mimic, α-methyl-DL-lysine (Figure 1.14) was tested.  These results indicate that 
the methyl group at the α-position dramatically decreases inhibitory properties of the 
molecule (IC50
app > 10 mM), possibly by preventing proper binding of molecules of the 
inhibitor in the proximal allosteric sites.55  
 
Figure 1.14 – α-methyl-DL-lysine  
 
1.5.6.2         R,R-bislysine Inhibits the ʟ-Lysine insensitive Y110F-DHDPS 
The Y110F mutation dramatically affects the ability of the enzyme to be inhibited by ʟ 
-lysine.  The removal of the hydroxyl group results in an estimated ʟ-lysine IC50 of about 
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40 mM; an increase of three orders of magnitude (Figure 1.10).47, 55  Despite the loss of 
sensitivity to the natural inhibitor, the synthetic inhibitor bislysine is capable of strongly 
inhibiting the Y110F mutant DHDPS.  The inhibitory efficiency of R,R-bislysine toward 
Y110F is almost as high as for wt-DHDPS (Figure 1.13).55  R,R-bislysine binds to Y110F 
approximately 100,000 times stronger than ʟ-lysine.  These recent inhibition results 
demonstrate that Tyr 110 is important for binding and inhibition of the natural inhibitor ʟ-
lysine, but they are not crucial for R,R-bislysine.  The high inhibitory effectiveness of R,R-
bislysine against Y110F indicates that Tyr110 is not the only essential component of the 
signal transduction system in C. jejeuni DHDPS.  Stronger inhibition may be attributable 
to tighter binding, or enhanced activation of allosteric mechanisms.  It is anticipated that 
crystallization of the synthetic inhibitor bislysine, with each of wild-type and Y110F-
DHDPS would provide insight into the mechanism for enhanced inhibition, and therefore 
natural inhibition of ʟ-lysine. 
1.6 Proposed Mechanism for Signal Transduction 
The exact mechanism of signal transduction from allosteric site to active site is not yet 
completely understood, although available crystal structures and molecular dynamics 
simulations allow us to propose a mechanism of allosteric regulation.  The carboxylic 
group of the allosteric ʟ-lysine creates a hydrogen bond with the phenolic OH of Tyr110, 
which may be altering its position.  This Tyr110 movement promotes a shift of Tyr111, 
which is a residue of the catalytic triad, and therefore its displacement causes a reduction 
in catalytic effectiveness within the active site.  Tyr110 participates in ʟ-lysine binding by 
donating a hydrogen bond to the carboxyl group of ʟ-lysine, while Tyr111 is a part of the 
catalytic triad. It is likely that signal transduction occurs via Tyr110 movement upon ʟ-
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lysine binding, where a shift of Tyr110 affects the position of the catalytic Tyr111, and 
alters the catalytic activity of the enzyme (Figure 1.15).47  Mutation of Tyr110 to Phe110 
has been found to significantly reduce the effectiveness of ʟ-lysine as an allosteric inhibitor. 
It is unclear if reduced the lack of inhibition is due to reduced binding affinity or disruption 
of signal transduction to the active site.47  
 
Figure 1.15 – Y110/111 links the allosteric site to the catalytic triad (Cj-DHDPS; PDB: 4M19).  A series 
of hydrogen bonds links ʟ-lysine in the allosteric site via Y110/111 to the catalytic triad in the active site.  
Monomer A is shown in orange, monomer B is shown in blue and ʟ-lysine is shown in purple.  The applicable 
hydrogen bonds are denoted with dark blue dashed lines.  
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Furthermore, according to Atkinson et al. (who studied V. vinifera DHDPS), Tyr131 
(equivalent of Tyr110 in C. jejuni) forms a hydrophobic stack with the catalytic triad 
residue Tyr132' (Tyr111' in C. jejuni).45  Disruption of this stack upon ʟ-lysine binding 
displaces the hydroxyl group of Tyr132' (Tyr111' in C. jejuni) and slows down or disrupts 
the function of the catalytic triad.  Previous inhibition studies of DHDPS consistently show 
that the presence of pyruvate somehow affects the sensitivity of the allosteric site for 
binding ʟ-lysine.  This is consistent with the proposed mechanism in which pyruvate binds 
before ʟ-lysine. 
The role of the aromatic residues Tyr110/111 is decidedly crucial for inhibition of 
DHDPS with its natural inhibitor, ʟ-lysine.  However, recent evidence for strong inhibition 
of Y110F-DHDPS by the R,R-bislysine indicates that Tyr110/111 is not the sole conduit 
for allosteric communication.  It is far more likely that allosteric inhibition is the result of 
a combination of structural effects which vary in the magnitude of their importance within 
the complete mechanism of allosteric inhibition.  To understand the various ways an 
allosteric inhibitor can have a negative effect on activity at the active site will aid in 
designing inhibitors across the diversity of homologous DHDPS. 
To understand inhibition as a sum of parts process we must also consider several other 
theories that have been proposed to explain mechanism of allosteric inhibition.  In Ec-
DHDPS, it was identified that inhibition may be linked to perturbation of the proton relay 
of the catalytic triad, resulting from a small change in the position of Tyr107' (Tyr111 in 
C. jejuni).40  Additionally, it has been proposed that Schiff base formation may be 
prevented by occlusion of a conserved water channel connecting the active site and 
allosteric sites.40  Furthermore, ʟ-lysine may stabilize a less catalytically competent 
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conformer to prevent the binding or reaction of ASA.82  The observed modes of inhibition 
suggest that ʟ-lysine and pyruvate can be bound at the same time, and kinetic studies of 
cooperativity show that pyruvate actually improves ʟ-lysine binding.19, 21, 65  More recently, 
the importance of the quarternary structure has been demonstrated.89  Dimeric variants of 
DHDPS exhibit reduced catalytic activity, suggesting that the tetrameric structure 
optimizes enzyme dynamics for catalysis.  Griffin et al. probed the sensitivity of the 
dimer−dimer interface with a series of point mutations90 and showed that single-point 
mutations have an effect on both catalysis and tetramerization.  In general the dimer−dimer 
interface is small and not well conserved across species; however, between DHDPS from 
E. coli and C. jejuni there is more agreement in this region than between DHDPS from 
other species.40, 53, 55, 90  It is not yet clear how ʟ-lysine binding affects the tetrameric 
structure or dynamics.  With more evidence we may begin to understand which 
mechanisms contribute the greatest, or most cohesive, effect to inhibition in any one, or 
all, DHDPS homologues. 
1.7 Competitive Active Site Inhibition and ASA 
Most research groups focus their attention on active site inhibitors of DHDPS.  There 
are a few weak inhibitors reported to be competitive with respect to ASA, such as succinate 
β-semialdehyde, and with respect to pyruvate, such as 2-ketobutyrate, 2-ketovalerate, 3-
fluoropyruvate and glyoxalate.12, 41  Several inhibitors of DHDPS are shown in Figure 1.16 
and given in Table 1.4.  Product mimics such as dipicolinic (1.1) and chelidamic (1.3) acids 
are weak millimolar inhibitors.41, 91  Interestingly, inhibition of growth of the late blight 
fungus Phytophthora infestans by millimolar concentrations of dipicolinic and chelidonic 
acids  (1.1 and 1.2 respectively) was observed  in vivo using infected potato leaf discs.92 
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Moderate inhibition of E. coli growth was observed for the piperidine diester (1.4) and 
chelidamic (1.3) acid at 20 mM.93  2-Ketopimelic acid was found to be a weak irreversible 
inhibitor, and based on this observation, several compounds mimicking the acyclic 
enzyme-bound condensation product of ASA and pyruvate have been proposed.12, 94  The 
continuation of that work was synthesis of phenolic ketoacid derivatives (1.7 and 1.8), 
which condense with the enzyme in a time-dependent manner.95  Analogues of 4-oxo-
heptanoic acid (1.5 and 1.6) proved to be irreversible inhibitors of DHDPS.96  The 
disadvantage of an active site inhibitor is the potential for non-specific aldolase 
interactions, and for the inhibitor to be overwhelmed by increased amounts of substrate.  
Furthermore current efforts proceed without a crystallographic model for binding of ASA 
in the active site, or what effect this may have on the allosteric inhibition.  
 
 
 
Figure 1.16 – Inhibitors targeting the active site of DHDPS 
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Table 1.4 – Inhibitors targeting the active site of DHDPS. 
Compound Inhibition 
parameter 
Organism Reference 
1.1 Ki 11 mM wrt pyr;  
18 mM wrt ASA 
1 mM decrease 
activity by 75% 
E. coli 
 
P. infestans 
41, 91 
 
92 
1.2 1 mM decrease 
activity by 54% 
P. infestans 92 
1.3 IC50 22 mM E. coli 
91 
1.4 IC50 20 mM E. coli 
91 
1.5 Ki
app 4.95 mM E. coli 96 
1.6 Ki
app 1.63 mM E. coli 96 
1.7 Ki
app 11.8 mM E. coli 95 
1.8 Ki
app 12.0 mM E. coli 95 
 
1.7.1    The bound conformation of ASA is unknown 
The second step in the reaction mechanism of DHDPS is the binding of ASA followed 
by aldol condensation (Scheme 1.1, Scheme 1.3).  In solution, ASA exists as an equilibrium 
of a number of species (Figure 1.3): however, the specific configuration which binds and 
reacts within the active site of DHDPS is unknown.12, 41, 42  At physiological pH the 
proportion of ASA in the hydrated form is estimated to be as high as 85%.97  Under 
physiological conditions the ASA lactol is not observed by 1H NMR.42  Blickling et al. 
have noted that G190 and R142 (Cj. numbering) are well placed in the active site to 
coordinate the hydroxyl groups of the hydrate.12  For these reasons it is widely believed 
that the aldehyde or hydrate form of ASA must be the catalytically relevant species.  
However, no crystal structure of DHDPS from any species has ever been determined with 
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ASA bound to the active site.  The absence of a suitable model for the binding of the natural 
substrate may be retarding efforts to design an active site inhibitor.   
The principle challenge of obtaining a crystal structure lies in the reactivity of the ASA.  
ASA may only bind once the enzyme has been activated by formation of the K166-pyr 
Schiff base.  Unfortunately, the activated enzyme will react with ASA preventing any 
stable complexation suitable for X-ray diffraction, and ASA will not bind in the absence 
of pyruvate.  One potential strategy is to create a DHDPS dead end complex which will 
approximate the active site of the catalytically competent DHDPS:pyr enzyme. 
If the double bond associated with the K166-pyruvate can be reduced the result would 
be a non-reactive tetrahedral adduct (Figure 1.17).  This strategy has been employed by 
others for various investigations; most often to demonstrate the formation of the Schiff 
base.15, 44, 71  Incubation of DHDPS with borohydride and either pyruvate or ASA is used 
as evidence that pyruvate is the first substrate.  DHDPS activity was eliminated when 
incubated with pyruvate and sodium borohydride, but not ASA and sodium borohydride.  
If the DHDPS:pyr complex is first inactivated by reduction, it may be possible to crystallize 
the dead end complex with ASA bound in the unreactive catalytic site.  No attempts at this 
have ever been reported. 
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Figure 1.17 – Reaction Scheme for the reduction of the K166-pyruvate Schiff Base Using sodium 
cyanoborohydride the DHDPS:pyr Schiff base is reduced to an sp3 hybridized dead-end complex. 
 
1.8 Proposal and Research Objectives 
The main goal of this research is to provide crystallographic data and structural analysis 
of DHDPS yielding insights about the natural allosteric inhibition mechanism that will be 
valuable for the design of synthetic inhibitors.  The attention of most research groups 
studying DHDPS is focused on inhibitors binding at the active site, and aside from random 
inhibitor screening, no attempts have been made to develop an inhibitor to specifically 
target the allosteric site.  The allosteric site was chosen as a target because noncompetitive 
inhibitors cannot be overwhelmed by an excessive amount of substrate, therefore pyruvate 
and ASA inside the cell would not interfere with allosteric inhibitors.  Until recently there 
has been no known noncompetitive inhibitor stronger than the natural inhibitor ʟ-lysine.  
Regardless of the strength of any reported noncompetitive inhibitors, the mechanism of 
allosteric signal transduction remains open to debate. 
This study aims to determine the subtleties of the allosteric mechanism of inhibition.  
This will be accomplished by obtaining crystal structures of wild type and Y110F DHDPS 
with different inhibitors of varying efficacy.  The structural effect that inhibitors have on 
the enzyme will be investigated and correlated to the known strength of each inhibitor.  
Ideally the crystal structures of wild type and Y110F DHDPS with different inhibitors will 
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allow us to identify those structural features which are most critical to signal transduction 
from the allosteric site to the active site.  Structural information gleaned throughout this 
study will contribute to the existing body of knowledge to rationally design synthetic 
inhibitors which will lead to the development of new clinical antibiotics.  
The secondary objective of this study will endeavor to obtain diffraction quality crystals 
of DHDPS with ASA bound to the active site and to solve the structure at a sufficient 
resolution to properly model ASA within the active site.  Such attempts have not been 
reported for DHDPS from any source.  The strategy employed will first attempt to create a 
non-reactive dead-end complex of DHDPS and pyruvate.  If this dead-end DHDPS will be 
stable in solution then crystallization with ASA is theoretically possible. 
1.9 Contributions of the Author to the Work Presented in this Thesis 
All experimental work was performed by the candidate except: 
 Cloning and transformation of the dapA gene from C. jejuni into E. coli XL1-Blue strain 
was performed by Yulia Skovpen; 
 DHDPS mutant Y110F was generated by Shuo Li; 
 Full kinetic characterization and inhibition studies of wt- and Y110F DHDPS was 
conducted by Yulia Skopvpen; 
 Synthesis of ASA was performed by Yulia Skovpen; 
 Design and synthesis of bislysine was undertaken by Yulia Skovpen. 
 The crystal structure of wt-DHDPS:pyr:lys (PDB: 4M19) determined by Cuylar Conly 
prior to initiation of this Thesis as part of an undergraduate Honours Project. 
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Inclusion of work done by Shuo Li and Yulia Skovpen is done so with their permission, 
and with that of their supervisor Dr. David Palmer. 
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Chapter 2   EXPERIMENTAL METHODS 
2.1 Chemical Reagents 
2.1.1    ASA Synthesis 
ASA was synthesized according to the reported procedure.1  Due to the hydroscopic properties 
of ASA, the concentration of each newly prepared solution of ASA was determined using the 
DHDPS-DHDPR coupled kinetic assay as previously described, in the presence of excess NADH.2  
ASA was synthesized by Yulia Skovpen who generously shared her secret stash. 
2.1.2    Bislysine Synthesis 
Bislysine was synthesized by Yulia Skovpen according to the procedures of Skovpen and 
Palmer,3 and generously provided on demand. 
2.2 Crystallographic Studies of DHDPS 
2.2.1    Protein Preparation 
2.2.1.1         Cloning and overexpression 
C.jejuni genomic DNA was prepared by Dr. Bonnie Chaban, Western College of Veterinary 
Medicine, University of Saskatchewan.  The dapA genes (encoding DHDPS) were PCR-amplified 
from genomic DNA using Kapa HiFi DNA polymerase (Kapa Biosystems) with the following 
forward and reverse primer pairs: 
5'-GAAAGGGGATCCATGGATAAAAATATTATCATTGGGGC-3', 
5'-ATTCTGCTGCAGTTAAAATCCTTTGATCTTATATTTTTTCATCACTTC-3'. 
The dapA gene was ligated into a pQE-80L vector (Qiagen) as a BamHI/PstI restriction 
fragment using T4 DNA ligase (New England BioLabs).  E. coli XL1-Blue competent cells were 
then transformed with these plasmids. Colonies containing the correct recombinant plasmids were 
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identified by analysis of restriction enzyme products, with positive candidates sequenced by the 
DNA Technologies Unit of the National Research Council, Saskatoon SK, Canada.  
A plasmid containing the dapA gene (encoding DHDPS or its mutant, and bearing an N-terminal 
hexahistidine tag) was transformed into E. coli as previously described4.  The cells were cultured 
at 310 K with shaking in Terrific Broth media, containing 50 mg/L ampicillin until cultures reached 
an OD600 of 0.5 – 0.6.  Over-expression of DHDPS was induced with the addition of IPTG 
(isopropyl-β-D-thiogalactopyranoside) to a concentration of 0.5 mM and incubated for a further 
15 hours at 288 K.  Cells were pelleted in 500 mL batches at 277 K by centrifugation at 4400 x g 
for 30 minutes, and stored at 190 K.  The sample was chilled in an ice bath during all 
manipulations. 
2.2.1.2         Purification 
Frozen cell pellets (from 500 mL batches) were resuspended in 25 mL of lysis buffer (50 mM 
HEPES, 500 mM NaCl, 5% glycerol, 5 mM imidazole, pH 7.9) with 0.2 mg DNAse and 0.4 mg 
lysozyme.  Cells were disrupted by sonication (15 seconds on, 15 seconds off for 3 minutes, level 
6) using a Virisonic 600 Ultrasonic Cell Disrupter.  The supernatant was separated from the cell 
debris by centrifugation at 27000 × g for 10 minutes at 277 K.  The supernatant was passed through 
a 0.45 µm filter and loaded onto a 1 mL GE Health Care Gravis His Trap Column (GE Healthcare).  
The column was operated according to the manufacturers recommended procedure with the 
following modifications:  the concentration of imidazole in the binding buffer was changed from 
20 mM to 50 mM; an additional wash step using 100 mM imidazole was added prior to enzyme 
elution to enhance the purity of the final eluent; DHDPS was eluted using the elution buffer 
described by the manufacturer;  prior to storage, the column was washed with 15 mL rather than 
10 mL of ethanol to ensure maximum cleanliness and improve the life of the column.  The purity 
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of collected fractions was assessed by SDS-PAGE.  Pure fractions of DHDPS were pooled and 
dialyzed overnight (20 mM HEPES, 250 mM NaCl, 2 mM DTT, 10% v/v glycerol), then 
concentrated using Sartorius Stedim Vivaspin 20 centrifuge filters.  The protein was aliquoted into 
50 μL fractions at ~10 mg/mL and flash frozen in liquid nitrogen before being stored at 193 K.  
Enzyme concentrations were determined by NanoDrop® ND-1000 using calculated parameters 
(protParam)5 (molecular weight and extinction coefficient) for DHDPS (MW 34069 Da,ε280 
=18068 M-1 cm-1).3, 5 
2.2.2    Crystallization Screening 
The commercially available screening kit PEGII Suite (Hampton Research, USA) was selected 
for its broad overlap of crystallization conditions reported for DHDPS from C. jejuni and other 
species6-9.  Crystallization trials were carried out at 287 K using 96 well sitting drop plates from 
Hampton Research, USA. Sitting drops were mixed with 1.0 µL wild type protein solution (~10 
mg/mL) and 1.0 µL precipitant solution with a 100 µL well of the same precipitant solution.  
Several positive hits were identified and selected for further optimization using the hanging drop 
method with 3 µL drops mixed 1:1 over a 500 µL well. 
2.2.3    Crystal Optimization 
For each of the wild type and mutant DHDPS, in combination with various substrates and 
inhibitors, hanging drop vapor diffusion trials were conducted to systematically optimize positive 
hits identified from the PEGII Suite (Hampton Research, USA).  Modifications were made to 
precipitant and protein concentrations, temperature, drop volume, and pH.  The best diffracting 
crystallization conditions for each obtained crystal structure is listed in Table A.1. 
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2.2.4    Ligand Soaking Experiments 
2.2.4.1         Soaking with L-lysine 
The inhibitor L-lysine was introduced to crystallized DHDPS as a component of the 
cryoprotectant solution (10% ethylene glycol, 30% PEG 400, 60% precipitant solution with 10 
mM lysine and 30 mM lysine in Y110F).  In the absence of lysine, crystals were stable in the 
cryoprotectant solution.  With lysine present in the cryoprotectant, crystal quality degraded if 
soaked for an extended period.  Crystals which maintained diffraction quality were soaked in the 
aforementioned cryoprotectant solution for 5 minutes before being flash-cooled in liquid nitrogen. 
2.2.4.1         Soaking with Thialysine 
The inhibitor thialysine was introduced to crystallized DHDPS as a component of the 
cryoprotectant solution (10% ethelyne glycol, 30% PEG 400, 60% precipitant solution with 30 
mM Thialysine).  In contrast with ʟ-lysine soaking, DHDPS was stable for extended periods of 
time in the presence of thialysine. 
2.2.5    Co-crystallization Experiments 
2.2.5.1         Co-crystallization with Bislysine 
Diffraction quality crystals were grown in a solution of 0.2 M sodium acetate, 16% PEG4000, 
0.1 mM Tris pH 8.5 using the hanging drop vapour diffusion method.  Protein and precipitant 
solutions were mixed in a 1:1 3 µL drop over 500 µL well.  DHDPS was pre-incubated with 20 
mM bislysine prior to setting up crystallization trials.  Crystals were transferred to a cryoprotectant 
solution consisting of 10% ethylene glycol, 30% PEG 400, 60% precipitant solution with 10 mM 
bislysine and then flash frozen in liquid nitrogen. 
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Co-crystallization of Y110F:bislysine was accomplished in a solution of 0.28 M Sodium 
Acetate, 13% P4000, 0.1 M Tris pH 8.5 using the hanging drop vapour diffusion method.  Protein 
and precipitant where mixed in a 1:1 3 µL drop over 500 µL well.  Y110F-DHDPS was pre-
incubated with 25 mM bislysine prior to setting up crystallization trials.  Crystals were transferred 
to a cryoprotectant solution consisting of 10% ethylene glycol, 30% P400, 60% precipitant solution 
with 20 mM bislysine and then flash frozen in liquid nitrogen. 
2.2.5.2      Dead end complexation with ASA 
2.2.5.2.1 Active Site Clearing with ASA 
Since the Cj-DHDPS enzyme co-purifies with pyruvate bound in the active site it was necessary 
to incubate with ASA in order to obtain the apoenzyme form of DHDPS.  apo-DHDPS crystals 
were cyoprotected in a solution of 10% ethylene glycol, 30% PEG 400, 60% precipitant solution.  
Prior to crystallization, purified DHDPS was incubated with 10 mM ASA for 30 min.  This was 
followed by dialysis (20 mM HEPES, 250 mM NaCl, 2 mM DTT) to remove excess ASA and 
dihydrodipicolinic acid. 
2.2.5.2.2 Crystallization with ASA 
To obtain DHDPS crystals with ASA it is necessary to ensure that no reaction will occur.  A 
strategy was developed to create a dead-end complex by reducing the Schiff base; therefore 
trapping pyruvate in the active site.  DHDPS samples were removed from storage (353.15 ˚K) and 
incubated with 3 mM pyruvate for 30 min to ensure full occupancy.  This is followed by 2 hour 
incubation with 6 mM sodium cyanoborohydride (NaCNBH3).  The modified DHDPS is then 
dialyzed (20 mM HEPES, 250 mM NaCl, 2 mM DTT) to remove excess pyruvate and NaCNBH3 
(BH).  Samples were then centrifuged to the desired concentration using Sartorius Stedim Vivaspin 
20 centrifuge filters. 
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2.2.5.2.3 Verification of dead-end complexation 
Dead-end complexation of BH-DHDPS:lac was verified using the DHDPS-DHDPR coupled 
assay, as described previously.2  A binary assessment of activity was made for the DHDPS 
enzymatic reaction by monitoring the decrease in absorbance at 340 nm due to oxidation of NADH 
(ε340 = 6220 M-1cm-1).  All kinetic measurements where performed on a Beckman DU640 
spectrophotometer at 25 ˚C maintained by a circulating water bath.  Only freshly prepared 
substrates were used in the assay.  All measurements where made using 100 mM HEPES buffer at 
pH 8.0.  A typical assay contained 0.16 mM NADH, 1.0 µg of DHDPS, 7.15 µg DHDPR and 
0.124 mM of ASA and 0.37 mM of pyruvate.  The excess amount of DHDPR was determined 
experimentally, to ensure that the DHDPS-catalyzed reaction would be rate-limiting.  Cuvettes 
containing the assay mixture were incubated for three minutes to equilibrate at 25 ˚C before the 
reaction was triggered by the addition of DHDPS. 
Modified DHDPS (without ASA) was crystallized using the hanging drop vapour diffusion 
method in a solution of 0.2 M sodium acetate, 15% PEG 4000, and 0.1 mM Tris buffer at pH 8.5.  
Crystals containing ASA were co-crystallized in the presence of 100 mM ASA using the hanging 
drop vapor diffusion method and a solution of 0.16 M Di-Ammonium tartarate, 12% PEG 3350, 
pH 8.5, with a protein concentration of 5.13 mg/mL.  Protein and precipitant solutions where mixed 
in a 1:1 with 3 µL drop over 500 µL well.  Crystals of reduced-DHDPS in the absence of ASA 
were cryoprotected in a solution of 10% ethylene glycol, 30% PEG 400, 60% precipitant and then 
flash frozen in liquid nitrogen.  Crystals of reduced-DHDPS co-crystallized with 100 mM ASA 
were flash frozen directly from the mother liquor without additional cryoprotection. 
 
 
52 
 
2.2.6    Diffraction, Data Collection, and Data Processing  
Diffraction experiments were conducted using synchrotron radiation at the Canadian 
Macromolecular Crystallography Facility (CMCF-1) beamlines (08ID-1 and 08B1-01) at the 
Canadian Light Source (CLS), Saskatoon, Saskatchewan, Canada.  The crystal was kept at a 
temperature of 100 K in a stream of nitrogen gas during data collection.  Diffracted x-rays were 
detected using a MAR 300CCD detector. Intensity data was indexed, integrated and scaled using 
either auto-XDS/XSCALE, or d*Trek10, 11.  Pertinent data-collection statistics and refinement 
parameters are given in Table A.1 in the appendix. 
2.2.7    Structure Solution and Refinement 
MolRep was used to find a molecular replacement solution for each DHDPS structure using the 
atomic coordinates of the solvent-stripped wild type structure (PDB: 3M5V) as the search model.12  
The solution found four monomers organized as a tetramer in the asymmetric unit, with the 
exception of the Y110F:pyr:lys (PDB: 4MLR) structure, and the wt-DHPS:thialysine structure 
which each contain two tetramers in the asymmetric unit.  Solvent content determined from 
Matthews coefficients were consistently between 40% and 50%.13  Further refinements were made 
using PHENIX14, with manual model correction in COOT.15  Final refinement statistics are given 
in Table A.2 in the appendix. 
2.2.8    Validation of Structures  
When the DHDPS structures could no longer be improved using refinement and modeling, the 
final model was validated using Molprobity14 in Phenix14 and validation tools in COOT.15 
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2.3 Determination of Dynamic Domains 
2.3.1    Use of DynDom 
DynDom web server and the associated domain movement database can be freely accessed at 
http://fizz.cmp.uea.ac.uk/dyndom/.  The web server accepts either direct upload of PDB files, or 
queries to the Protein Data Bank.  DynDom can be used as a web application or downloaded for 
offline use.  For a brief introduction to the function of dynDom see Appendix B; for an in depth 
review see the original work of Hayward and Poornam et al. (1994-1996).16-19  
DynDom was used extensively to examine each structure in Table A.1 against each other 
structure in Table A.1.  The dynDom program allows the user to designate which of two structures 
will be the reference, and which will be the moving structure.  Each structure from Table A.1 was 
assigned the role of reference structure in turn.  The program allows, per run, the comparison of 
one monomer from the moving structure against one monomer of the reference structure.  Thus 
each of four monomers of the designated moving structure was compared to each of four 
monomers of the designated reference structure.  The roles of reference and moving structure were 
reversed and comparisons were made again.  This process was repeated for all possible structure 
pairings from Table A.1.  Results of each pairing are discussed in the applicable sections to follow. 
2.4 Calculation of Cavity Volumes 
2.4.1    Use of CASTp 
CASTp is made freely available at the website http://cast.engr.uic.edu.  The web server accepts 
direct upload of PDB files, and delivers outputs by e-mail.  For a brief introduction to the function 
of CASTp see Appendix B; for an in depth review see the origional work of Edelsbruner et al. 
(1994-1996).20-23  
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All solvent molecules are explicitly removed from the input model.  Ligands and hetero atoms 
were excluded for each calculation.  A probe of radius of 1.2 Å was used for water during the 
calculations.24  The outputs of all computations give two sets of parameters, one based on 
molecular surface (MS) and one based on solvent accessible surface (SA).25, 26  Molecular 
visualization of pockets and cavities are generated using RasMol.27 
Each DHDPS structure was submitted in turn.  All solvent molecules and inhibitors were 
excluded from the analysis.  In order to properly define the active site it was necessary to submit 
only the tight-dimer half of DHDPS, rather than the complete structure.  This was due to a 
computational anomaly where the location of active sites ("within the DHDPS doughnut hole"; 
Figure 2.1) allowed the algorithm to encompass all 4 active sites within a single defined cavity.  
Visualizations and structural superposition was carried out in pymol using the CASTp extension.  
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Figure 2.1 – The DHDPS Tetramer.  Each monomer has one active site which is accessible through the large solvent 
void formed by the tetrameric formation.  Purple arrows indicate access to each of the active sites. (PDB: 4M19) 
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Chapter 3   Results and Analysis 
3.1 Crystallization of DHDPS 
3.1.1    WT Crystallization with and without ʟ-Lysine 
Crystals of wt-DHDPS (PDB: 4LY8) were first obtained using commercial screens.  The PEG-
II suite from Hampton Research, USA was used for the sitting drop vapour diffusion method (drop 
size and well volume).  Several positive hits were identified and optimized using the hanging drop 
vapour diffusion method.  Iterative changes were made to the concentration of protein and 
precipitants, drop volumes, well volumes, temperature, and pH.  The final crystallization condition 
(0.25 M sodium acetate, 18% PEG4000, 0.1 M TRIS, pH 8.5) afforded crystals of wt-DHDPS 
which diffracted to 1.6 Å.  The cryoprotectant consisted of 10% ehthylene glycol, 30% PEG 400, 
and 60% precipitant solution. 
Crystals grown under similar conditions (0.25 M sodium acetate, 20% PEG4000, 0.1M TRIS, 
pH 8.5) were used for soaking experiments with ʟ-lysine (PDB: 4M19).  wt-DHDPS crystals were 
looped from the mother liquor and placed into a solution of 10% ethylene glycol, 30% PEG 400, 
and 60% precipitant solution, with 10 mM of ʟ-lysine.  Crystals were soaked for 5-10 min; a short 
soak time was necessary as crystals were observed to degrade if soaked for longer periods.  The ʟ-
lysine soaking solution also served as the cryoprotectant.  The best diffracting crystals from this 
procedure were 2.0 Å.  
The wt-DHDPS (PDB: 4LY8) was found to be of the space group P212121, and was solved by 
molecular replacement using Cj-DHDPS (PDB: 3M5V) previously solved by the CSGID and 
refined to a resolution of 1.6 Å  (Pertinent statistics can be found in Table A.1).  The structure of 
Cj-DHDPS:pyr (4LY8) is similar to the structures deposited by the CSGID (PDB: 3LER & 3M5V) 
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with a Cα rmsd of 0.29 Å.  As observed in other DHDPS structures, Cj-DHDPS crystallizes as a 
tetramer, composed of a dimer of tight dimers. 
3.1.2    Y110F Crystallization with and without ʟ-Lysine 
Crystallization conditions for the Y110F mutant (PDB: 4MLJ) were adapted from those of the 
wt-DHDPS crystals described above.  Y110F crystallized in a solution of 0.2 M sodium acetate, 
18% PEG4000, 0.1M TRIS, pH 8.5, and using hanging drop vapour diffusion method at 287 ˚K.  
These crystals were looped and placed in a cryoprotectant of 10% ethylene glycol, 30% PEG 400, 
60% precipitant solution.  The best diffracting crystals had resolution of 2.1 Å. The Y110F crystal 
was found to be of the space group P212121.  The structure was solved by molecular replacement 
and was refined to a resolution of 2.1 Å.  Pertinent refinement statistics are presented in Table A.1.  
The tetrameric structure was found to contain pyruvate at the active site.  Comparison of the 
Y110F:pyr (4MLJ) structure with the wt:pyr (4LY8) structure indicates that they are nearly 
identical (Cα- rmsd of 0.25 Å).  The position of F110 is un-altered relative to the position of Y110 
in the wild-type structure. 
As with the wt-DHDPS, crystals of Y110F:pyr:lys (PDB: 4MLR) were obtained with the 
soaking method.  The crystals where grown in 0.15 M sodium acetate, 17 % PEG4000, 0.1M TRIS, 
pH 8.5, using hanging drop vapour diffusion method at 287 ˚K.  Crystals were looped and soaked 
for 5 – 10 min in a solution of 10% ethylene glycol, 30% PEG 400, and 60% precipitant solution 
containing 30 mM of ʟ-lysine.  Higher concentration of ʟ-lysine was necessary presumably 
because of weaker binding to the mutated allosteric site.  The soaking condition also served as the 
cryoprotectant, and the best diffracting crystals had a resolution of 2.2 Å.  The Y110F crystals 
soaked in ʟ-lysine (PDB: 4MLR) were found to be of the space group P21.  The structure was 
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solved using molecular replacement and refined to a resolution of 2.2 Å.  Pertinent Data collection 
and refinement statistics can be found in Appendix A (Table A.1 and A.2). 
3.1.3    Crystallization of apo-DHDPS 
It had been found that wt (4LY8) and Y110F (4MLJ) DHDPS each co-purified and crystallized 
with pyruvate covalently bound to the active site.  It was therefore necessary to treat protein 
preparations with excess ASA to ensure that all co-purified pyruvate had been reacted.  Prior to 
crystallization, samples of DHDPS were incubated 30 minutes with 10 mM ASA, which is a 
sufficient excess to react all co-purified pyruvate.  The sample was then dialyzed to remove all 
ASA and HTPA/DHDP from the solution. 
The apo-DHDPS (PDB: 4R53) was then crystallized in a solution of 0.2 M sodium acetate, 20% 
PEG4000, 0.1 M TRIS, pH 8.5, using the hanging drop vapour diffusion method at 287 ̊ K.  
Crystals were looped into a cryoprotectant of 10% ethylene glycol, 30% PEG 400, 60% precipitant 
solution, and flash frozen in liquid nitrogen.  The best diffracting apo-DHDPS crystals had a 
resolution of 2.0 Å.  The apo-DHDPS crystals were found to be of the space group P21.  The 
structure was solved using molecular replacement and refined to a resolution of 2.0 Å.  Pertinent 
data collection and refinement statistics can be found in Appendix A (Table A.1 and A.2). 
3.1.4    Crystallization of WT and Y110F with bislysine 
Unsuccessful attempts were made to adapt the above soaking procedure for the synthetic 
inhibitor bislysine.  It was concluded that the increased size of the inhibitor did not lend itself well 
to diffusion through protein crystal solvent channels.  An alternative strategy was employed to co-
crystallize DHDPS with bislysine. 
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Using the hanging drop vapour diffusion method wt-DHDPS co-crystallized with 10 mM (±)-
bislysine (tetrahydrochloride salt; final concentration) in a solution of 16% P4000, 0.1 mM Tris 
(pH 8.5) at 287 ̊ K.  These crystals were cryoprotected in a solution of 10% ethylene glycol, 30% 
PEG400, 60% precipitant solution with 10 mM bislysine.  Co-crystallization of wt-DHDPS and 
bislysine produced crystals diffracting to 1.6 Å (PDB: 4RT8).  Co-crystals of wt-
DHDPS:pyr:bislysine (PDB: 4RT8) were found to be of the space group P212121.  The structure 
was solved by molecular replacement and refined to a resolution of 2.2 Å.  As with previous 
structures the tetrameric structure contained pyruvate at the active site, and the inhibitor bislysine 
was easily identified from the Fo-Fc map (Figure 3.1). 
The mutant Y110F co-crystallized with 25 mM (±)-bislysine (tetrahydrochloride salt; final 
concentration) in a solution of 0.2 M sodium acetate, 16% PEG4000, 0.1 mM TRIS (pH 8.5).  The 
hanging drop vapour diffusion method was used at 287 ˚K.  The crystals were cryoprotected in a 
solution of 10% ethylene glycol, 30% PEG 400, 60% precipitant solution with only 20 mM (±)-
bislysine (tetrahydrochloride salt) due to limited availability of bislysine.  Despite similar binding 
affinities for bislysine in wild-type and Y110F DHDPS it was necessary to use twice as much 
bislysine to obtain crystal structures with Y110F-DHDPS.  We speculate that the higher 
concentration of bislysine required is somehow related to the loss of one hydrogen bond in the 
allosteric site.  The best diffracting co-crystals of Y110F-bislysine had resolution of 2.35 Å (PDB: 
4RT9).  The Y110F-bislysine crystalized in the space group P212121, and was solved by molecular 
replacement and refined to 2.35 Å (PDB: 4RT9).  Rather uncharacteristically, the enzyme does not 
have pyruvate bound at the active site.  However, bislysine is easily identified in the allosteric site 
from the Fo-Fc map (Figure 3.2).  With the exception of the missing hydroxyl at F110 there is no 
obvious structural differences from wt-DHDPS:bislysine (4RT8). 
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Figure 3.1 – Electron Density of bislysine in wt-DHDPS Purple bislysine bound to the allosteric site of wt-DHDPS 
in green (PDB: 4RT8).  The Green Mesh is the electron density omit map scaled at 3.0 σ. 
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Figure 3.2 – Omit map for bislysine bound in the allosteric site of Y110F-DHDPS. Purple bislysine bound to the 
allosteric site of Y110F-DHDPS in blue (PDB:4RT9).  The Green Mesh is the electron density omit map scaled at 3.0 
σ. 
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3.1.5    Crystallization of wt-DHDPS with ʟ-Thialysine 
Crystals of wt-DHDPS with ʟ-thialysine were obtained using the ligand-soaking technique.  
Crystals were grown in a solution of 0.2 M sodium acetate, 20% PEG 4000, 0.2 M Tris, pH 8.5 
using the hanging drop vapour diffusion method at 287 ˚K.  The cryoprotectant was 30 µL PEG 
400, 10 µL ethelyne glycol, 60 µL well solution and included 30 mM ʟ-thialysine; the best 
diffracting crystals had a resolution of 1.9 Å.  The crystals were found to be of the space group 
P21, solved by molecular replacement and refined to 1.9 Å.  Pyruvate was bound to the active site, 
and ʟ-thialysine could be easily identified from the Fo-Fc map (Figure 3.3).  The electron density 
associated with the inhibitor ʟ-thialysine was less well defined than previously solved crystal 
structures with ʟ-lyisine, which suggests a lower occupancy. 
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Figure 3.3 – Omit map for thialysine bound in the allosteric site of wt-DHDPS. wt-DHDPS is shown in brown, 
and ʟ-thialysine is depicted in grey.  The green mesh represents the electron density of the Fo-Fc Omit map rendered 
at 3.0 σ.  The shape of the electron density is not as clearly defined as for ʟ-lysine or bislysine; however, it is 
convincingly attributable to ʟ-thialysine. 
 
3.1.6    Crystallization of wt-DHDPS with ASA 
The method for crystallizing DHDPS with ASA in the active site requires several preliminary 
steps prior to setting up the actual crystallization experiments.  The protein sample is first incubated 
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for 30 min with excess pyruvate (30 mM), to ensure 100% active site occupancy.  Following this, 
the active site Schiff base (pyruvate-K166 double bond) is reduced by treatment with NaCNBH3 
(BH) for 2 hours.  The sample is then dialyzed to remove all excess and reacted reagents. 
The reduced BH-DHDPS:lac is then co-crystallized with 100 mM ASA in a solution of 0.16 M 
di-ammonium tartrate, 12% PEG 3350 at 287 ˚C using the hanging drop vapour diffusion method.  
Crystals proved highly unstable in a variety of cryoprotectant solutions; fortunately, the mother 
liquor proved to be a suitable cryoprotectant.  Crystals from these preparations diffracted to 1.93 
Å in the absence of ASA and 2.37 Å when co-crystallized with ASA.  The final resolution of 
refinement was also 1.93 Å in the absence of ASA and 2.37 Å when co-crystallized with ASA.  
Pertinent diffraction and refinement statistics can be found in Appendix A (Table A.1 and A.2). 
3.1.7 DHDPS from C. jejuni co-purifies with Pyruvate 
Pyruvate was not added to any sample of DHDPS during either purification or crystallization; 
with the exception of treatment with sodium cyanoborohydride.  In all cases we observed that 
pyruvate was present in the active site (Figure 3.4), with the exception of Y110F:bislysine (PDB: 
4RT9).  Since pyruvate was not added to any samples of DHDPS this indicates that it must co-
purify, and then co-crystallize with DHDPS, suggesting that the F-form of the enzyme, with 
pyruvate bound, is likely the preferred state of the enzyme. 
The one exception is the crystal structure of Y110F-DHDPS:bislysine where there is no 
indication of pyruvate at the active site.  It has been shown in Cj-DHDPS that ʟ-lysine enhances 
the affinity of the enzyme for pyruvate.1-3  Several possibilities exist to explain the absence of 
pyruvate in Y110F-DHDPS:bislysine.  Some aspect of the crystallization condition may have 
changed the equilibrium to favor unbound pyruvate.  Since bislysine can bind to either the 'E-form' 
or 'F-form' of the enzyme, it is possible that conditions used here selectively crystalize the Y110F-
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DHDPS:bislysine without pyruvate.  Finally, it may be that bislysine, unlike ʟ-lysine, influences 
the mutant enzyme to favor a vacant active site. 
 
Figure 3.4 – Pyruvate is well represented in the active site.  The image here is from the wt:pyr structure (4M19).  
The Green mesh is the Fo-Fc omit map (scaled at 3.0 σ) and is representative of electron density observed in the active 
site of all DHDPS crystal structures presented in this thesis. 
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3.2 Structural effects of ʟ-lysine on wt-DHDPS 
3.2.1    Structure of wt-DHDPS with ʟ-Lysine in the allosteric site 
The wt-DHDPS:pyr:lys (PDB: 4M19) crystals occupy the space group P21.  The structure was 
solved by molecular replacement and refined to a resolution of 2.0 Å (Table A.2).  As with 
DHDPS:pyr (PDB: 4LY8), the active site was found to contain pyruvate bound to K166, without 
intervention.  ʟ-Lysine was clearly identified by the outline of its electron density in the Fo-Fc map.  
As observed in DHDPS from other species ʟ-lysine binds to the allosteric site in a 'head-to-head' 
orientation, that is, with α-carbons in close proximity, in the allosteric site. 
The allosteric binding site exists at the tight-dimer interface and the binding site for a single ʟ-
lysine molecule is comprised of residues from both monomers.  Consistent with other DHDPS, 
two ʟ-lysine molecules bind in a head-to-head fashion with 2-fold symmetry (Figure 3.5, panel A), 
and each ʟ-lysine makes hydrogen bond interactions with both monomers.4-7  A list of lysine 
hydrogen bond interactions is presented in Table 3.1 and depicted graphically in Figure 3.5, panel 
B.  
For a ʟ-lysine molecule bound to the allosteric site of monomer A, the carboxyl of ʟ-lysine is 
hydrogen bonded to Tyr110 in monomer A.  The α-amino group is hydrogen bonded to Ala52 
from monomer A, and Asn84/Glu88 from monomer B.  The ε-amino group forms hydrogen bonds 
with His59, and the back-bone carbonyls of Ser51 and Leu54 of monomer A.  The two fold 
symmetry of Cj-DHDPS results in the same interactions for the ʟ-lysine bound to monomer B. 
This is consistent with ʟ-lysine binding patterns reported from homologous species.8 
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Figure 3.5 – Difference Density and Hydrogen bonding interactions completed by ʟ -lysine in the allosteric site.  
ʟ-Lysine bound DHDPS, monomer A in orange, monomer B (primed residues) in blue. Panel A shows the omitt map 
for ʟ-lysine bound to the allosteric site of wt-DHDPS (4LY8). Green electron density map represents the SA omit map 
with no ʟ-lysine present, contoured at 3 σ.  Panel B is a close up of one ʟ-lysine highlighting the newly formed 
hydrogen bonds.  A single ʟ-lysine molecule forms hydrogen bonds with residues from both monomers and the second 
ʟ -lysine binds with two fold symmetry. 
 
 
 
Table 3.1 – List of all hydrogen bonds made by ʟ-lysine in the Allosteric Site 
Hydrogen Bond Distance 
ʟ-lysine-N to N84' 2.8 Å 
ʟ-lysine-N to E88' 2.8 Å 
ʟ-lysine-O to N84' 3.0 Å 
ʟ-lysine-O to Y110 3.3 Å 
ʟ-lysine-OXT to Y110 2.6 Å 
ʟ-lysine-Nζ to H59 3.0 Å 
ʟ-lysine-Nζ to S51(CO) 2.8 Å 
ʟ-lysine-Nζ to L54(CO) 3.3 Å 
 
A B 
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3.2.2    Comparison of wt-DHDPS with and without ʟ-Lysine 
A comparison of the Cj-DHDPS:pyr:lys (PDB: 4M19) structure to the Cj-DHDPS:pyr (PDB: 
4LY8) structure reveals several side chain movements to accommodate ʟ-lysine in the allosteric 
site (Figure 3.6).  Furthermore there are notable shifts in the backbone Cα's in helices flanking the 
allosteric site.  It appears as if the helices shift into the allosteric site when ʟ-lysine is bound. 
The principle interest is the effect that ʟ-lysine has on the active site; however, there are only 
minor changes observed between the active sites of Cj-DHDPS:pyr (4LY8) and Cj-
DHDPS:pyr:lys (4M19) upon binding of ʟ-lysine to the allosteric site.  Small but measurable 
changes in the distance between pairs of residues are seen for the following pairs: Y137 – T47 (3.4 
Å to 2.9 Å), Y137 – Y111' (4.7 Å to 4.2 Å), and C1 of the pyruvyl Schiff base and the carbonyl of 
I207 and G190 (3.8 Å to 4.5 Å and 4.7 Å to 3.7 Å respectively). 
Interestingly the largest structural changes occur in side chains at the weak dimer interface.  The 
secondary structures at the weak dimer interface remain largely intact.  The notable movements 
include significant shifts in Cα positions and side chain orientations.  Historically, this region of 
the protein structure has received the least attention, but will be critical in understanding reports 
of inhibitor cooperativity across the weak dimer interface. 
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Figure 3.6 – Superposition of Cj-DHDPS:pyr:lys and wt:pyr.  The CjDHDPS:pyr:lys structure (PDB: 4M19) is 
shown in green, and the Cj-DHDPS:pyr structure (PDB: 4LY8) is shown in puple (different shades indicate each 
monomer).  There is some disorder introduced at the side-chain of S51, therefore two possible positions are 
represented.  The superposition highlights that many residues make minor shifts to accommodate the binding of ʟ-
lysine (shown in magenta). 
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3.2.3    Determination of Dynamic Domains 
While the structure Cj-DHDPS:pyr:lys (4M19) was very similar to the Cj-DHDPS:pyr (4LY8) 
structure, crystal quality was observed to degrade when ʟ-lysine was included in the cryoprotectant 
solution, but remained stable when ʟ-lysine was absent from the cryoprotectant.  These 
observations suggest ʟ-lysine may induce certain conformational changes.  Close examination of 
the superimposed structures revealed notable misalignment and contracted helices.  We used the 
program DynDom to reveal a subtle concerted domain movement.9-11  DynDom identifies domains 
based on vector movements and determines the average vector movements based on a reference 
structure.  Each identified domain is matched to the equivalent section in the unbound protein 
using a root mean square difference (rmsd) of Cα's.  Our analysis of the Cj-DHDPS:pyr:lys (4M19) 
structure demonstrated that there is a concerted domain movement caused by the binding of ʟ-
lysine.  The fixed domain is comprised of the N and C terminus, residues 1-80 and 188-298. The 
moving domain consists of residues 104 to 184.  At the interface of moving and fixed domains are 
residues which lie on or very near the bending axis.  Identified domains are highlighted on a single 
monomer and on the tight dimer formation in Figure 3.7. 
The bending axis is defined by a closure value of 0.798, which represents the amount of hinging 
as opposed to twisting.  A value greater than 0.5 indicates a predominantly hinged motion rather 
than a screw axis.9-11  The moving domain shifts 3.8˚ on its hinge axis resulting in maximal Cα 
displacement of 2.0 Å at Thr115.  Domain movements indicate that half of each monomer rotates 
toward the allosteric site (Figure 3.7).  The domain shifts are consistent with the closing of the 
helices around the ʟ-lysine in the allosteric site.  
The moving domain extends from the allosteric site to the weak dimer interface, and at its center 
includes the aromatic residues Y110/111.  Notably Y110 is one of only 3 residues (Y110, N84, and 
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E88) in the moving domain that makes a direct hydrogen bond to the inhibitor ʟ-lysine.  The neighboring 
residue Y111 interdigitates across the tight dimer interface to complete the catalytic triad in the active site 
of the neighboring monomer (Figure 3.8).  This is an important observation because Y110/111 has 
been critically implicated in the mechanism of allostery and presents a probable link between the 
allosteric site and the active site via domain movement.1, 3  Therefore Y110/Y111 was identified as a 
possible link between the allosteric site and the active site.  It appears that the movements of the very 
rigid Y110/111 are the result of domain movements, or possibly that domain movements are the 
result of shifts to the aromatic core.  Furthermore, inhibition of Cj-DHDPS demonstrates 
cooperativity across the weak dimer interface.1, 2 The dynamic domains identified here apparently 
link the allosteric site to the weak dimer interface and may play some role in the mechanism of 
cross dimer communication. 
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Figure 3.7 – Domain movements in wild type Cj-DHDPS. Panel A shows the highlighted domains in a superposition 
of Cj-DHDPS:pyr:lys (4M19) and Cj-DHDPS:pyr (4LY8). On the Cj-DHDPS:pyr:lys structure (PDB: 4M19) the 
fixed domain is blue, moving domain is red and hinging residues are in green. The Cj-DHDPS:pyr structure (PDB: 
4LY8) is shown in yellow. ʟ-Lysine bound to the allosteric site (magenta) belongs to the blue and red structure. The 
blue arrow shows the monomeric hinging action where the moving (red) domain shifts to close the allosteric site. 
Panel B shows the interplay of monomers at the tight dimer interface. Identical domain movements in each monomer 
close the allosteric site around two ʟ-lysine molecules. Panel B shows a close up of the active site and allosteric site.  
The moving domain (red) moves towards the allosteric site with a maximal Cα displacement of 2.0 Å at T115.  
 
 
A B 
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Figure 3.8 – The aromatic pair Y110/Y111 links the allosteric site and the active site.  Cj-DHDPS:pyr:lys (PDB: 
4M19) shown in purple with ʟ-lysine in magenta, and Cj-DHDPS:pyr (PDB:4LY8) is in green (different shades 
indicate each monomer).  The aromatic pair of Y110/Y111 links the carboxyl of the inhibitor ʟ-lysine to the catalytic 
triad of the active site. 
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3.2.4    Analysis of Cavity Volumes 
The observed domain movements appear to be coupled with closure of the allosteric site when 
ʟ-lysine binds; reflected in the changing Cα positions of helices comprising the allosteric site.  This 
observation led us to measure the volume of the active site and allosteric site in each of our wild 
type crystal structures.  Using CASTp12, 13 we compared the solvent accessible volume of active 
sites and allosteric sites in apo-Cj-DHDPS (4R53), Cj-DHDPS:pyr (4LY8), Cj-DHDPS:pyr:lys 
(4M19).  Calculations of the allosteric site were done with ʟ-lysine removed from the model.  
When calculating the volume of the active site pyruvate was included in the model, since it defines 
the active site available for ASA.  These comparisons reveal that the binding of each ligand 
changes the volume of both the active site and the allosteric site (Table A.3).  The binding of 
pyruvate to apo-Cj-DHDPS (4R53) decreases the active site volume by 44% from 36 Å3 to 20 Å3. 
Additionally, the allosteric site is reduced by 16% to 417 Å3 from 494 Å3.  The reduction in 
allosteric site volume could improve the affinity of the allosteric site for ʟ-lysine by both improving 
the orientation of binding groups and providing an entropic effect of limiting ʟ-lysine 
conformations. 
Binding of ʟ-lysine reduces the volume of the allosteric site by a further 43% from 417 Å3 to 
239 Å3.  At the active site, the volume increases by 30% from 20 Å3 to 26 Å3 upon ʟ-lysine binding.  
An image representative of the change in allosteric site volume from apo-Cj-DHDPS (4R53) to 
Cj-DHDPS:pyr:lys (4M19) was generated using the program Hollow14 and is shown in Figure 3.9; 
overall the cavity is observed to shrink in all dimensions as the surrounding helices and residues 
move towards the center of the cavity.  The increased volume at the active site may play a crucial 
role in the inhibition of the enzyme, likely by reducing the affinity of the active site for ASA.   
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Figure 3.9 – Volume change of the allosteric site.  The calculated allosteric cavity is rendered with the program 
Hollow14 for apo-Cj-DHDPS (4R53) in transparent yellow (larger), and Cj-DHDPS:pyr:lys (4M19) in blue (smaller). 
The structure of apo-Cj-DHDPS (4R53) is in yellow, and Cj-DHDPS:pyr:lys (4M19) is in blue. The allosteric site is 
observed to shrink in all dimensions as the surrounding helices and side chains move toward the center of the cavity. 
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3.2.5    Effects at the Dimer-Dimer Interface 
The moving domain includes significant contacts at the region of both the tight and weak dimer 
interface.  The tetrameric structure is critical for natural activity and inhibition.15 It is well 
documented that at the tight dimer interface, two ʟ-lysine molecules bind cooperatively in each 
allosteric cleft.4-7  Additionally, we have shown that ʟ-lysine binding in Cj-DHDPS is cooperative 
across the weak dimer interface, as indicated by Hill coefficients > 2.2  The moving domain 
extends from the allosteric site into the weak dimer interface.  At this interface, we find several 
cross-dimer interactions that have shifted in the DHDPS:pyr:lys (4M19) structure.  
Rearrangements include the breaking of several hydrogen bonds:  H181'/N242, and D173'/Y241 
(Figure 3.10, panel A ); disruption of hydrogen bonds between N201'/D238, N201'(CO)/K234, 
and S200'(CO)/Y196 (Figure 3.10, panel B).  Furthermore, upon binding ʟ-lysine at the allosteric 
site there is significant rearrangement of a hydrophobic pocket (I172, I194, I172', I194',V176; 
Figure 3.10, panel C) at the weak dimer interface, where each residue moves by 1.5 – 2.0 Å.  These 
residues may be implicated in the weak dimer cooperativity signal and should be examined as a 
part of future work. 
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Figure 3.10 – Changes at the dimer-dimer interface. Cj-DHDPS:pyr:lys (PDB: 4M19) shown in green and Cj-
DHDPS:pyr (PDB: 4LY8) shown in purple (different shades indicate each monomer).  The dashed blue line denotes 
hydrogen bonds which are only present in the DHDPS:pyr:lys structure (4M19), while the red dashed line denotes 
hydrogen bonds only present in the DHDPS:pyr structure (4LY8).  Panel A depicts the breaking of a hydrogen bond 
between H181' to N242, and D173' to Y241; and formation of hydrogen bonds between H181' to Y241, and another 
between D177' to K245. Panel B shows the disruption of hydrogen bonds between N201' to D238, N201'(CO) to 
K234, and S200'(CO) to Y196; the residues K234/D238 move together to retain their hydrogen bond.  Panel C shows 
the rearrangement of a hydrophobic pocket formed by I172, I194, I172', I194' and V176.  These changes may 
contribute to the cooperativity observed between four ʟ-lysine binding sites. 
 
 
C 
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3.3 Structural effects of ʟ-lysine on Y110F-DHDPS 
As described in section 1.5.5 the Y110F mutation of Cj-DHDPS greatly diminishes the 
enzymes sensitivity to inhibition by ʟ-lysine. 
3.3.1    Analysis of Y110F-DHDPS with ʟ-Lysine 
As in the Cj-DHDPS:pyr:lys (4M19) structure, ʟ-lysine was clearly seen in the initial Fo-Fc 
electron density map, and is bound in the allosteric site in a head-to-head orientation in the 
Y110F:pyr:lys (4MLR) structure.  All side chain positions and hydrogen bonding networks 
observed in the Cj-DHDPS:pyr:lys (4M19) structure are preserved in the Y110F:pyr:lys (4MLR) 
structure with the exception of the missing tyrosine hydroxyl group.  This result reveals that ʟ-
lysine still binds to the mutant Y110F despite the fact that there is little to no attenuation of catalytic 
activity.  The Y110F-DHDPS is insensitive to ʟ-lysine inhibition, and yet the crystal structure 
affirms that the inhibitor binds to the enzyme in the same position and conformation as it does in 
the wild-type DHDPS.  The observation that the inhibitor binds to the allosteric site, and enzyme 
activity remains high suggests that the hydrogen bond between the inhibitor ʟ-lysine and Tyr110 
is of critical importance in the effective allosteric signal transduction. 
3.3.2    Comparison of Y110F-DHDPS with and without ʟ-Lysine 
As with the wild type enzyme, binding of ʟ-lysine to the Y110F allosteric site induces several 
small side chain movements.  There is some shifting observed in the backbone carbonyls of the 
helices flanking the allosteric site; although it is not to the same extent as the wt-DHDPS (4LY8).  
Similar to the wt-DHDPS, ʟ-lysine appears to induce very little structural change at the active site. 
There are only minor changes observed between the active sites of Y110F:pyr (4M19) and 
Y110F:pyr:lys (4MLR) upon binding of ʟ-lysine to the allosteric site.  Small but measurable 
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changes in the distance between residues are seen for the following pairs: Y137 – Y111' (4.6 Å to 
5.1 Å) increases in length (the opposite effect from wild type); and C1 of the pyruvyl Schiff base 
and the carbonyl of G190 (and 4.5 Å to 4.2 Å respectively).  Several movements observed between 
wt:pyr and wt:pyr:lys are not observed in the comparison of Y110F:pyr and Y110F:pyr:lys, 
including: Y137 – T47 (3.5 Å to 3.5 Å), and C1 pyruvyl Schiff base to the carbonyl of I207 (3.8 
Å to 3.8 Å). 
As with ʟ-lysine binding in the wild type DHDPS, we observe rearrangement of several residues 
located at the allosteric site of Y110F-DHDPS when ʟ-lysine binds.  The distance between E88-
H56 is reduced (decreasing from 3.7 Å – 3.2 Å), R60 side chain moves (decreasing from 9.1 Å to 
3.1 Å) to support the side chain of H56 in its new position, and the R60 side chain forms a new 
hydrogen bond (decreasing from 5.6 Å to 3.4 Å)  with the back bone H56(CO).  Furthermore, R60 
side chain has moved from 11.4 Å – 3.8 Å relative to G91(CO) to form a new hydrogen bond.  As 
the allosteric site contracts, G80(CO) can form a hydrogen bond to H59 (distance decreasing form 
4.0 Å – 2.7 Å).  Unlike the wild-type DHDPS, the distance between E88-E88', which is reduced 
in wt-DHDPS, remains unchanged when ʟ-lysine binds to Y110F, suggesting the size of the 
allosteric site does not decrease to the same extent as the wild type. 
In wt-DHDPS (4M19), ʟ-lysine has a considerable effect at the weak dimer interface.  However, 
when Y110F:pyr:lys (4MLR) is compared to Y110F:pyr (4MLJ), an examination of the weak 
dimer interface reveals little to no change due to binding of ʟ-lysine at the allosteric site.  This may 
be due to either weaker binding of ʟ-lysine, or disruption of the mechanism for inducing such a 
change. 
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3.3.3    Absence of Domain-Scale Movements in Y110F:pyr:lys 
Although the helices flanking the allosteric site shift when ʟ-lysine is bound in Y110F, the 
domain scale movements noted by DynDom for Cj-DHDPS:pyr:lys (4M19) are absent in the 
Y110F:pyr:lys (4MLJ) structures.  That is to say, although there are obvious shifts in secondary 
structures and in side chains, as a whole the changes do not occur in concerted vectors.  When 
Y110F:pyr (4MLJ) is compared to wt:pyr:lys (4M19) DynDom identifies the same domain 
movements observed for both wild-type structures.  However, when comparing Y110F:pyr:lys 
(4MLR) to the wt:pyr:lys (4LY8), again we observe no domain movements.  This suggests that 
the Y110F structure may exist between the two wild-type states; or, that it does not contain 
identifiable domains.  That is, the sum of any changes cannot be defined as either a hinge or a 
screw axis.   
Close inspection of the domains identified in the wt-DHDPS reveals that Y110 is located in the 
middle of the moving domain.  According to B-factors and allowed Ramachandran angles, this is 
one of the most rigid regions of the enzyme.  It stands to reason that with the absence of the Tyr110 
hydroxyl, this region may not move as it does in the wild type structure; exclusion of this region 
may reduce the size, unity, or magnitude of movement in identifiable domains to less than the 
detection threshold of DynDom.  This would suggest that the hydrogen bond from Y110 to the 
inhibitor is critically important for proper domain movement.  It is possible that domain movement 
simply cannot occur without involvement of Y110.  Or, perhaps the mobile domain no longer 
moves as a unit and conformational changes in Cj-DHDPS cannot be defined on a domain scale.   
In wt-DHDPS, the moving domain extends from the active site to the weak dimer interface 
(Figure 3.11).  When examining Y110F with and without ʟ-lysine we observe no domain 
movement and no changes at the weak dimer interface.  Therefore, domain movement induced by 
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ʟ-lysine binding at the allosteric site may be necessary to alter the arrangement at the weak dimer 
interface; and potentially signal cooperative ʟ-lysine binding at the antipodal allosteric binding 
site.  Absence of dynamic domains in Y110F-DHDPS implies that interaction of the inhibitor with 
the hydroxyl of Y110 is a prerequisite for domain movement and therefore, possibly cross dimer 
cooperativity. 
 
Figure 3.11 – Quaternary relationship of Dynamic Domains.  On the Cj-DHDPS:pyr:lys structure (PDB: 4M19) 
the fixed domain is blue, moving domain is red and hinging residues are in green.  The Cj-DHDPS:pyr structure (PDB: 
4LY8) is shown in yellow. ʟ-Lysine bound to the allosteric site (magenta) belongs to the blue and red structure.  Panel 
A shows the tetrameric arrangement of DHDPS.  It is clear from this angle that the red moving domain comes into 
contact with other monomers at both the weak and tight dimer interface.  Panel B shows the interplay of monomers at 
the weak dimer interface where the moving domain of each monomer meats the fixed domain of the neighbor. 
 
3.3.4    Y110F is Still Inhibited at High Concentrations of ʟ-Lysine 
Kinetic analysis of the Y110F mutant DHDPS was conducted by Yulia Skovpen.1  Similar to 
wild-type, Y110F displays ping-pong kinetics, and demonstrates approximately half the enzymatic 
activity of wild-type.1, 3   The ʟ-lysine IC50 for Y110F was found to be approximately 40 mM 
(figure 3.8), which indicates that the Y110F mutation drastically changes the ability of the enzyme 
to be inhibited by ʟ-lysine.  This makes the enzyme insensitive to ʟ-lysine regulation at its 
A B 
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physiological concentrations, however; when sufficiently saturated (> 80 mM) the Y110F enzyme 
displays partial allosteric ʟ-lysine inhibition (Figure 3.8).  Due to very weak ʟ-lysine inhibition 
cooperativity coefficients where not estimated.1 
3.3.5    Analysis of Y110F Cavity Volumes 
Using CASTp, 12, 13  we calculated the volume of the allosteric site and active site in DHDPS 
Y110F both with and without ʟ-lysine.  Although there is no domain movement associated with ʟ-
lysine binding in the Y110F mutant, we do observe a decrease in solvent accessible volume in the 
allosteric site and movement of Cα positions which are similar to those observed between wt-
DHDPS:pyr and wt-DHDPS:pyr:lys.  The volume of the allosteric site of Y110F:pyr:lys (4MLR)  
is reduced by only 26% from 446 Å3 to 332 Å3 (compared to 43% in the wild-type enzyme) and 
the active site volume decreases by only 6% from 22 Å3 to 20 Å3 (compared to an increase of 22% 
in wild type; Table A.3).  The magnitude of ʟ-lysine's effect on the allosteric site is clearly less 
than that observed in wild type structures. 
3.3.6    ʟ-Lysine Binds to Y110F-DHDPS with Minimal Structural Effects  
With the exception of the missing hydrogen bond at the F110 position, ʟ-lysine adopts the same 
conformational side chain positions.  Hydrogen bonding networks observed in the Cj-
DHDPS:pyr:lys (4M19) structure are preserved in the Y110F:pyr:lys (4MLR) structure.  As in the 
Cj-DHDPS:pyr:lys (4M19) structure, ʟ-lysine was clearly seen in the initial Fo-Fc electron density 
map, and is bound in the allosteric site in a head-to-head orientation in the Y110F:pyr:lys (4MLR) 
structure.  As for the structures without ʟ-lysine, comparison of the Y110F:pyr (4MLJ) structure 
with the wt:pyr (4LY8) structure shows that they are nearly identical (Cα rmsd of 0.25 Å).  
Therefore from a structure-function perspective the lack of hydroxyl at F110 must play a 
significant role in the observed dynamics of catalysis and inhibition.  
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Phe110 is unable to form a hydrogen bond with ʟ-lysine, and the structure displays few of the 
shifts associated with the Cj-DHDPS:pyr:lys (4M19) structure.  Although the helices flanking the 
allosteric site shift when ʟ-lysine is bound in Y110F, the changes noted for wt-Cj-DHDPS at the 
weak dimer interface are missing in the Y110F:pyr:lys (4MLR) structure.  Additionally, the 
domain scale movements noted by DynDom for Cj-DHDPS:pyr:lys (4M19) are absent in the 
Y110F:pyr:lys (4MLJ) structure.  Therefore we can conclude that the Y110F:pyr:lys (4MLR) 
structure is more similar to the Cj-DHDPS:pyr (4LY8) structure than to the Cj-DHDPS:pyr:lys 
(4M19) structure.  Finally, the changes to solvent accessible volume at the allosteric, and active 
sites are significantly less upon ʟ-lysine binding in Y110F compared to wt-Cj-DHDPS.   
It is remarkable that all structural changes associated with ʟ-lysine binding in wt-Cj-DHDPS 
have been significantly reduced, or eliminated with the loss of a single hydrogen bond in the 
allosteric site.  The kinetic data indicates that Y110 is important for ʟ-lysine inhibition; while the 
crystal structures clearly demonstrate that ʟ-lysine binds, but has muted structural effects on the 
enzyme.  Therefore the hydrogen bond between the inhibitor ʟ-lysine and Tyr110 is of critical 
importance in the effective allosteric signal transduction.  
3.4 Structure of WT and Y110F-DHDPS with Bislysine  
The history and efficacy of the bislysine inhibitor is described in section 1.5.6. 
3.4.1    Secondary Bislysine Binding Site 
In addition to bislysine at the allosteric site, two more bislysine molecules were found within 
the crystal’s asymmetric unit.  The secondary bislysines were bound to the same surface site in 
two out of four monomers.  The secondary binding site is located at the opposite end of the β-
barrel from the enzyme’s active site.  The binding site is composed of random surface loops, with 
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minimal rearrangement to accommodate the binding of bislysine (Figure 3.12).  On the other 
monomers one secondary binding site was buried by crystal contacts from a symmetry related 
molecule and the other is open to solvent space.  Examination of the protein structure does not 
reveal any logical link from the secondary bislysine binding site to either the active site or the 
known allosteric binding site.  Throughout all inhibition studies there has not been any indication 
of either secondary inhibitor binding or effect.  Therefore, it is reasonable to conclude that this 
secondary binding site is an artifact of the crystallization conditions. 
 
Figure 3.12 – An Artifactual binding site for bislysine. Panel A gives a global view of the DHDPS tetramer 
indicating the location of four bound bislysine molecules (PDB: 4RT8).  Two bislysine are bound in the known 
allosteric site and two bislysine are bound at a newly identified site.  Panel B shows Fo-Fc electron density omit map 
of bislysine and highlights the residues forming this secondary binding site. 
 
3.4.2    Effects of Bislysine on wt-DHDPS 
A comparison of the Cj-DHDPS:pyr:bislysine (4RT8) structure to the Cj-DHDPS:pyr (4LY8) 
structure reveals several side chain movements to accommodate bislysine in the allosteric site 
(Figure 3.13).  There is notable contraction around the allosteric site; it appears as if the helices 
shift into the allosteric site when bislysine is bound, as noted by the backbone Cα's in helices 
A B 
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flanking the allosteric site.  Using CASTp, we calculate the solvent accessible volume of the 
allosteric site to be 214 Å3, which represents a 49% reduction in volume from the wt:pyr structure 
(4LY8). 
 
Figure 3.13 – Superposition of wt:pyr:bislysine with wt:pyr:lys and wt:pyr.  The structure of wt:pyr (4LY8) is 
depicted in sliver, wt:pyr:lys (4M19) is orange with ʟ-lysine in blue, and wt:pyr:bislysine (4RT8) is green with 
bislysine in purple.  Upon binding of bislysine DHDPS undergoes the same conformational changes at the allosteric 
site as it does when binding ʟ-lysine. 
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Since bislysine is a 300-fold more effective inhibitor than ʟ-lysine, we anticipated either 
enhanced structural affects in the active site or stronger binding affinity, or both.  However, 
contrary to the effects of ʟ-lysine; bislysine induces only one change to the geometry of the 
catalytic triad: the hydrogen bond distance of two residues, Y137 – T47, in the catalytic triad is 
reduced (3.4 Å to 3.0 Å; Figure 3.16, panel C).  However, the solvent accessible active site volume 
increases 35% from 20 Å3 to 27 Å3 (Table A.3).  These observations underscore the significance 
of the catalytic triad, and the importance of a proper-sized active site.  
Inhibition studies indicate that two bislysine molecules exhibit binding cooperativity across the 
weak dimer interface.1  For this reason comparisons were made on the conformation of the weak 
dimer interface in wt:pyr (4LY8), and wt:pyr:bislysine (4RT8).  At the weak dimer interface, the 
secondary structures remain largely intact; indeed, there is less rearrangement than observed for 
wt:pyr:lys (4M19).  The effects that ʟ-lysine has at the weak dimer interface are not captured in 
the wt:pyr:bislysine crystal structure, and yet cooperativity is observed across the weak dimer 
interface, making the structural basis for cooperativity particularly difficult to explain. 
3.4.3    Comparison of wt-DHDPS with ʟ-lysine and with Bislysine 
As expected, bislysine occupies the binding site of two ʟ-lysine molecules within one allosteric 
site.  The bislysine completes all of the hydrogen bonds and side chain accommodations as 
described previously for ʟ-lysine binding to wt-DHDPS.  Indeed, of all the hydrogen bonds formed 
between the enzyme and inhibitor, only one is significantly different from those in the wt:pyr:lys 
(4M19).  The bond between the ʟ-lysine-Nζ, and the carbonyl oxygen of Leu54 is longer in the 
bislysine structure (4.2 Å) than in wt:pyr:lys (3.3 Å; Figure 3.14). 
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Figure 3.14 – A small difference in hydrogen bonding at the Nζ of ʟ-lysine vs bislysine.  Thewt:pyr:bislysine 
structure (4RT8) is shown in green with bislysine in purple.  The wt:pyr:lys structure (4M19) is shown in grey with 
ʟ-lysine also in grey.  There is an obvious change in length for the hydrogen bond from Nζ to L54(CO).  However, 
the hydrogen bond difference between Nζ to H59 cannot be considered significant. 
 
Bislysine is known to inhibit wt-DHDPS 300 times more effectively than the natural inhibitor, 
ʟ-lysine.1  One possibility is that any structural changes critical to inhibition would be enhanced 
or become more obvious.  However, a number of structural changes observed when ʟ-lysine binds 
to wt-DHDPS are not seen when bislysine binds to DHDPS.  Notably there is no detection of 
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concerted domain movements, despite the obvious movement in helices close to the allosteric site.  
It is possible that the structural distortions caused by bislysine do not induce unified domain 
movement.  Or, perhaps that domains labeled in the binding of ʟ-lysine have become too small or 
distorted to be considered proper domains. 
As noted above, the allosteric site of wt:pyr:bislysine (4RT8) is 49% smaller than that of the 
wt:pyr structure (4LY8).  Whereas the wt:pyr:lys (4M19) allosteric site is only 43% smaller than 
the solvent accessible volume of the wt:pyr structure (4LY8).  At the active site, bislysine increases 
the solvent accessible volume by 35% from that of wt:pyr (4LY8), while the natural inhibitor ʟ-
lysine induces only 27% increase in solvent accessible volume.  This observation leads us to 
believe that the volume of the active site may be critical to effective catalysis, and therefore a 
potential control mechanism. 
When comparing the active site of the wt:pyr:lys (4M19) structure to the wt:pyr (4LY8) 
structure, a number of small changes were noted (Section 3.2.3).  Interestingly, many of these 
small changes are not observed when comparing the active site of the wt:pyr:bislysine (4RT8) 
structure to the wt:pyr (4LY8) structure.  Active site changes which are not observed between 
wt:pyr:bislysine and wt:pyr are: Y137 – Y111' (4.7 Å to 4.7 Å); the C1 of the pyruvyl Schiff base 
and the carbonyl of I207 (3.8 Å to 3.8 Å); and G190 (and 4.7 Å to 4.5 Å).  The major changes to 
the catalytic triad (Y137 – T47; 3.4 Å -> 2.9 Å) are affected by both ʟ-lysine and bislysine.  Many 
prior studies have indicated the importance of the catalytic triad by eliminating one or more 
residues.4, 16  However, it would appear that the length of hydrogen bonds between members of 
the catalytic triad may be as important as their identity and presence.  
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Both ʟ-lysine, and bislysine have been shown to exhibit cooperativity across the weak dimer 
interface.  Comparison of this region between wt:pyr (4LY8) and wt:pyr:lys (4M19) revealed 
several dramatic rearrangements potentially facilitating cooperativity between allosteric sites cross 
the weak dimer interface.  Interestingly, none of these structural changes are present in the 
wt:pyr:bislysine structure (4RT8).  Changes identified in the wt:pyr:lys structure (4M19) are 
potentially involved in cross dimer communication; however, their absence in the wt:pyr:bislysine 
(4RT8) is contradictory and the cooperativity phenomenon remains difficult to explain. 
3.4.4    The Effects of Bislysine Binding to Y110F DHDPS 
The point mutation Y110F is particularly interesting as the loss of a single hydroxyl group at 
the allosteric site results in extreme insensitivity to the natural inhibitor ʟ-lysine.  The IC50 for 
Y110F-DHDPS with ʟ-lysine is approximately 40 mM, which is 600 times weaker than the 65 µM 
IC50 of wt-DHDPS with ʟ-lysine.  The synthetic inhibitor bislysine is capable of strongly inhibiting 
the Y110F mutant DHDPS.1  Evidently, the hydroxyl of Y110 is important to the mechanism of 
allosteric inhibition but, the efficacy of bislysine indicates that there must be other structure-
function links between the allosteric site and the active site; therefore, the structure of Y110F-
DHDPS with bislysine in the allosteric site should reveal communication between the allosteric 
and active site which are not attributable to tyrosine 110. 
Unique to the crystal structure of Y110F:bislysine (4RT9) is the fact that the K166-pyruvate 
Schiff base adduct did not resolve within the active site.  It cannot be ruled out that crystallization 
with bislysine may be selective for a pyruvate-free active site or drives pyruvate release.  As with 
other DHDPS structures, pyruvate was never introduced to the enzyme prior to crystallization.  In 
addition to possible inhibitory effects, there may have been a shift in equilibrium due to differences 
in crystallization conditions or cryoprotection which are not present in other DHDPS workups.  
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Both ʟ-lysine and bislysine have been shown to enhance the binding of pyruvate,1 and thus a likely 
explanation is one of low occupancy due to crystallization conditions, rather than an inhibitory 
effect. 
3.4.4.1         Absence of Domain Movement in Y110F:bislysine 
Bislysine binds to Y110F-DHDPS in the same manner as bislysine in wt-DHDPS; which, for 
both wt-DHDPS and Y110F-DHDPS bislysine occupies the same space as two ʟ-lysines do in 
either wild-type or Y110F-DHDPS.  The same network of new hydrogen bonds is completed in 
all structures.  As with structures described previously, the helices flanking the allosteric site, in 
Y110F-DHDPS, appear to move towards the inhibitor bislysine, as judged by Cα positions (Figure 
3.15).  We used DynDom to examine Y110F:bislysine (PDB: 4RT9) for domain scale movement.  
Similar to the case of Y110F-DHDPS with ʟ-lysine, DynDom does not detect any domain scale 
movements.  In the wild-type DHDPS, Y110 is at the heart of the moving domain, and is observed 
to move more than 1 Å to accommodate the inhibitor in the allosteric site.  In Y110F-DHDPS this 
accommodation is absent.  It is possible that without the movement of the aromatic core, the 
integrity of the domain has been lost such that moving regions have become too small or movement 
vectors are no longer synchronous and thus dynamic domains cannot be defined.  Whatever the 
case may be, it appears that Y110 is correlated to domain movement, and said domain movement 
is not critical to the inhibition of the enzyme.  
At the active site, there is only one notable change: the distance between Y111' and Y137 has 
increased from 4.6 Å to 5.0 Å (Figure 16, panel A).  Interestingly, this is the same change observed 
for ʟ-lysine bound to Y110F-DHDPS, but not observed in any wt-DHDPS with either ʟ-lysine or 
bislysine (Figure 16 panels B, C, D).  In the case of wt:pyr:lys (PDB: 4M19) the same distance 
between Y111' - Y137 is reduced from 4.7 Å to 4.2 Å (Figure 16, panel D).  The changes observed 
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in the catalytic triad of wt:pyr:lys are all distinctly different from those changes observed in 
wt:pyr:bislysine (4RT8), where the catalytic triad shifts in the hydrogen bond between Y137-T47 
from 3.4 Å to 3.0 Å (Figure 16, panel C).  Nevertheless, it appears that in all cases of inhibitor-
binding to DHDPS, the geometry of the catalytic triad has been affected.  
 
Figure 3.15 – Superposition of Y110F:bislysine with Y110F:pyr:lys and Y110F:pyr  The structure of Y110F:pyr 
(4MLJ) is depicted in yellow, Y110F:pyr:lys (4MLR) is pink with ʟ-lysine in white, and Y110F:pyr:bislysine (4RT9) 
is blue with bislysine in purple.  Upon binding of bislysine, Y110F-DHDPS undergoes the same conformational 
changes at the allosteric site as it does when binding ʟ-lysine.  We note the Cα of flanking helices move towards the 
allosteric site; however, there is no concerted domain movements. 
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Figure 3.16 – Allosteric effect at the active site.  Panel A shows Y110F:bislysine (PDB: 4RT9) in blue super-
positioned on Y110F:pyr (4MLJ) shown in yellow.  The distance between Y137/Y111' is increased from 4.6 – 5.0 Å 
when bislysine binds.  Panel B shows Y110F:pyr:lys (4MLR) in pink superimposed on Y110F:pyr (4MLJ) in yellow.  
Here, we also see he distance between Y137/Y111' has increased from 4.6 – 5.0 Å.  Panel C shows wt:pyr:bislysine 
(4RT8) in green superimposed on wt:pyr (4LY8)shown in silver.  In the wild type structure we see the distance 
between Y137/Y111' is unchanged, and the distance between Y137/T47 is decreased 3.4 – 3.0 Å when bislysine binds.  
Panel D shows wt:pyr:lys (4M19) in purple and wt:pyr (4LY8) in silver.  We see that when ʟ-lysine binds it affects 
the distance between Y137/Y111'; however, the bond is shortened 4.7 - 4.2 Å rather than lengthened as we see in other 
structures. 
 
 
 
A B 
C D 
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3.4.4.2         Cavity volumes in Y110F:bislysine 
As with other structures, the shifting Cα positions around the allosteric site was readily 
apparent.  We therefore examined the solvent accessible volume of both the active site and 
allosteric site using CASTp.  The solvent accessible volume of the Y110F:bislysine (PDB: 4RT9) 
allosteric site is 278 Å3,  which is 33% smaller than wt:pyr (4LY8), 38% smaller than Y110F:pyr 
(4MLJ), 16% smaller than Y110F:pyr:lys (4MLR), and 16% larger than wt:pyr:lys (4M19; Table 
A.3).  Unfortunately, Y110F:bislysine (PDB: 4RT9) did not crystallize with pyruvate at the active 
site.  This makes direct comparisons of the active sites between all DHDPS structures difficult.  
Using CASTp we measured the pyruvate free active site volume of Y110F:bislysine (4RT9) as 42 
Å3.  We can compare this directly to the active site volume of the apo-DHDPS (PDB: 4R53), which 
is 36 Å3; thus bislysine induces a 17% increase in the active site volume over that of apo-DHDPS.   
If we assume that changes in active site volume between apo-DHDPS (PDB: 4R53) and each 
of wt:pyr (4LY8), and Y110F:pyr (4MLJ) are exclusively due to the presence of pyruvate and not 
rearrangement of the enzyme, then we can hypothesize the effects bislysine may have on the active 
site of Y110F:bislysine (4RT9).  The average difference between the active site volume of wt-apo-
DHDPS and wt/Y110F:pyr is 15 Å3, which we determine to be the volume occupied by the 
pyruvate adduct, based on previous assumptions.  Based on this, 15 Å3 is subtracted from the 
measured active site volume of Y110F:bislysine (41.8 Å3), and the remaining volume if pyruvate 
was present would be approximately 26 Å3.  From this analysis the active site volume of 26 Å3 
represents a 18% increase from the active site volume of 22 Å3 in Y110F:pyr (4MLJ).  Thus 
Y110F:pyr:lys (PDB: 4MLR) demonstrates little to no change in active site volume relative to 
Y110F:pyr (4MLJ) which corresponds with little to no inhibition; whereas bislysine restores the 
 
 
97 
 
trend for increasing the volume of the active site when strong inhibition is observed.  These results 
reinforce the correlation noted between strong inhibition and increasing volume at the active site. 
3.4.5    Discussion: Possible Contributions to Stronger Bislysine Inhibition 
Bislysine inhibits wt-DHDPS 100,000 times stronger than the natural inhibitor ʟ-lysine.1  
Despite near incomplete insensitivity to ʟ-lysine, Y110F-DHDPS is inhibited by bislysine at nearly 
the same potency as wt-DHDPS.  Stronger inhibition may be attributable to tighter binding or 
enhanced activation of allosteric mechanisms.  It was anticipated that crystallization of the 
synthetic inhibitor bislysine, with each of wild-type and Y110F-DHDPS would provide insight 
into the mechanism for enhanced inhibition, and therefore natural inhibition of ʟ-lysine. 
It must be considered that entropy of binding is the most obvious contribution to enhanced 
inhibition.  Results of Isothermal Titration Calorimetry experiments performed by Phenix and 
Palmer indicate that binding of ʟ-lysine has a large entropic component.17  Combining two ʟ-lysine 
molecules with a 2-carbon linker will decrease the entropic barrier for binding of the second 
inhibitor molecule to occupy both sides of the allosteric site.  The result is a greater increase in 
entropy for the binding event, which would lead to an overall greater decrease in free energy.1, 17   
Furthermore, inhibition studies of DHDPS with bislysine indicate that binding of bislysine is a 
slow two-step process.1  The crystal structure indicates that much of the bislysine inhibitor is buried 
within the allosteric site, with H56 acting as a cap.  One can imagine that a series of conformational 
changes must occur to both the enzyme and inhibitor as bislysine slides into each half of the 
allosteric site (Figure 3.17).  It is highly likely that a similar sequence of conformational changes 
must happen during dissociation.  Therefore, it is likely that dissociation is an equally slow two-
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step process which contributes favorably to enhanced inhibition.  The H56 probably plays a very 
important role when capping the allosteric site. 
 
Figure 3.17 – Molecular Surface around the DHDPS allosteric binding pocket.  The figure depicts bislysine 
(purple) bound within the allosteric site of wt-DHDPS (PDB: 4RT8) in green.  Select residues are shown which form 
a "lid" on the allosteric site.  One can envision that a series of conformational changes are required for bislysine to 
either bind or dissociate from the allosteric site. 
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In addition to arguments for tighter binding of bislysine, consideration must be made for 
enhancement of the allosteric signal for inhibition.  Although increased binding affinity may 
contribute the most to enhanced inhibition there are subtle differences between the structures of 
DHDPS with ʟ-lysine or bislysine which suggest enhancement or changes to the structural 
mechanism of inhibition.  Structural analysis of DHDPS with bislysine are considerably less 
numerous than the myriad of effects noted for the binding of ʟ-lysine.  That is to say, in the case 
of bislysine we observe only a handful of specific structural changes upon binding of bislysine to 
either wild type, or Y110F-DHDPS.  One can envision two dynamic structural states of the 
enzyme which exist in equilibrium: an uninhibited state, and a maximally inhibited state.  It is 
possible that the diverse changes of the wt:pyr:lys (PDB: 4M19) structure, relative to wt:pyr 
(PDB: 4LY8) represents an incomplete shift in equilibrium towards the maximally inhibited 
structure; whereas, the stronger inhibitor, bislysine, will drive the enzyme to be dominated by a 
fully inhibited conformation.  If inhibition of DHDPS is indeed dependent on an equilibrium of 
dynamic conformations then protein dynamics may play a large role which we have not 
empirically examined.  Logically those structural changes which are observed for both ʟ-lysine 
and bislysine should be considered more important to the mechanism of allostery than those 
structural changes which are observed only in the case of ʟ-lysine. 
In a comparison of six structures (wt:pyr, 4LY8; Y110F:pyr, 4MLJ; wt:pyr:lys, 4M19; 
Y110F:pyr:lys, 4MLR; wt:pyr:bislysine, 4RT8; Y110F:bislysine, 4RT9) we can identify two 
changes to the active site common to the binding of both the allosteric inhibitors ʟ-lysine and 
bislysine (Figure 3.16).  Both inhibitors induce changes in the geometry of the catalytic triad 
(Y137, T47, Y111'), though the specific change is unique to either wt-DHDPS or Y110F-DHDPS.  
In wt-DHDPS we note that both ʟ-lysine, and bislysine decrease the hydrogen bond distance 
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between Y137-T47 from 3.4 Å to 2.9 Å, and 3.0 Å respectively.  In contrast, binding of ʟ-lysine 
or bislysine to Y110F-DHDPS increases the distance between Y111'-Y137 from 4.6 Å to 5.1 Å 
and 5.0 Å respectively.  Interestingly, in the wt-DHDPS the distance between Y111'-Y137 is 
decreased from 4.7 Å to 4.2 Å when ʟ-lysine is bound, but is unaffected when bislysine is bound.  
Deletion of any residue involved in the catalytic triad has been shown to have a dramatic effect on 
the enzymes activity.4, 16  The observations suggest that modification of local pKa’s in an 
inherently dynamic catalytic triad may be integral to inhibition, as well as catalysis.  Unfortunately, 
consideration of the catalytic triad alone cannot fully explain the difference in inhibitor sensitivity 
between Y110F:pyr:lys and Y110F:bislysine.  
Regarding the phenomenon of antipolar cooperation, there are select residue movements at the 
weak dimer interface observed when ʟ-lysine binds to wt-DHDPS suggesting possible means for 
cross dimer communication.  However, no such residue movements are observed in either 
wt:pyr:bislysine (PDB: 4RT8) or Y110F:bislysine (4RT9).  This is drastically different from the 
multiple rearrangements observed in wt:pyr:lys (4M19), making it impossible to draw any 
convincing conclusions. 
Interestingly, the absence of domain movement in structures with bislysine suggests that 
domains highlighted when ʟ-lysine binds to wt-DHDPS have only coincidental importance.  
Domain movements are clearly outlined when comparing the structures of wt:pyr (PDB: 4LY8) 
with wt:pyr:lys (4M19).  However, there are no domain movements observed when either ʟ-lysine 
or bislysine binds to Y110F-DHDPS.  It is possible that the central location of the point mutation 
Y110F splits the domain such that the bulk of the enzyme does not move as a whole.  However, 
the structure of wt:pyr:bislysine (4RT8) is also lacking in well-defined domain movements relative 
to wt:pyr (4LY8), despite the intact hydrogen bond to Y110, which is more difficult to rationalize.  
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Bislysine remains a highly effective inhibitor and the simplest conclusion is that domain 
movements are not critical for reducing catalytic activity of DHDPS.  This gives more weight to 
local effects at the active site; such as solvent accessible volume, and the arrangement of the 
catalytic triad.   
The dynamic domains likely have some peripheral role.  Perhaps dynamic domains contribute 
to the mechanism of cross dimer cooperativity, or govern the inherent dynamics and stability of 
Cj-DHDPS.  Based on inhibition analysis and Hill coefficients, subtle differences may be 
anticipated in the cooperativity of ʟ-lysine vs bislysine;1 which may result in slightly different 
structural effects.  
The most profound correlation is that of solvent accessible volume in the active site and 
allosteric site relative to the strength of inhibition.  At the allosteric site the greatest enzyme 
inhibition is correlated to the greatest decrease in solvent accessible volume (Figure 3.18).  
Considering the dynamic model of protein-ligand binding this would appear to be intuitively linked 
to the strength of inhibitor binding.  However, we must also consider that, although the mechanism 
of allostery is unknown, the magnitude of structural displacement at the allosteric site is likely to 
have effects throughout the protein, including the active site.  The volume phenomenon at the 
allosteric site is mirrored at the active site, where the strength of the inhibitor is correlated to 
increasing solvent accessible volume.  The active site volume of wt:pyr (PDB: 4LY8) and 
Y110F:pyr (4MLJ) are effectively the same, at 20 Å3 and 22 Å3 respectively.  When an inhibitor 
is bound to DHDPS the solvent accessible volume of the active site is increased relative to wt:pyr: 
Y110F:pyr:lys ±0%, wt:pyr:Lys +30%, Y110F:bislysine +30%, and wt:pyr:bislysine +35%.  
Clearly, the solvent accessible volume of the active site is strongly correlated to the activity of the 
enzyme.  Unlike the previously noted changes to the geometry of the catalytic triad, which may 
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affect the reactivity of ASA, changes in the volume of the active site are likely to affect the binding 
affinity of ASA. 
The increased volume of the active site may reduce the enzymes affinity for ASA or destabilize 
the catalytically competent conformation of ASA.  When bislysine is bound the active site volume 
increases on par with wt-DHDPS:pyr:bislysine.  Since the mutant enzyme is inhibited to the same 
extent as the wild-type enzyme then changes in the volume of the active site very likely play an 
important role in the mechanism of inhibition.  The changes noted for the active site suggest that 
inhibition of DHDPS may be a combined result of perturbations to the catalytic triad and increase 
in solvent accessible volume of the active site. 
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** Estimated solvent accessible volume if pyruvate had been present in the active site. 
Figure 3.18 – Bar Charts depict volume changes at the active site and allosteric site.  Solvent accessible volumes 
calculated using CASTp12, 13 as described in the text, and excluding ʟ-lysine from the model.  Changes to the solvent 
accessible volume are correlated to the strength of inhibition.  (■) Cavity Volume; (■) % DHDPS activity.     
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3.5 Structure of wt-DHDPS with ʟ-Thialysine 
ʟ-Thialysine is a weak inhibitor of DHDPS.  Despite its similarities with the natural inhibitor 
ʟ-lysine, ʟ-thialysine has an IC50 of only 2 mM, which is 30 times weaker than ʟ-lysine (IC50 65 
µM).1  It is unclear why such a similar molecule should be so ineffective as an inhibitor.  Structural 
studies will help to reveal the subtleties of inhibitor strength. 
3.5.1    wt-DHDPS with ʟ-Thialysine 
Despite weaker electron density, ʟ-thialysine is readily modeled into the allosteric site.  Two ʟ-
thialysine molecules bind in each dimeric allosteric site in a "head-to-head" fashion, with two fold 
symmetry (Figure 3.3).  Superficially, ʟ-thialysine appears to bind in the very same fashion as that 
of ʟ-lysine.  The strongest argument for weak inhibition would appear to be the strength of binding; 
this is supported by weak electron density, in the Fo-Fc map, indicating low occupancy, and the 
higher concentration of ʟ-thialysine which was required to obtain the crystal structure relative to 
ʟ-lysine. 
3.5.2    Comparison of wt-DHDPS with and without ʟ-Thialysine 
As with ʟ-lysine and bislysine, we first compare the wt:pyr:thialysine structure to that of wt:pyr.  
From a global perspective there is remarkably little structural difference, with an rmsd of 0.38 Å.  
Whereas comparison of wt:pyr:thialysine to wt:pyr:lys (PDB: 4M19) has an rmsd of 0.40 Å.  There 
is of course some movement of side chains in and around the allosteric site to accommodate ʟ-
thialysine (Figure 3.19).  We can also see the Cα's of helices closing the allosteric site; although, 
not as pronounced as observed for ʟ-lysine or bislysine.  As was performed for other DHDPS 
structures, we examine the structures for domain movement, and made measurements of the 
volume of the allosteric and active sites. 
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Structural analysis of wt:pyr:thialysine and wt:pyr (PDB: 4LY8) using DynDom reveals 
domain movements only in one of eight wt:pyr:thialysine monomers.  Although the pattern of 
moving and stationary domains is the same as that for wt:pyr:lys (4M19), a one in eight 
representation can only be considered inconclusive at best, and is more than likely anomalous.  
Optimistically, examination of symmetry related molecules reveals that there is no reason to 
believe that this is a result of crystal packing, and therefore low representation of domain 
movement may be correlated to the low occupancy of ʟ-thialysine. 
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Figure 3.19 – Superposition of wt:pyr:thialysine with wt:pyr.  The structure of wt:pyr (PDB: 4LY8) is depicted in 
white, wt:pyr:thialysine is brown with ʟ-lysine in blue.  Upon binding of thialysine wt-DHDPS undergoes the same 
conformational changes at the allosteric site as it does when binding ʟ-lysine.  We note the Cα of flanking helices 
move towards the allosteric site; however, only 1 in 8 monomers suggests any domain movements. 
 
Using CASTp we can measure the solvent accessible volume of the wt:pyr:thialysine active site 
and allosteric site.  The allosteric site has a solvent accessible volume of 267 Å3, and the active 
site has a solvent accessible volume of 21 Å3.  Each of these measurements agrees with the 
previously noted correlations between strength of inhibitor and solvent accessible volume at the 
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active site (Table A.3).  When ʟ-thialysine binds to wt:pyr (PDB: 4lY8), the allosteric site 
decreases in size by 36%, while the active site solvent accessible volume is effectively unchanged.  
Therefore, although ʟ-thialysine binds to DHDPS, it does not induce the principal change at the 
active site that we associate with strong inhibition.  This suggests that the relationship between 
inhibitor strength and active site volume is indeed one of cause and effect and a necessity for 
successful inhibition. 
Not surprisingly, there is very little movement of individual residues within the active site of 
wt:pyr:thialysine, and   an examination of the weak dimer interface of wt:pyr:thialysine compared 
to wt:pyr (4LY8) revealed no changes.  The only notable rearrangement is within the catalytic 
triad.  The hydrogen bond between Y137 and T47 is reduced from 3.4 Å, to 2.9 Å (Figure 3.20).  
The same movement for these residues is seen in the structure of wt:pyr:lys (4M19), and 
interestingly, is also the sole residue movement observed in the active site of wt:pyr:bislysine 
(4RT8).  The limited inhibition observed for ʟ-thialysine is probably attributable to this change at 
the catalytic triad, while volume changes serve to enhance the effects of ʟ-lysine and bislysine. 
 The reduction of the hydrogen bonding distance between Y137 to T47 is observed with three 
allosteric inhibitors of varied efficacy, suggesting that the length of this bond is critical to the 
mechanism of allosteric inhibition.  However, despite observing the same residue movement when 
each inhibitor is bound, the efficacy of each is highly variable.  This suggests the observed change 
in hydrogen bonding length is not solely responsible for inhibition of the enzyme.  Regardless of 
the inhibitory magnitude attributable to this one hydrogen bond, the observations reinforce our 
conviction that modifications to the geometry of the catalytic triad are required for effective 
enzyme inhibition. 
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Figure 3.20 – Allosteric effect at the active site of wt:pyr:thialysine.  This figure depicts wt:pyr:thialysine (brown) 
super-positioned on wt:pyr (4LY8) shown in whit.  The hydrogen bond between Y137/T47 is decreased 3.4 – 2.9 Å 
when thialysine binds. Which is analogous to the allosteric effect of bislysine; where the hydrogen bond between 
Y137/T47 is reduced 3.4 – 3.0 Å.  In contrast the allosteric effect of ʟ-lysine is to reduce the distance between 
Y137/Y111': 4.7 – 4.2 Å. 
3.5.3    Comparison of WT-DHDPS with ʟ-Lysine and ʟ-Thialysine 
As mentioned previously (section 3.5.1), ʟ-thialysine appears to bind to DHDPS in the same 
manner as ʟ-lysine.  Only a handful of structural changes are conserved between binding of ʟ-
lysine or ʟ-thialysine; however, in many cases the magnitude of the effect is less.  Many of the 
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structural effects noted for binding of ʟ-lysine to wt-DHDPS are entirely absent in 
wt:pyr:thialysine.  It is for this reason that one might describe the changes observed between wt:pyr 
(PDB: 4LY8) and wt:pyr:thialysine as incomplete.   
The most obvious trend is the effect that ʟ-thialysine has on cavity volumes at the allosteric site 
and at the active site.  Whereas ʟ-lysine induces a 43% reduction in the volume of the allosteric 
site and a 30% increase in the volume of the active site; the effect of ʟ-thialysine binding is less 
intense, with a 36% reduction in volume at the allosteric site, and no significant change at the 
active site (Figure 3.18).  This observation supports the previously identified correlation between 
the strength of an inhibitor and its effect on solvent accessible volume of the active site and 
allosteric site.  Furthermore, at the active site we identify one change which is common to the ʟ-
thialysine and ʟ-lysine structures.  At the active site, the hydrogen bond between Y137 and T47 is 
reduced from 3.4 Å to 2.9 Å.  As members of the catalytic triad, the Y137-T47 pair is of significant 
importance to the enzyme’s catalytic mechanism.  
3.5.4    Discussion 
As a weak inhibitor (IC50), ʟ-thialysine provides a necessary contrast to the structural 
examination of the natural inhibitor ʟ-lysine, and the super inhibitor bislysine.  Logically, the role 
of structural changes induced by both ʟ-thialysine and other stronger inhibitors should be 
discounted in their contribution to enzyme inhibition.  However, if the strength of the binding 
interaction is the primary reason for weaker inhibition, then it would be reasonable to expect that 
overwhelming concentrations of a weak inhibitor should activate the same structural mechanism 
for allosteric inhibition.  In essence, the argument is either for mechanical non-activation of 
allostery, or non-inhibition due to non-binding of the inhibitor. 
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The inhibitor ʟ-thialysine bears remarkable similarity to the natural inhibitor ʟ-lysine, and is 
known to inhibit DHDPS at sufficiently high concentrations.1  Examination of crystal structures 
in this study reveals that ʟ-thialysine occupies the same binding site and conformation as the 
natural inhibitor.  It should be noted that occupancy of ʟ-thialysine is less than ʟ-lysine, despite 
using three times the concentration in the crystallization conditions.  Structural changes noted 
between wt:pyr (PDB: 4LY8) and wt:pyr:thialysine (though muted) are common to both wild-type 
and mutant structures containing ʟ-lysine or bislysine.   
The structure of wt-DHDPS:pyr:thialysine suggests that certain structural changes are 
incompletely stimulated by ʟ-thialysine.  Therefore, it would appear that weak inhibition of ʟ-
thialysine is attributable to weak binding rather than non-activation of the allosteric mechanism.  
Weak binding may be attributable to two factors, each related to the inclusion of sulfur at the C-4 
position: the length and volume of the side chain due to a larger atomic radius of sulfur, and the 
pKa of the terminal amino group which is 9.52 in ʟ-thialysine and 10.53 in ʟ-lysine.1 
3.6 Crystallization of wt-DHDPS with (S)-ASA 
3.6.1    DHDPS with Reduced Schiff Base 
Prior to crystallization, DHDPS was incubated with pyruvate followed by sodium 
cyanoborohydride (BH).  Under these conditions, pyruvate will bind to the enzyme forming an sp2 
hybridized Schiff base, and sodium cyanoborohydride will reduce the Schiff base to a dead-end 
sp3 hybridized tetrahedral adduct (BH-DHDPS:lac; Scheme 3.1).  After treatment with sodium 
cyanoborohydride the enzyme activity was found to be zero according to the assay methods of 
Skovpen et al. outlined in section 2.2.5.2.3 of the Methods Chapter in this thesis.1, 2  After dialysis, 
crystals of the reduced BH-DHDPS:lac crystallized as previously described.  Examination of the 
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Fo-Fc map around K166-pyr in the active site indicates successful sp
3 hybridization, which is 
further reinforced by a complete absence of enzymatic activity. 
 
Scheme 3.1 – Reaction Scheme for the reduction of the K166-pyruvate Schiff Base.  Using sodium 
cyanoborohydride the DHDPS:pyr Schiff Base is reduced to an sp3 hybridized dead-end complex BH-DHDPS:lac. 
 
Comparison of the reduced BH-DHDPS:lac with the wt:pyr (PDB: 4LY8) structure reveals a 
high degree of similarity: 0.195 Cα rmsd.  Despite this, we can identify two key structural changes 
involving the catalytic triad and the solvent accessible volume of active and catalytic sites.  At the 
active site of wt-BH-DHDPS:lac, the solvent accessible volume is reduced 10% relative to the 
wt:pyr (4LY8); from 20 Å3 to 18 Å3.  Interestingly, examination of the catalytic triad reveals 
changes similar to those observed when ʟ-lysine binds to the allosteric site in wt:pyr:lys (4M19).  
The hydrogen bond between Y137-T47 is reduced from 3.4 Å to 2.9 Å, and the distance between 
Y111'-Y137 is reduced from 4.7 Å to 4.1 Å.  At the allosteric site, we see a 15% reduction in 
solvent accessible volume from 417 Å in wt:pyr:lys (4M19), and to 355 Å to BH-wt:pyr.  
The observations outlined above present a perplexing contradiction, since no inhibitor is present 
in the allosteric site.  Therefore consideration must be given to what may be cause and effect.  
Previously we proposed that binding of ʟ-lysine induced the noted structural changes.  
Alternatively, changes observed may be attributed to stabilization of enzyme dynamics, rather than 
the nature of the inhibitor.  If we consider that reducing the Schiff-base to a dead end complex may 
result in a stabilizing effect on the enzyme, then we may be artificially inducing similar structural 
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changes as binding a stabilizing inhibitor.  Unfortunately, the reduced form of DHDPS is not 
catalytically competent, which limits any biochemical insight of the observed structure; therefore, 
it is not clear if structural changes observed in BH-DHDPS would not result in inhibition if the 
enzyme were catalytically competent. 
3.6.2    DHDPS with Reduced Schiff Base and ASA 
The reduced DHDPS:pyr enzyme was co-crystallized in the presence of 100 mM ASA as 
previously described in this thesis (section 2.2.5.2 and 3.1.6).  At the active site the sp3 hybridized 
K166-lactate adduct is well-resolved.  There is also the addition of a strong, but poorly defined, 
blob of electron density at the position where ASA might be expected to bind.  Due to the 
amorphous nature of the electron density, it is not clear how ASA should be modeled (Figure 21, 
panel A). 
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Figure 3.21 – Preliminary modelling of ASA in the active site using Fo-Fc Map. Panel A: Amorphous electron 
density occupying the likely binding location of ASA.  Fo-Fc Omit map rendered at 0.5 σ.  Panel B: ASA modeled as 
the hydrate into the amorphous Fo-Fc omitt map at 0.5 σ prior to the use of the FEM algorithm. Panel C: Shows the 
Fo-Fc omit map for K166-lac scaled at 3 σ.  Proton positions are predicted for K166-lac and ASA.  For comparison 
Panel D shows the Fo-Fc map for K166-pyr (pdb: 4LY8) scaled at 3 σ. 
 
3.6.3    Identification of ASA in the Active Site 
The density blob in the active site is not attributable to any solvent molecules, or protein 
residues, and occupies the expected binding site for ASA.  When the electron density is scaled 
A B 
C D 
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between 0.5 – 0.7 σ it takes on the approximate size and shape of ASA (Figure 21, panel A).  We 
attempted to model ASA into the omit map, but the specific conformation is not obvious (Figure 
21, panel B).  The Phenix suite of crystallography software includes a program for calculating 
Feature Enhanced Maps (FEM).18, 19  The FEM program uses a series of algorithms to enhance the 
signal-to-noise ratio of the electron density map.19  The FEM program was run using the original 
MTZ map, and a fully refined protein model with ASA excluded to limit modeling bias.  The 
output feature-enhanced map is remarkably sharper than the standard omit map (Figure 22, panel 
A).  The amorphous electron density previously assumed to belong to ASA at 0.5 – 0.7 σ is now 
representative of a single conformation of ASA at 1.0 -1.5 σ (Figure 22, panel B). 
 
Figure 3.22 – Modeling ASA at the active site using the FEM algorithm Panel A: Feature Enhanced Map (FEM) 
of unidentified electron density in the active site displayed 1.0 σ.  The shape of the electron density is less ambiguous 
than the standard Omit map.  Panel B: ASA modeled as the aldehyde into the Feature Enhanced Map.   Proton positions 
are predicted for K166-lac and ASA. 
 
3.6.4    Occupancy and Conformation of ASA 
Several attempts were made to co-crystalize DHDPS with ASA at lower concentrations of ASA 
that did not come to fruition.  In order to observe even amorphous ASA electron density it was 
A B 
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necessary to use 100 mM of ASA.  Under these conditions ASA occupancy is calculated to be 
80% which gives confidence to the model.  The amorphous nature of the original Fo-Fc map may 
be the result of weak transient binding, or an averaging of several contributing conformations.20  
Furthermore, alteration of the enzymes active site by modifying K166-pyr from trigonal planar to 
tetrahedral may weaken the strength of binding, or provide "looseness" for alternative 
conformations. 
Indeed, the natural catalytic mechanism may be such that the incoming ASA reacts in a 
Theorell-Chance mechanism, where no stable complex is formed without reaction; therefore, two 
possibilities exist.  The first is that in its natural state, ASA is in a rapid equilibrium between bound 
and unbound states, where the unbound state is greatly favoured; however, once condensation 
occurs the reaction is driven downhill to cyclization, forming HTPA.  Thus, in the modified 
enzyme where no reaction is possible, ASA would favour the unbound over the bound state and 
the result will be lower and/or ambiguous occupancy.  The second possibility is that the reductive 
modification of the enzyme active site has altered the geometry or protein dynamics of the binding 
site such that ASA no longer has a high affinity. 
The reduction of the K166-pyr Schiff base from a trigonal planar to a tetrahedral conformation 
will of course alter the geometry and/or protein dynamics of the active site.  As well, loss of the 
double bond may have some effect on enzyme-substrate electrostatic interactions.  The FEM 
algorithms are designed to enhance the signal-to-noise ratio in the model of electron density.  
Should the original amorphous shape of ASA density be the average result of several 
conformations then the FEM algorithm is expected to extract the dominant conformation.19  We 
must remain open-minded that the dominant conformation may not be the requisite reactive 
conformation.  Furthermore, the modifications that have been made to the active site may have 
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altered the equilibrium of bound ASA conformations (such that a non-reactive conformation has 
become dominant), or that enzyme modifications have created the environment in which multiple 
bound conformations are possible. 
3.6.6    Comparison of DHDPS with and without ASA 
The dead end complex of DHDPS with ASA is the first of its kind, and gives us the opportunity 
to examine the structure function relationship of ASA in catalysis and inhibition.  It has been 
shown that ASA will reduce the enzyme’s affinity for the natural inhibitor ʟ-lysine, and vice-
versa.1, 2  Through an examination of the structure containing ASA we hope to better understand 
not only catalysis, but also inhibition of the enzyme. 
Superficially, there is little difference between the structures of DHDPS with ASA and without 
ASA.  The tetramer and all secondary structures remain intact.  Superposition of BH-DHDPS:ASA 
with wt:pyr reveals a 0.378 Cα rmsd, and no obvious structural rearrangements.  As with previous 
structure examination we leveraged several tools to examine key themes of structural 
rearrangement. 
Using CASTp we measured the solvent accessible volume of the active site and allosteric site.  
We determined the volume of the allosteric site to be 610 Å3 which represents a 46% increase in 
volume from the structure of wt:pyr (PDB: 4LY8; 417 Å3), and a 72% increase from the BH-
DHDPS (355 Å3; Figure 3.18).  This observation reveals an interesting branch to a previously 
noted trend.  In all structures containing an inhibitor at the allosteric site, we noted decreases in 
allosteric site volume proportional to the strength of inhibition.  We know that ASA reduces the 
enzyme’s affinity for ʟ-lysine, and here the crystal structure presents one possible explanation: 
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binding ASA induces expansion of the allosteric site volume which likely reduces the enzymes 
affinity for inhibitory molecules. 
The solvent accessible volume of the active site was determined using CASTp.  Here, the 
implications of our observations are less clear.  In previous structures with various inhibitors there 
is a trend in active site volume correlated to the strength of inhibition; however, the active site 
volume of BH-DHDPS:ASA is 60 Å3, which is 200% larger than the active site in wt:pyr (20 Å3; 
PDB: 4LY8), and 233% larger than the active site of BH-DHDPS (18 Å3).   
This observation appears to directly contradict the previously noted trend, implying that a larger 
active site is necessary for ASA binding rather than a factor of inhibition.  Another possibility is 
that of a dynamic model of induced fit, wherein a small active site is necessary to invite binding 
after which ASA induces a better fit with a larger active site.  Furthermore, one would expect 
obvious and significant structural rearrangement to accompany such a magnitude of volume 
increase.   
Of all residues within the active site, there are no notable changes relative to the structure of 
wt:pyr (PDB: 4LY8).  However, relative to the structure of BH-DHDPS there are two changes to 
the geometry of the catalytic triad.  The hydrogen bond between Y137-T47 and geometric distance 
between Y111'-Y137 are lengthened from 2.9 Å to 3.5 Å and 4.1 Å to 4.7 Å respectively.  With 
changes limited to the geometry of the catalytic triad, the most likely explanation for increased 
volume is that binding of ASA has induced some minor topological anomaly which allows the 
CASTp algorithm to expand its definition for the active site cavity.   
An examination of the weak dimer interface reveals a cross dimer hydrogen bond which is 
broken upon binding of ASA.  In wt:pyr (PDB: 4lY8), D173 forms a hydrogen bond (2.8 Å) with 
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K245' across the weak dimer interface (Figure 3.23).  In the BH-DHDPS:ASA structure, this 
hydrogen bond has been broken (6.9 Å) and K245’ extends away from the enzyme into solvent 
space.  The implications of breaking this hydrogen bond are not obvious.  The catalytic mechanism 
is known to be cooperative throughout the tetramer, and any structural changes at the weak dimer 
interface may be implicated in the mechanisms of cooperativity.  Therefore, K245 and D173 may 
have some role to play in attenuating the cooperativity observed between allosteric sites. 
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Figure 3.23 – Disruption of a hydrogen bond at the weak dimer interface of wt-BH-ASA. This figure depicts wt-
BH-ASA in purple which is superimposed on the grey wt:pyr structure.  For each structure the 2Fo-Fc is shown scaled 
at 1 σ.  The hydrogen bond shown in red is disrupted in the wt-BH-ASA structure and may have a role in cross dimer 
communication. 
3.6.7    Comparison of DHDPS with ASA and DHDPS with ʟ-Lysine 
Throughout this study there is an emerging trend suggesting opposing structural effects of 
DHDPS binding ʟ-lysine or ASA.  Superposition allows direct structural comparisons between 
wt:pyr:lys (pdv: 4M19) and BH-DHDPS:ASA, where the contrasting structural details may 
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provide insight into the biochemical opposition of ASA and the inhibitor ʟ-lysine.  When 
comparing the structure of BH-DHDPS to wt:pyr:lys (4M19) there is almost all of the same Cα 
and side chain movements at the allosteric site; as in the comparison of wt:pyr (4LY8) with 
wt:pyr:lys (4M19), with one exception. In wt-DHDPS the hydrogen bond between E88-H56 
supports a network of hydrogen bonds, and is speculated to act as a cap on the allosteric site after 
ʟ-lysine binds (Figure 24).  In wt:pyr (4LY8) the length of this hydrogen bond is 3.2 Å, and upon 
ʟ-lysine binding is reduced to 2.8 Å; however, this hydrogen bond is eliminated (7.2 Å) as H56 
flips away from E88 when ASA is bound to the DHDPS active site.  The hydrogen bond network 
which was proposed to cap the allosteric site has been eliminated (Figure 24).  Without H56 
capping of the allosteric site, the enzyme’s affinity for ʟ-lysine may be reduced: this is one possible 
explanation for ASA reducing the affinity of ʟ-lysine.  
Furthermore, the solvent accessible volume of the allosteric site appears to be strongly affected 
by the binding of ASA.  There is an emerging trend wherein the volume of the allosteric site 
decreases, upon inhibitor binding, proportional to the strength of inhibition.  This is perhaps 
directly related to the tightness of inhibitor binding.  Interestingly, in the structure of BH-
DHDPS:ASA the volume of the allosteric site is 46% larger than that of wt:pyr (PDB: 4LY8), and 
a full 155% larger than wt:pyr:lys (4M19).  This would appear to offer an explanation for why 
ASA reduces the enzyme’s affinity for ʟ-lysine; although, tracing the exact mechanism for 
inducing the volume increase is unclear. 
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Figure 3.24 – ASA disrupts Hydrogen Bonds at the allosteric site. This figure depicts wt:pyr:lys (PDB: 4M19) in 
orange with ʟ-lysine in blue and wt-BH-ASA is superimposed in purple.  A number of hydrogen bonds (shown in red) 
which are found in wt:pyr:lys (4M19) are completely disrupted in wt-BH-ASA.  It appears that ASA creates a number 
of conformational changes which are very opposite to the conformational changes induced when ʟ-lysine binds.  The 
ghost white wt:pyr (PDB: 4LY8) structure is included as a reference. 
 
For most inhibitors there is an increase in the solvent accessible volume at the active site 
proportional to the strength of inhibition (Figure 3.18).  For instance, the active site of wt:pyr:lys 
(4M19) is 30% larger than that of wt:pyr (4LY8).  The correlation between cavity volumes and 
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inhibitor strength indicates an increase in active site volume may contribute to inhibition of the 
enzyme.  Surprisingly, there is an even greater increase in active site volume upon binding of ASA 
to the active site.  The active site of BH-DHDPS:ASA is 200% larger than that of wt:pyr (4LY8), 
and 131% larger than wt:pyr:lys (4M19).  Such a dramatic change suggests significant structural 
rearrangement, however there is little evidence of this, which leads us to believe that minor 
changes have allowed CASTp an alternative definition of the active site cavity (Figure 25).  In 
particular a subtle difference in the orientation of K113' appears to be strongly correlated to the 
overflow of the active site identified by CASTp.  After manual rearrangement of K113' from wt-
BH-ASA to match that of K113' from wt-BH the CASTp definition of the active site cavity returns 
to that which is typical of other DHDPS crystal structures: with a measured solvent accessible 
volume of 22 Å3.  This manual manipulation is not supported by the observed electron density, 
leading to the conclusion that K113' may be of some biological importance for the binding of ASA 
or its condensation with pyruvate. 
The active site of BH-DHDPS:ASA is very similar to that of wt:pyr (PDB: 4LY8).  It is not 
surprising then that all of the same minor residue changes are found between BH-DHDPS:ASA 
and wt:pyr:lys (PDB: 4M19).  Small but measurable changes in the distance between pairs of 
residues are seen for the following pairs: Y137 – T47 (3.5 Å to 2.9 Å), Y137 – Y111' (4.7 Å to 4.2 
Å), and C1 of the pyruvyl Schiff base to each of the carbonyls of I207 and G190 (3.6 Å to 4.5 Å, 
and 4.5 Å to 3.7 Å respectively).  Perhaps more interesting is to also consider the structure of BH-
DHDPS. 
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Figure 3.25 – CASTp defines a different active site when ASA is bound to BH-DHDPS.  This figure depicts a 
super position of wt-BH-ASA (purple) on wt-BH (grey).  Panel A depicts the surface of the active site as defined in 
wt-BH (surface in yellow, wt-BH in grey).  Panel B depicts the surface of the active site as defined in wt-BH-ASA 
(surface in blue, wt-BH-ASA in purple) the yellow active site surface shown in panel A is typical for all DHDPS 
crystal structures except wt-BH-ASA.  The blue active site surface is only identified in the wt-BH-ASA crystal 
structure. 
 
As outlined above, the BH-DHDPS structure reveals two changes in hydrogen bonds of the 
catalytic triad relative to wt:pyr (PDB: 4LY8).  The hydrogen bonds between Y137-T47 and 
between Y111'-T47 each become shorter, however the length of each of these hydrogen bonds is 
restored upon binding of ASA, matching that of the wt:pyr structure (4LY8).  The significance of 
this observation is unclear. 
In the structure of wt:pyr:lys (PDB: 4M19) the largest structural changes relative to wt:pyr 
(4LY8), occur at the weak dimer interface.  These structural changes have been previously 
discussed in section 3.2.6 wt:pyr:lys (4M19) shows the most variance in this region of any 
structure.  Upon ASA binding there appears to be a single cross-dimer hydrogen bond (2.8 Å) 
between D173-K245' which is broken (6.9 Å; Figure 23). 
A B 
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3.6.8    Discussion 
This study presents the first ever DHDPS crystal structure with ASA bound at the active site, 
although there are uncertainties which make drawing definitive conclusions challenging.  
Nevertheless, when this structure is compared to each previous DHDPS structures it provides new 
insights and possible leads for better understanding catalysis and inhibition in the future. 
The initial electron density associated with ASA was amorphous and difficult to interpret.  The 
FEM algorithm proved useful to enhance the signal to noise and identify a single conformation of 
ASA.  The ambiguous Fo-Fc electron density of ASA is most likely attributable to weak or transient 
binding.  The extreme (100 mM) concentration of ASA that was required is further indicative of 
weak binding. 
It is very likely that the tetrahedral geometry of the K166-lactate adduct has a profound effect 
on the enzymes ability to properly bind ASA.  This could be an unfavourable change to the shape, 
enzyme dynamics or electrostatic profile of the active site.  Weak ASA occupancy may also 
suggest a Theorell-Chance mechanism wherein binding of ASA is inherently unfavourable, but 
once the reaction is initiated it will proceed downhill to the products.  Since no reaction is possible 
in the BH-DHDPS then binding cannot be driven by subsequent condensation. 
Comparing the structure of wt-BH-ASA with other DHDPS structures reveals an interesting 
relationship relative to previously noted structural trends.  In particular the effects that ASA has 
on the solvent accessible volumes as well as subtle changes to hydrogen bonding at the allosteric 
site and in the catalytic triad. 
Using CASTp to measure cavities has revealed a trend where the volume of the allosteric site 
of DHDPS is substantially reduced in the presence of inhibitors, and the volume at the active site 
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is marginally increased.  Inspection of the raw measurement for solvent accessible volume 
suggests that ASA induces a dramatic increase in the volume of both the allosteric site and the 
active site.  A closer visual inspection using the CASTp pymol plugin reveals that the increased 
volume of the allosteric site in wt-BH-ASA appears to be the result of changing hydrogen bond 
network involving E88, H56, and R60 (Figure 3.24).  These residues define how the allosteric site 
meets the bulk solvent, and may act as a lid on the allosteric site when ʟ-lysine is bound.  These 
observations may play a significant role in the mechanism through which ASA would reduce the 
enzymes affinity for ʟ-lysine.  These structural changes may explain the relationship between ASA 
and ʟ-lysine, where ʟ-lysine reduces the enzymes affinity for ASA, but ASA reduces the enzymes 
affinity for ʟ-lysine.1, 2 
The effects of ASA at the active site are considerably more perplexing.  The trend noted in other 
DHDPS structures had indicated that changes to the geometry of the catalytic triad coupled with 
marginal increases in the volume of active site are correlated to binding allosteric inhibitors.  Yet, 
in the structure of wt-BH-ASA we note similar changes to the geometry of the catalytic triad and 
massive change to the solvent accessible volume (Figure 25).  However, close inspection of the 
structures and the CASTp output reveals an algorithmic explanation for the increase in solvent 
accessible volume. 
It appears that a subtle change in the orientation of K113' has allowed the CASTp algorithm to 
change its definition of active site cavity.  This is confirmed by manually manipulating the 
conformation of K113' wherein the calculated active site volume and definition of the active site 
again resembles that of every other DHDPS.  However, such manual manipulation is not supported 
by the observed electron density.  Therefore, the altered definition for the active site may not be 
 
 
126 
 
an artifact, and would suggest some undetermined biological role of K113' in binding or 
condensation of ASA. 
As with the wt:pyr:lys (PDB: 4M19) structure there are subtle changes at the weak dimer 
interface.  Although the changes noted in wt-BH-ASA are distinct from those noted for wt:pyr:lys 
(4M19), it is possible that there may be some role in the known cross dimer cooperativty of 
inhibition.  In either case, it is not apparent upon examination of crystal structures what link these 
residues have to either the allosteric site or the active site. 
The conformation determined for ASA in the active site of Cj-DHDPS:lac suggests that 
condensation should produce the (R)-isomer of HTPA.  This contradicts previous studies of 
substrate mimetic molecules with Ec-DHDPS which suggest formation of the (S)-isomer of HTPA 
(Figure 3.26).21-23   
Although contradictory each interpretation is not without the need for circumstantial 
consideration.  The structure reported with succinate semi-aldehyde is based on the reaction of a 
substrate mimetic, which may be an imperfect estimation of the preferred stereochemistry of ASA.  
However, the structure of DHDPS:lac:ASA has a modified enzyme active site which may allow 
(or favor) a non-reactive conformation.  Ultimately, when HTPA is released from the DHDPS 
active site it will dehydrate in solution to form DHDP regardless of stereochemistry.4, 24, 25  
Therefore stereo-selectivity of HTPA may be inconsequential to the evolved enzymatic function 
of DHDPS. 
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Figure 3.26 – Superposition of Cj-DHDPS:lac:ASA with Ec-DHDPS:SAS.  The structure of Cj-DHDPS:lac:ASA 
is white, with ASA in magenta, and indicates that condensation would form R-HTPA.  The structure of Ec-DDPS:SAS 
is yellow, with SAS in orange, and demonstrates that condensation with SAS has formed the S-isomer. 
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Chapter 4   Conclusions 
 
4.1 Conclusions 
This study presents the high resolution crystal structures of wild type and Y110F Cj-DHDPS 
with various substrates and inhibitors.  From a global perspective all structures are highly similar 
with little in the way of gross structural changes.  As a body of work these structures begin to 
reveal the subtle structural changes required for enzymatic inhibition.  At the outset of this work 
Y110 was emerging as a potential trigger point for inhibition of DHDPS.  However 
crystallographic and kinetic data1 of DHDPS with bislysine demonstrate that Y110F cannot be 
solely responsible for the mechanism of allostery.  Furthermore inhibition of Y110F with bislysine 
indicates that Y110 is not necessary for inhibition of DHDPS. 
There are at least three explanations for inhibition of Y110F-DHDPS by bislysine but not by 
ʟ-lysine. 1) ʟ-lysine and bislysine each inhibit DHDPS according to the same mechanism and the 
enhanced inhibition of bislysine is solely due to the enhanced binding affinity of bislysine.  If this 
is the case then Y110F should have nothing to do with signal transduction and only contribute to 
binding affinity.  2) Bislysine inhibits DHDPS according to a completely different mechanism than 
ʟ-lysine.  This has not been reflected in available inhibition studies.1  Furthermore, the structural 
similarities between ʟ-lysine and bislysine suggest that the mechanism of inhibition would be very 
similar.  3) Inhibition of DHDPS is the sum of a number of contributing structural factors, each 
with variable importance.  Bislysine is perhaps changing the significance away from Y110 and 
onto some other mechanism which is present to a lesser extent during inhibition by ʟ-lysine.  The 
evaluation of the above hypothesis should be the subject of future works.  
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Crystallographic results indicate inhibition of DHDPS appears to be due to a combination of 
changes to the geometry of the catalytic triad and changes in the solvent accessible volume of the 
active site.  In general changes at the active site are restricted to the hydrogen bond lengths between 
members of the catalytic triad (T47, Y111', Y137), and typically 0.4-0.6 Å.  The specific change 
at the catalytic triad is different in wild-type and Y110F, and when ʟ-lysine or bislysine is bound.  
Changes to the length of hydrogen bonds between members of the catalytic triad is likely to affect 
the pKa of Y137 and thus its ability to donate and accept protons during the condensation step of 
the enzymatic mechanism.2  Although the means by which the inhibitor attenuates the geometry 
of the catalytic triad is not clear. 
A trend emerged where solvent accessible volume of the active site is correlated to the strength 
of the inhibitor, and the volume of the allosteric site is inversely correlated to the strength of 
inhibitor.  Increases to the volume of the active site are likely to affect the binding affinity of ASA.  
Furthermore, the presence of ASA in the active site appears to have the opposite effect on solvent 
accessible volumes: at least at the allosteric site.  These changes to the solvent accessible volume 
at the allosteric site offer a potential explanation for the reduced binding affinity of lysine in the 
presence of ASA. 
At the active site the solvent accessible volume is dramatically increased when ASA is bound 
to Cj-DHDPS.  The majority of this change in volume is attributable to a small movement in the 
side chain of K113'.  It is unclear if this has biological significance or if this movement is an 
anomaly of crystallization conditions.  Although for a residue that crosses the dimer-dimer 
interface K113' is potentially interesting from an enzyme cooperativity perspective. 
 
 
132 
 
 
Binding of lysine induces domain movement in the wild-type enzyme not previously observed, 
suggesting that the hydrogen bond network created by the inhibitor molecules between subunits 
tethers the domain in place, preventing relaxation to a catalytically active conformation.  This 
concerted domain movement seems to have relatively little effect on the observed positions of the 
active-site residues relative to the lysine-free structure.  The Domain movements do not appear to 
be essential to the inhibition of DHDPS but likely play some peripheral role related to dimer-dimer 
communication or governing protein dynamics.  The moving domains of individual monomers 
meet at the weak dimer interface, and a rearrangement of cross-monomer interactions takes place.  
We have identified several residues at the weak dimer interface which may be involved in cross 
dimer communication.  Several of these residues where identified when lysine binds to wt-
DHDPS:pyr where cross monomer communication may be the result of domain movements: I172, 
D173, V176, I 194, Y196, S200, N201, K234, D238, Y241, N242.  Furthermore, the super position 
of DHDPS:lac:ASA with DHDPS:pyr reveals two more residues at the weak dimer interface which 
are rearranged upon ASA binding: K245 and D173.  Each of the aforementioned residues, in 
particular D173 which is common to both cases, may play some role in the cooperativity observed 
for inhibition by ʟ-lysine in Cj-DHDPS.1, 3  These residues are not implicated in any Y110F 
structure, however inhibitor cooperativity was not determined for the Y110F-DHDPS.1  Bislysine 
does exhibit cooperative inhibition of wild-type Cj-DHDPS, however there are no changes to the 
weak dimer interface when comparing the structures of DHDPS:pyr:bislysine vs DHDPS:pyr.  
Therefore the potential role of these residues cannot be considered a certainty and should constitute 
a portion of future works.  None of these residues have been implicated in prior studies examining 
the tetramerization of DHDPS.4  
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The series of crystal structures presented here, and in particular the structure of wt-
DHDPS:pyr:thialysine, suggests that certain structural changes may be incompletely stimulated 
by weaker inhibitors.  Therefore, it would appear that weaker inhibition is attributable to weaker 
binding rather than non-activation of the allosteric mechanism.  DHDPS may be moving between 
two conformational states, an uninhibited catalytically competent state and a maximally inhibited 
state.  Protein dynamics may play a significant role in the inhibition of DHDPS for which we have 
not yet been able to study. 
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Chapter 5   Future Work 
5.1 Deconvolution of mechanisms contributing to inhibition of Cj-DHDPS 
Increasingly the inhibition of DHDPS does not appear to be the result of any single chemical 
or structural change.  Rather, successful inhibition is more likely the weighted aggregate result that 
all small changes will contribute to inhibition.  Future work should focus on identifying which 
structural features are most important to catalysis and inhibition.  The real challenge will lie in 
determining which of these mechanisms can be exploited when designing inhibitors, and also will 
be robust in the face of natural selection.  Moreover, as suggested by bislysine, each new inhibitor 
may slightly change the importance of any one piece of the inhibition puzzle.   
5.1.1    What role does protein dynamics play in inhibition of Cj-DHDPS  
Protein dynamics is often discussed, as a catch all descriptor, to explain the sum of minor 
structural changes that contribute to enzyme function.  However, protein dynamics should also be 
considered independently as one of many small changes contributing to the enzymes function, or 
dysfunction.  Research studies on DHDPS from other sources have suggested that protein 
dynamics may be an important aspect of catalysis.1-4  Protein dynamics may be modified by, or 
contribute to, the structural effects noted when various substrates and inhibitors bind to Cj-
DHDPS.  Protein dynamics for Cj-DHDPS in the context of effects observed at the catalytic triad, 
the role of dynamic domains, changes to cavity volumes, cross dimer communication, and as an 
independent structural phenomenon are currently being studied using Hydrogen Deuterium 
Exchange Mass Spectrometry (HDX-MS) in collaboration with Konerman et al. at The University 
of Western Ontario and may enhance the understanding of the known crystal structures.5   
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5.2 Mutagenesis to confirm the link between cooperativity and select residues at 
the weak dimer interface 
Past research has focused on examining the structural integrity of the weak dimer interface; 
often with the goal of producing stable dimeric DHDPS.  In these studies, residues where selected 
for mutation based on their potential to destabilize the dimer-dimer association.  However, to 
examine the channels for cross-dimer cooperativity the weak dimer interface must remain intact 
while only highly suspect residues are selected for mutation.  The crystal structures of 
DHDPS:pyr:lys and DHDPS:lac:ASA each present residues at the weak dimer interface which 
may play a role in cross dimer cooperativity rather than dimer-dimer stability.  Candidate residues 
for mutation studies include: I172, D173, V176, H181, I194, Y196, S200, N201, K234, D238, 
Y241, N242, and K245.  Interestingly none of these residues have been previously examined in 
studies of dimer-dimer stability. 
5.3 Mutagenesis to confirm the role of K113' in either catalysis or inhibition of Cj-
DHDPS 
Examination of the structure of DHDPS:lac:ASA lead to the serendipitous identification of 
K113' as potentially involved in normal functions of DHDPS.  When ASA is bound to the active 
site the side chain of K113' shifts slightly to change the shape of the active site mouth.  Although 
this movement may be anomalous it is worth exploring the role of K113' for two reasons.  First, 
the small movement of K113' when ASA is bound to the enzymes active site is supported by clear 
electron density.  Second, similar to Y111', K113' crosses the tight dimer interface to join the active 
site of the opposite monomer; therefore, K113' may have evolved for a specific role in catalysis or 
structural integrity of the active site. 
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5.4 Confirmation of the stereochemistry of HTPA produced by Cj-DHDPS 
The crystal structure of Cj-DHDPS:lac:ASA indicates that ASA binds in a conformation that 
would produce the (S)-isomer of HTPA.  However, studies of Ec-DHDPS have given evidence to 
indicate that the product of DHDPS is (R)-HTPA. 6-8  More evidence is needed to confirm the 
stereochemistry of HTPA produced by Cj-DHDPS.  It is possible for either the 'R' or the 'S' isomer 
of HTPA to dehydrate forming DHDP.  Therefore, it may be possible that Cj-DHDPS and Ec-
DHDPS actually produce opposite isomers of HTPA.  However, the methods used to obtain crystal 
structures of Cj-DHDPS:lac:ASA may have induced an artifactual conformation of ASA within 
the modified active site.  Additional evidence may be obtained from NMR studies of the product 
produced by Cj-DHDPS, or to improve the crystallographic methods. 
5.5 Confirmation of ASA crystal structure with an alternative dead-end complex 
The structure of DHDPS:lac:ASA was dependent upon formation of a dead end complex, to 
prevent condensation with ASA.  This was accomplished by reducing the active site K166-pyr 
Schiff base to form K166-lac.  However, the K166-lac has a tetrahedral geometry, as opposed to 
the trigonal planar geometry of K166-pyr.  This change may be enough to alter the preferred 
binding conformation of ASA. 
Another method for dead-end inhibition of DHDPS was described by Karsten et al.9 using β-
fluoropyruvate; although, another report indicates that β-fluoropyruvate is not an inhibitor.10  
Karsten et al.9 used this strategy for kinetic studies of E. coli DHDPS to determine binding order 
of substrates.  At pH 8.0, β-fluoropyruvate is a competitive inhibitor with respect to pyruvate, and 
a noncompetitive inhibitor with respect to ASA.9  Other fluorinated pyruvate derivatives may 
behave similarly such as 3,3-Difluoro-2-oxopropanoic acid, and 3,3,3-Trifluoro-2-
oxopropanoic acid; but, these have not been studied. β-fluoropyruvate binds to Ec-DHDPS with a Ki 
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which is similar to the Km of pyruvate,
9 therefore it may remain covalently bound throughout the 
crystallization process as seen with pyruvate.11  Once covalently bound to the active site K166, the 
subsequent K166-βfp would be expected to retain a trigonal planar geometry (Scheme 5.1).  
Subsequent crystallization and diffraction with ASA would be able to confirm or refute the 
observations we have made with DHDPS:lac:ASA. 
 
Scheme 5.1 – Proposed irreversible inhibition of DHDPS by β-fluoropyruvate.  The trigonal plannar geometry is 
expected to be retained during dead-end inhibition with β-fluoropyruvate.  It may be possible to crystalize DHDPS:βfp 
with ASA.  This strategy may confirm the binding conformation of ASA in a DHDPS active site with the natural 
confirmation of the Schiff base. 
 
5.6 Further development of synthetic inhibitors. 
The synthetic inhibitor R,R-bislysine was designed to mimic the symmetrical binding of two ʟ-
lysine molecules.  Exceptional inhibition of DHDPS by R,R-bislysine can be largely attributed to 
an anticipated decrease in binding entropy.  In other words, R,R-bislysine binds tighter than ʟ-
lysine, but does not significantly alter the structural changes to the enzyme that contribute to 
inhibition.  To enhance allosteric inhibition further it would be necessary for an inhibitor to either 
bind tighter or to target specific structural changes which have been correlated to inhibition: or 
both. 
The bivalent inhibitor design comes with entropy advantages and will likely provide a 
successful skeleton for the foundation of future functionalization.  Three avenues to explore 
include: the nature of the 2 carbon linker, the terminal amino group, and the carboxyl groups.  
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Design of a new spacer, instead of the 2 carbon bridge, may include double bonds or ring structures 
to add rigidity, or perhaps inclusion of additional hydroxyl or amine groups to provide additional 
interactions with the enzyme.  In wt-DHDPS Y110 makes hydrogen bond to the carboxyl of ʟ-
lysine, or bislysine.  However, studies of Y110F-DHDPS have demonstrated that the hydroxyl of 
Y110 is not mandatory for inhibition.  Therefore it may be able to modify the carboxyl group to 
favor tighter binding or increased structural perturbation.  Finally interactions between H56, H59 
and the terminal amino group of the inhibitor are important for inhibition; although the underlying 
reason is not clear.  It may be possible to modify the carbon chain or terminal group by adding 
bulk or modifying the ionic characteristic, each of which may result in tighter binding or increased 
structural perturbation. 
5.7 Allosteric inhibition of ʟ-lysine-Insensitive DHDPS. 
DHDPS from gram positive bacteria, such as S. aureus, are inherently insensitive to ʟ-lysine 
inhibition.12-14  Although the overall structure is similar to other DHDPS certain modified residues 
at the tight dimer cleft prevent the binding of ʟ-lysine and its mimics.  Residues equivalent to H56, 
H59 and E88 in Cj-DHDPS are often substituted for Lys (or Arg) in DHDPS from gram positive 
bacteria (Figure 5.1).12-16  Although the tertiary and secondary structures necessary for an allosteric 
site are intact, the increased density of positive charge prevents allosteric inhibition by ʟ-lysine. 
However, inhibition of Cj-Y110F-DHDPS by bislysine has demonstrated that single point 
mutations cannot eliminate the potential for DHDPS to be allosterically inhibited.17  Therefore, it 
is likely possible to design synthetic inhibitors which will successfully bind to the latent allosteric 
site of gram positive DHDPS and successfully inhibit enzymatic activity.  A symmetrical molecule 
having the same 2,5-diamino adipic acid scaffold as R,R-bislysine will serve as a good starting 
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point.  The symmetric scaffold could then be functionalized with shorter tail and polar, non-
positive functional groups.   
Mutagenesis studies could be conducted on DHDPS from gram positive bacteria to introduce 
allosteric ʟ-lysine inhibition as a proof of concept.  Each combination of Lys/Arg in the latent 
allosteric site would be systematically mutated to match the equivalent residue in Cj-DHDPS.  If 
allosteric inhibition can be introduced it would enforce the idea that an inspired synthetic molecule 
could be developed to inhibit the wild type gram positive DHDPS. 
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Figure 5.1 – Super Position of Cj-DHDPS:pyr:lys (4M19) and Sa-DHDPS:pyr (3DI1).  Structural alignment 
depicting the differences at the allosteric site of Cj-DHDPS:pyr:lys (white), and Sa-DHDPS:pyr (green).  The inhibitor 
ʟ-lysine is shown in purple.  Residue labels belonging to Sa-DHDPS are underlined. 
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APPENDIX A  
Table A.1 – Pertinent Data Collection Statistics of each structure presented in this thesis. 
Crystal apo:DHDPS 
(4R53) 
wt:pyruvate 
(4LY8) 
wt:pyr:lys 
(4M19) 
Y110F:pyr 
(4MLJ) 
Y110F:pyr:lys 
(4MLR) 
Wt:pyr:thialysine Wt:pyr:bislysine 
(4RT8) 
Y110F:bislysine 
(4RT9) 
BH-DHDPS:lac BH-
DHDPS:lac:ASA 
Growth conditions 0.2 M sodium 
acetate, 20% 
PEG4000, 0.1M 
TRIS, pH 8.5 
0.25 M sodium 
acetate, 18% 
PEG4000, 0.1M 
TRIS, pH 8.5 
0.25 M sodium 
acetate, 20% 
PEG4000, 0.1M 
TRIS, pH 8.5 
0.2 M sodium 
acetate, 18% 
PEG4000, 0.1M 
TRIS, pH 8.5 
0.15 M sodium 
acetate, 17% 
PEG4000, 0.1M 
TRIS, pH 8.5 
0.2 M sodium 
acetate, 20% 
PEG4000,  0.2 M 
TRIS, pH 8.5 
0.2 M sodium 
acetate, 16% P4000, 
0.1 mM Tris pH 8.5 
0.28 M sodium 
Acetate, 30% PEG 
4000, 0.1 M TRIS 
pH 8.5 
0.2 M sodium 
acetate, 15% 
PEG4000, 0.1 mM 
TRIS, pH 8.5 
0.16 M di-
ammonium 
Tartarate, 12% 
PEG3350, pH 8.5 
Temperature (K) 100 100 100 100 100 100 100 100 100 100 
X-ray source CLS (08BM-01) CLS (08ID-01) CLS (08B1-1) CLS (08ID-01) CLS (08ID-01) CLS (08ID-01) CLS (08ID-01) CLS (08ID-01) CLS (08ID-01) CLS (08B1-1) 
Wavelength (Å) 0.97952 0.9796 0.9798 0.9798 0.9795 0.9795 0.9798 0.9795 0.9798 1.0332 
Distance (mm) 250.00 239.993 289.995 250.00 239.936 260.289 239.019 280.123 228.127 279.38 
Space group P21 P212121 P21 P212121 P21 P21 P212121 P212121 P212121 P212121 
Unit cell 
parameters (Å) 
77.2, 97.6, 82.4 
90, 104.47, 90 
81.3, 101.4, 148.0 
90, 90, 90 
78.6, 97.0, 79.6 
90, 111.5, 90 
81.1, 97.9, 149.7 
90, 90, 90 
91.0, 97.6, 131.4 
90, 92.1, 90 
91.3, 97.35, 132.15 
90, 92.1, 90 
81.27, 96.95, 
146.97 
90, 90, 90 
79.59, 96.78, 
145.98 
90, 90, 90 
78.67, 103.36, 
135.95 
90, 90, 90 
86.50, 110.79, 
140.12 
90, 90, 90 
Resolution range 46-2.0 
(2.07-2.0) 
43.01-1.60 
(1.66-1.60) 
50 – 2.0 
(2.05 -2.0) 
41-2.10 
(2.17-2.10) 
43.45-2.20 
(2.28-2.20) 
47.52 – 1.90 
(1.97 – 1.90) 
48.48 – 2.20 
(2.79 – 2.20) 
48.39 – 2.35 
(2.43 – 2.35) 
48.31 – 1.93 
(1.99 – 1.93) 
43.45 – 2.37 
(2.46 – 2.37) 
Measured 
reflections 
324248 886712 280550 251823 485813 725968 444885 392031 695113 595175 
Unique reflections 77665 158522 73356 63293 116487 178323 59651 47688 83957 54596 
Rsym (%) 17.8 (117.7) 14.0 (54.1) 8.1(51.2) 19.2 (60.8) 16.8 (78.4) 11.82 (66.40) 16.73 (78.1) 16.73 (95.2) 14.00 (83.50) 10.1 (69.6) 
Rmerg (%) 25.3 (116.0) 12.9 (44.0) 12.99(56.9) 16.8 (52.6) 14.7 (68.6) 10.27 (61.38) 15.57 (72.87) 15.67 (89.6) 13.12 (74.58) 9.4 (65.0) 
Completeness (%) 99.9 (99.9) 98.3 (89.1) 97.6(80.8) 90.16 (93.15) 99.9 (100) 98.07 (92.78) 100 (100) 99.98 (99.4) 100 (100) 98.56 (96.81) 
Mean I/σ (I) 7.95 (1.64) 5.8 (1.5) 17.61(3.21) 7.16 (2.18) 4.5 (1.4) 10.73 (2.55) 11.79 (3.45) 11.71 (3.53) 12.83 (3.06) 10.26 (1.82) 
Matthews coef. 
(Å3/Da) 
2.15 2.24 2.07 2.18 2.14 2.16 2.13 2.07 2.03 2.47 
Solvent content 
(%) 
42.87 45.15 40.65 43.7 42.66 43.03 42.25 40.53 39.51 50.27 
# Molecules in 
ASU 
4 4 4 4 8 8 4 4 4 4 
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Table A.2 – Final Refinement Statistics of each structure presented in this Thesis 
 
Crystal apo:DHDPS 
(4R53) 
wt:pyruvate 
(4LY8) 
wt:pyr:lys 
(4M19) 
Y110F:pyr 
(4MLJ) 
Y110F:pyr:lys 
(4MLR) 
Wt:pyr:thialysine Wt:pyr:bislysine 
(4RT8) 
Y110F:bislysine 
(4RT9) 
BH-DHDPS:lac BH-
DHDPS:lac:ASA 
Resolution 
range (Å) 
46.03 – 2.00 43.03 – 1.70 48.51 – 1.99 48.6 – 2.1 43.45 – 2.20 47.53 – 1.90  48.49 -2.20 48.4 – 2.35 48.32 – 1.93 43.46 – 2.37 
Rwork/Rfree (%) 
17.4 / 21.3 20.9 / 25.5 15.1 / 19.2 20.19 / 24.36 21.9 / 26.8 19.26 / 23.50 15.71 / 20.28 17.06 / 22.93 14.89 / 20.03 19.63 / 24.71 
# Amino acid 
residues 
1183 1190 1185 1187 2371 2366 1186 1186 1181 1185 
# Solvent 
atoms 
579 651 533 407 202 971 401 302 561 136 
# Ligand 
Atoms 
92 272 85 37 126 149 160 108 250 36 
Rmsd 
          
      Bond 
lengths (Å) 
0.005 0.006 0.006 0.007 0.003 0.008 0.008 0.010 0.010 0.007 
      Bond 
angles (°) 
0.928 1.11 1.02 1.09 0.820 1.15 1.04 1.04 1.18 0.98 
B-factors (Å2) 
22.40 29.10 24.10 20.20 49.90 21.5 24.6 34.40 20.60 66.30 
      Protein 
21.70 28.00 23.80 19.80 49.80 20.90 24.1 34.20 19.40 66.40 
      Ligand/ion 
42.30 55.10 27.40 37.80 65.60 43.20 41.1 45.80 42.60 92.60 
      Water 
30.70 34.30 28.90 26.50 41.90 29.10 29.9 31.00 31.00 50.00 
Ramachandran 
(%) most 
favoured 
97.79 97.19 97.16 98 96.88 98.0 99.0 98.0 98.0 97.0 
Additionally 
allowed (%) 
2.21 2.13 2.49 2.00 2.90 2.0 1.0 1.75 2.0 2.75 
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Table A.3 – Effect of ligand binding on the active site and allosteric site volumes of wild-type and Y110F DHDPS. 
 
DHDPS crystal Structures 
 
apo 
(4R53) 
wt:pyr 
(4LY8) 
wt:pyr:lys 
(4M19) 
 
wt:pyr: 
bislysine 
 
Y110F:pyr 
(4MLJ) 
Y110F:pyr:lys 
(4MLR) 
 
Y110F: 
bislysine 
 
wt:pyr: 
thialysine 
wt:BH:lac 
wt:BH:lac: 
ASA 
Active 
site 
volume
 a 
(Å3) 
 
36 ± 1 20 ± 1 26 ± 5 27 ± 1 22 ± 2 20 ± 1 26 ± 3** 21 ± 1 18 ± 1 60 ± 2 
Allosteri
c site 
volume a 
(Å3) 
 
494 ± 14 417 ± 15 239 ± 5 214 ± 2 446 ± 41 332 ± 7 278 ± 29 267 ± 11 355 ± 1 609 ± 103 
** Estimated solvent accessible volume if pyruvate had been present in the active site. 
a Solvent accessible volumes calculated using CASTp as described in the text, and excluding ʟ-lysine from the model 
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Figure A.1 – Sequence alignment of DHDPS from various species.a 
 
B.subtilis                 -------------------------------------------------- 
B.licheniformis            -------------------------------------------------- 
B.anthracis                -------------------------------------------------- 
C.glutamicum               -------------------------------------------------- 
S.aureus                   -------------------------------------------------- 
T.maritima                 -------------------------------------------------- 
E.coli                     -------------------------------------------------- 
P.aeruginosa               -------------------------------------------------- 
C.jejuni                   -------------------------------------------------- 
T.aestivum                 MPYLQPPRPHPHPHPTSRLSRASPPSPFPFFPAGTSRSGRLQPVPVSGHS 50 
Z.mays                     --MISPTNLLPARKITP-VSNGGAATASPSSPSVAARPRRLP----SG-L 42 
N.tabacum                  ---MSSSIIGRCHFVADSIEAAG--------------------------T 21 
V.vinifera                 ---MAMLKNYGACLKDSTLQFPRPNC--------------------GDIN 27 
                                                                               
 
B.subtilis                 -----------------------------------MNFGNVSTAMITPFD 15 
B.licheniformis            -----------------------------------MNFGNIATAMVTPFD 15 
B.anthracis                ----------------------------------MIDFGTIATAMVTPFD 16 
C.glutamicum               ------------------------MSTGLTAKTGVEHFGTVGVAMVTPFT 26 
S.aureus                   ---------------------------------MTHLFEGVGVALTTPFT 17 
T.maritima                 ------------------------------------MFRGVGTAIVTPFK 14 
E.coli                     ------------------------------------MFTGSIVAIVTPMD 14 
P.aeruginosa               ------------------------------------MIAGSMVALVTPFD 14 
C.jejuni                   --------------------------------MDKNIIIGAMTALITPFK 18 
T.aestivum                 ASRVSKGKFAVAAVTLDDYLPMRSTEVKNRTSTDGIKSLRLITAVKTPYL 100 
Z.mays                     QSVTGRGKVSLAAITLDDYLPMRSTEVKNRTSTDDITRLRLITAVKTPYL 92 
N.tabacum                  KRRTTRWRSPRAAVIPSFHLPMRSNEVKNRTFADDIKALRLITAIKTPYL 71 
V.vinifera                 KRRNAKWKSAQAAVIPNFHLPMRSFEVKNRTSVDDIKSLRLITAIKTPYL 77 
                                                                     .*: **   
 
B.subtilis                 NKGNVDFQKLSTLIDYLLKNGTDSLVVAGTTGESPTLSTEEKIALFEYTV 65 
B.licheniformis            KNENIDFQKLSKLIDYLINNGTDSLVVAGTTGESPTLSEEEKVALIQYSV 65 
B.anthracis                INGNIDFAKTTKLVNYLIDNGTTAIVVGGTTGESPTLTSEEKVALYRHVV 66 
C.glutamicum               ESGDIDIAAGREVAAYLVDKGLDSLVLAGTTGESPTTTAAEKLELLKAVR 76 
S.aureus                   NN-KVNLEALKAHVNFLLENNAQAIIVNGTTAESPTLTTDEKELILKTVI 66 
T.maritima                 NG-ELDLESYERLVRYQLENGVNALIVLGTTGESPTVNEDEREKLVSRTL 63 
E.coli                     EKGNVCRASLKKLIDYHVASGTSAIVSVGTTGESATLNHDEHADVVMMTL 64 
P.aeruginosa               AQGRLDWDSLAKLVDFHLQEGTNAIVAVGTTGESATLDVEEHIQVIRRVV 64 
C.jejuni                   NG-KVDEQSYARLIKRQIENGIDAVVPVGTTGESATLTHEEHRTCIEIAV 67 
T.aestivum                 PDGRFDLEAYDSLINTQINGGAEGVIVGGTTGEGHLMSWDEHIMLIGHTV 150 
Z.mays                     PDGRFDLEAYDSLINMQIEGGAEGVIVGGTTGEGHLMSWDEHIMLIGHTV 142 
N.tabacum                  PDGRFDLEAYDTLVNLQIENGAEGVIVGGTTGEGQLMSWDEHIMLIGHTV 121 
V.vinifera                 PDGRFDLEAYDALVNMQIVDGAEGVIVGGTTGEGQLMSWDEHIMLIGHTV 127 
                               .            :  .  .::  ***.*.      *:         
 
 
a Catalytic triad is shown in green, the key catalytic lysine (K166) is shown in cyan, a residue of interest at the active 
site (K113') is shown in pink, residues implicated at the weak dimer interface are shown in purple. 
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B.subtilis                 KEVNG-RVPVIAGTGSNNTKDSIKLTKKAEEAGVDAVMLVTPYYNKPSQE 114 
B.licheniformis            KEAAG-RVPIIAGTGSNNTKASIKLTKKAEEAGADAVMLVTPYYNKPSQE 114 
B.anthracis                SVVDK-RVPVIAGTGSNNTHASIDLTKKATEVGVDAVMLVAPYYNKPSQE 115 
C.glutamicum               EEVGD-RAKLIAGVGTNNTRTSVELAEAAASAGADGLLVVTPYYSKPSQE 125 
S.aureus                   DLVDK-RVPVIAGTGTNDTEKSIQASIQAKALGADAIMLITPYYNKTNQR 115 
T.maritima                 EIVDG-KIPVIVGAGTNSTEKTLKLVKQAEKLGANGVLVVTPYYNKPTQE 112 
E.coli                     DLADG-RIPVIAGTGANATAEAISLTQRFNDSGIVGCLTVTPYYNRPSQE 113 
P.aeruginosa               DQVKG-RIPVIAGTGANSTREAVALTEAAKSGGADACLLVTPYYNKPTQE 113 
C.jejuni                   ETCKGTKVKVLAGAGSNATHEAVGLAKFAKEHGADGILSVAPYYNKPTQQ 117 
T.aestivum                 NCFGA-NIKVIGNTGSNSTREAVHATEQGFAVGMHAALHVNPYYGKTSTE 199 
Z.mays                     NCFGS-RIKVIGNTGSNSTREAVHATEQGFAVGMHAALHINPYYGKTSAE 191 
N.tabacum                  NCFGG-SIKVIGNTGSNSTREAIHATEQGFAVGMHAALHINPYYGKTSLE 170 
V.vinifera                 NCFGG-SIKVIGNTGSNSTREAIHATEQGFAVGMHAALHINPYYGKTSLE 176 
                           .        :: ..*:* *  ::         *  . : : ***.:.. . 
 
B.subtilis                 GMYQHFKAIAAETSLPVMLYNVPGRTVASLAPETTIRLAADIPNVVAIKE 164 
B.licheniformis            GMYRHFRAIAEETSLPVMLYNVPGRTAASLAPETTIRLA-EIPNIIAIKE 163 
B.anthracis                GMYQHFKAIAESTPLPVMLYNVPGRSIVQISVDTVVRLS-EIENIVAIKD 164 
C.glutamicum               GLLAHFGAIAAATEVPICLYDIPGRSGIPIESDTMRRLS-ELPTILAVKD 174 
S.aureus                   GLVKHFEAIADAVKLPVVLYNVPSRTNMTIEPETVEILS-QHPYIVALKD 164 
T.maritima                 GLYQHYKYISERTDLGIVVYNVPGRTGVNVLPETAARIAADLKNVVGIKE 162 
E.coli                     GLYQHFKAIAEHTDLPQILYNVPSRTGCDLLPETVGRLA-KVKNIIGIKE 162 
P.aeruginosa               GMYQHFRHIAEAVAIPQILYNVPGRTSCDMLPETVERLS-KVPNIIGIKE 162 
C.jejuni                   GLYEHYKAIAQSVDIPVLLYNVPGRTGCEISTDTIIKLFRDCENIYGVKE 167 
T.aestivum                 GLISHFKEVLPMG--PTIIYNVPSRTSQDIPPPVIEALS-SYSNMAGVKE 246 
Z.mays                     GMISHFEAVLPMG--PTIIYNVPSRSAQDIPPEVILAIS-GYTNMAGVKE 238 
N.tabacum                  GLISHFESVLPMG--PTIIYNVPSRTGQDIPPRVIQTMA-KSPNLAGVKE 217 
V.vinifera                 GLVSHFESVLPMG--PTVIYNVPSRTGQDIPPGVIHTVA-QSANLAGVKE 223 
                           *:  *:  :         :*::*.*:   :   .   :      : .:*: 
 
B.subtilis                 ASGDLEAITKIIAETPE---DFYVYSG-DDALTLPILSVGGRGVVSVASH 210 
B.licheniformis            ASGDLDAITKIVAETPE---DFAVYSG-DDSLTLPALSVGARGIVSVASH 209 
B.anthracis                AGGDVLTMTEIIEKTAD---DFAVYSG-DDGLTLPAMAVGAKGIVSVASH 210 
C.glutamicum               AKGDLVAATSLIKET-----GLAWYSG-DDPLNLVWLALGGSGFISVIGH 218 
S.aureus                   ATNDFEYLEEVKKRIDTN--SFALYSG-NDDNVVEYYQRGGQGVISVIAN 211 
T.maritima                 ANPDIDQIDRTVSLTKQARSDFMVWSG-NDDRTFYLLCAGGDGVISVVSN 211 
E.coli                     ATGNLTRVNQIKELVSD---DFVLLSG-DDASALDFMQLGGHGVISVTAN 208 
P.aeruginosa               ATGDLQRAKEVIERVGK---DFLVYSG-DDATAVELMLLGGKGNISVTAN 208 
C.jejuni                   ASGNIDKCVDLLAHEPR----MMLISG-EDAINYPILSNGGKGVISVTSN 212 
T.aestivum                 CVGHERVKCYTDKG-------ISIWSGNDDECHDSRWKYGATGVISVASN 289 
Z.mays                     CVGHERVKHYADKG-------ITIWSGNDDECHDSKWKHGATGVISVTSN 281 
N.tabacum                  CVGNDRVEQYTSDG-------VVVWSGNDDECHVSRWDYGATGVISVTSN 260 
V.vinifera                 CVGNDRIKQYTDNR-------IVVWSGNDDQCHDAKWDYGATGVISVTSN 266 
                           .  .                 .   ** :*         *. * :** .: 
 
 
 
a Catalytic triad is shown in green, the key catalytic lysine (K166) is shown in cyan, a residue of interest at the active 
site (K113') is shown in pink, residues implicated at the weak dimer interface are shown in purple. 
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B.subtilis                 IAGTDMQQMIKNYTNGQTANAALIHQKLLPIMKELFKAPNPAPVKTALQL 260 
B.licheniformis            IIGPEMQEMIKHYTEGNTAQAALIHQKLLPLMKGLFAAPNPSPLKTALQL 259 
B.anthracis                VIGNEMQEMIAAFQAGEFKKAQKLHQLLVRVTDSLFMAPSPTPVKTALQM 260 
C.glutamicum               AAPTALRELYTSFEEGDLVRAREINAKLSPLVAAQGRLGGVSLAKAALRL 268 
S.aureus                   VIPKEFQALYDAQQSG--LDIQDQFKPIGTLLSALSVDINPIPIKALTSY 259 
T.maritima                 VAPKQMVELCAEYFSGNLEKSREVHRKLRPLMKALFVETNPIPVKAALNL 261 
E.coli                     VAARDMAQMCKLAAEGHFAEARVINQRLMPLHNKLFVEPNPIPVKWACKE 258 
P.aeruginosa               VAPRAMSDLCAAAMRGDAAAARAINDRLMPLHKALFIESNPIPVKWALHE 258 
C.jejuni                   LLPDMISALTHFALDENYKEAKKINDELYNINKILFCESNPIPIKTAMYL 262 
T.aestivum                 LVPGLMHSLMFEGENA------ALNEKLLPLMKWLFCEPNPIGLNTALAQ 333 
Z.mays                     LVPGLMHSLMYKGENA------TLNEKLSPLMKWLFCQPNPIALNTALAQ 325 
N.tabacum                  LVPGLMRELMFGGKNP------ALNSKLMPLMEWLFHEPNPIALNTALAQ 304 
V.vinifera                 LIPGLMRQLLFKGKNP------SLNAKIMPLVNWLFEEPNPIGLNTALAQ 310 
                                :  :                  :  :        .    :      
 
B.subtilis                 RGLDV-GSVRLPLVPLTEDERLSLSSTISEL------------------- 290 
B.licheniformis            KGLDV-GSVRLPLIPLNEDERLRLSSLMNGL------------------- 289 
B.anthracis                VGLDV-GSVRLPLLPLTEEERVTLQSVMQSIPR----------------- 292 
C.glutamicum               QGINV-GDPRLPIMAPNEQELEALREDMKKAGVL---------------- 301 
S.aureus                   LGFGN-YELRLPLVSLEDTDTKVLREAYDTFKAGENE------------- 295 
T.maritima                 MGFIE-NELRLPLVPASEKTVELLRNVLKESGLL---------------- 294 
E.coli                     LGLVATDTLRLPMTPITDSGRETVRAALKHAGLL---------------- 292 
P.aeruginosa               MGLIP-EGIRLPLTWLSPRCHEPLRQAMRQTGVLA--------------- 292 
C.jejuni                   AGLIESLEFRLPLCSPSKENFAKIEEVMKKYKIKGF-------------- 298 
T.aestivum                 LGVVR-PVFRLPYTPLPLEKRVEFVRIVEAIGRENFVGQKESRVLDDDDF 382 
Z.mays                     LGVAR-PVFRLPYVPLPLEKRAEFVRIVESIGRENFVGQKEAQVLDDDDF 374 
N.tabacum                  LGVVR-PVFRLPYVPLTKAKREEFVKIVKEIGRENFIGERDVQILDDNDF 353 
V.vinifera                 LGVVR-PVFRLPYVPLPLAKRVEFVNIVKEIGRENFVGEKDVKVLDDDDF 359 
                            *.      ***           .                           
 
B.subtilis                 ------ 
B.licheniformis            ------ 
B.anthracis                ------ 
C.glutamicum               ------ 
S.aureus                   ------ 
T.maritima                 ------ 
E.coli                     ------ 
P.aeruginosa               ------ 
C.jejuni                   ------ 
T.aestivum                 VLISRY 388 
Z.mays                     VLISRY 380 
N.tabacum                  ILVGRY 359 
V.vinifera                 ILVGRY 365 
 
 
 
 
a Catalytic triad is shown in green, the key catalytic lysine (K166) is shown in cyan, a residue of interest at the active 
site (K113') is shown in pink, residues implicated at the weak dimer interface are shown in purple. 
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APPENDIX B 
B.1 Brief Description for Uncommon Software 
B.1.1 Introduction to dynamic Domains 
Biomolecular function involves conformational change in response to the change of state that 
occurs when a biomolecule carries out its task.  It is currently accepted that this change in 
conformation is not merely an unimportant side effect of function but is integral to it.  This is 
certainly true for an allosteric mechanism where the binding of a ligand at one site affects binding 
affinities at a distant site.1  
Many large proteins are built from domains, and interdomain motions are likely to be the 
slowest of all motions in proteins.  Functional sites are often located at interdomain clefts, implying 
that these interdomain motions are of functional significance.2  It has been suggested that domain 
motions, which have been described as hinge, shear, or a combination of hinge and shear motions, 
correspond to low energy conformational changes available to the protein at its functional 
temperature.3  Although for some proteins the domain structure is obvious, others may exist in a 
dynamical sense and may not be easily recognizable from the structure.4  
DynDom is a program that analyzes conformational change in proteins for dynamic domains, 
hinge axes, and hinge-bending regions.  It is primarily used by X-ray crystallographers when they 
have more than one conformation of a protein for analysis of its domain motion.5  
B.1.2 Brief Summary of the dynDom Algorithm 
The DynDom program will determine dynamic domains, hinge axes, and hinge-bending 
residues from two protein structures, representing the conformational change.  Details of the basic 
methodology are given in the original publication, and a brief description follows here.6  The intent 
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of DynDom is to identify those regions of a protein which move as a unit in the same direction and 
with the same magnitude.  These regions are named dynamic domains.  The algorithm for 
identifying domains uses a combination of a group of methods for identifying conformational 
change, rather than those methods based purely on structural information.4  DynDom assumes that 
some proteins can, in the first approximation, consist of parts that can be treated as behaving 
dynamically as rigid bodies which can be distinguished by their differing rotational properties in 
the low frequency modes.5  These parts may or may not have any correspondence to structurally 
defined domains, and to distinguish them from structurally defined domains they are termed 
"dynamical domains".  This approximation requires that the interaction between these parts be 
small when compared with interactions within a single part.4  
Movement of domains is identified by generation of short main-chain segments using a sliding 
window.  The sliding window serves to reduce the noise of local variations, and the overlapping 
segments smoothes the distribution of rotation points.7  The calculation of rotation vectors of each 
of these segments relative to a reference structure reveals segments that rotate together, and 
perhaps comprise a rigid domain within the protein.7  The demarcation between domains is based 
on their differing rotation relative to a reference structure.  Thus, DynDom is used to analyze the 
conformational change between two structures in terms of a model whereby domains move.  
DynDom is not designed to detect or measure individual residue movements, nor will it define 
multiple movement vectors which are not of similar direction or magnitude. 
Once the dynamical domains have been identified, the interdomain screw axis can be 
determined.  One domain is fixed in space, and the motion of the other domain, the rotating 
domain, is described by a screw axis.5  The method is such that the location of the interdomain 
screw axis reveals the type of motion occurring.  If the interdomain screw axis is located between 
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the two domains near regions known to be involved in the interdomain motion, we could 
reasonably assume that the interdomain connections effectively create a physical hinge axis.4  
Usually a number of residues are involved in the motion of one domain relative to another.  For 
example, this may involve the bending of an interdomain helix.  Hinge axes are further classified 
into two extreme types; twist, and closure axes.4  A twist axis is one located along or parallel to an 
imaginary line joining the center of mass for each domain,   whereas a closure axis lies 
perpendicular to the imaginary line which joins the center of mass for each domain.4  Any hinge 
axis may represent simultaneous properties of twist and closure.  DynDom thus describes a hinge 
axis as a certain percentage where 100% is perfect closure, and 0% is a perfect twist.4    
B.2.1 Introduction to CASTp for the definition of protein pockets and cavities 
 Cavities on a protein’s surface as well as specific amino acid positioning within it create the 
physico-chemical properties needed for a protein to perform its function.  Allosteric 
transformations in proteins are associated with changes in domain contacts and concomitantly with 
sizes and shapes of interfacial cavities.  Furthermore, water-filled cavities play the role of 
modulating pKa values of acidic and basic residues surrounding the cavities.
8  
The Computer Atlas of Surface Topography program (CASTp) identifies pockets and cavities 
in protein crystal structures and quantifies their size.  The method of the CASTp algorithm is a 
computational geometry treatment of complex shapes, based on alpha shape and discrete flow 
theory, and a related suite of programs.9-12  CASTp provides a full description of protein pockets 
and cavities including: volume, surface area, protein atoms that line the concavity, and features of 
pocket mouths including identification of mouth atoms as well as measurement of mouth area and 
circumference.13 
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Pockets are defined as empty concavities on protein surface into which solvent (probe 1.2 Å) 
can gain access.  Shallow depressions are excluded from the calculation.  The criterion of a pocket 
is as follows: among the infinite number of possible cross sections of a pocket, at least one is larger 
than the mouth opening of the pocket.  A cavity (or void) is an interior empty space that is not 
accessible to the solvent probe. It has no mouth openings to the outside bulk solvent. 
CASTp uses the models of Lee and Richards for solvent accessible surfaces (SA) and molecular 
surfaces (MS) of proteins.14  The model presents a molecule as the union of many fused spherical 
balls in three-dimensional space where each ball represents an atom by adopting spatial location 
and the appropriate van der Waals radius of the atom.  Thus, the van der Waals (VW) model is the 
union of these spherical balls.8  The SA and the MS models are defined by the same solvent sphere 
rolling about the VW model.  The solvent is treated as a sphere of appropriate radius and is rolled 
around the van der Waals surface of the protein.  The center of the solvent sphere sweeps out the 
surface of the solvent accessible or SA model, while the front of the solvent sphere defines the 
molecular surface or MS model.14, 15  This subtle distinction means the area and the volume of the 
two models may differ significantly.  
CASTp uses an algorithm based on alpha shapes for measuring space-filling-based molecular 
models (such as van der Waals, solvent accessible, and molecular surface descriptions).8  Utilizing 
the surfaces defined by the solvent probe, alpha shape theory is used to define the cavities and 
compute their volume (an introduction to alpha shape theory can be found on the web site 
http://alpha.ncsa.uiuc.edu/alpha).  In brief, alpha shape theory provides a quantitative method to 
accurately describe and compute shapes at multi-levels of detail in three-dimensional space.9, 16  It 
is integral to computation of molecular surface area and volume for both SA and MS.17   
 
 
154 
 
B.2.2 Availability of CASTp 
CASTp web server and the associated mapping database can be freely accessed at 
http://cast.engr.uic.edu. 
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